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CHAPTER 1 – INTRODUCTION
1.1 Introduction to Nanomedicine
Over the past decade, a boom in new therapeutics has emerged in the industry and academic
sector that are coined under the term “nanomedicine”. Nanomedicine has attracted a lot of attention
in the clinical setting. This new wave of scientific interest employs nanotechnology, or nano-sized
tools, for the purpose of diagnosis, treatment, and even prevention of diseases ranging from cancer
to sexually transmitted diseases.(1-3) Backing this development of nanomedicine is the
combination of multiple fields, including biology, chemistry, material science, engineering, and
clinical practice.(2) Nanoparticles offer the advantage of accessing diseased organs or cells with
the ability to be engineered to perform more efficiently than non-modifiable chemical or biological
molecules.(1, 4) Although this recent trend of molding these fields together has grown
exponentially in publications within the last decade, the first example of researchers using
nanomaterials for a therapeutic purpose actually originated well before this surge. One of the first
studied concepts of the field of nanomedicine used liposomes for drug delivery. Subsequently, the
first FDA approved nanomedicine was a liposomal delivery system also.
Liposomes are spherical lipid vesicles which have a hydrophilic core. They are made of a
similar amphiphilic bilayer structure as the one that comprises a cellular membrane.(5, 6)
Therefore, liposomes can readily cross cell membranes and be used to package drugs within their
aqueous core. Researchers first became aware of liposomes and their drug loading capabilities in
1965.(2, 7) Liposomes offer the unique ability to load both hydrophobic drugs within the bilayer
and hydrophilic drugs within their core. Their ability to load drugs within their structure to form
solid dispersions alleviates the issue of solubilizing very hydrophobic drugs, such as doxorubicin,
within harsh organic solvent solutions to use in patients.(7-9) Since the 1960s, multiple variations
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of the liposome structure have been introduced paralleled by an increase regarding the variety of
drugs that can be loaded into the inner core and membrane. One popular modification to the surface
of the liposome was the use of polyethylene glycol (PEG) to coat the outer layer with the aim of
increasing biocompatibility, evading phagocytosis by immune cells, and decreasing aggregation
and the binding to serum proteins.(7, 10) In 1995, the first nanoparticle based therapy was
approved by the FDA which utilizes a PEGylated liposome that encapsulates doxorubicin. Doxil,
as it was termed, has been approved in the clinic to treat Kaposi’s sarcomas and ovarian epithelial
cancers.(7, 11, 12) Liposomes, such as Doxil, rely upon the so-called enhanced permeation and
retention effect (EPR effect) to localize within the tumor due to leaky blood vasculature and retain
within the tumor interstitium for a prolonged period of time due to insufficient lymph drainage.(13,
14)
The EPR effect allows for nanoparticles to preferentially accumulate within the tumor due
to the abnormal and chaotic growth of blood vessels which result in larger and less ordered
fenestrations within the blood vessel wall.(15, 16) This passive accumulation mechanism is also
utilized by the FDA approved drug Abraxane. Abraxane is a nanoparticle of albumin-bound
paclitaxel used to treat a variety of cancers such as breast and lung cancer.(17, 18) These two
nanoparticle based drugs allow researchers to avoid the use of harsh organic solvents which would
be required for drugs being administered as a solution. However, by encapsulating them in
nanoparticles, these harsh solvents, which normally cause biocompatibility concerns, are not
needed. Encapsulating them onto and within nanoparticles allows for normally water insoluble
drugs to no longer require harsh organic solvents which are necessary if solutions of the drugs are
administered. Furthermore, passive targeting of nanoparticles based on the EPR effect has been
shown to decrease off target toxicity in the heart and kidneys after administration of doxorubicin
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and toxic neutropenia commonly caused by paclitaxel.(12) Additionally, due to the inherent
accumulation within tumors, Abraxane dosing regimens allow for lower doses of the drug to be
administered to achieve the same clinical responses.
Taken together, the two currently approved nanoparticle based treatments, Doxil and
Abraxane, demonstrate the efficacy and the need for nanoparticles in the clinic which can
ultimately decrease off target toxicity caused by common chemotherapy.
1.2 Targeted Nanomedicine
Traditional chemotherapeutic compounds have been in use since the 1950s. Many of these
chemotherapy agents are still being used today; however, they have several drawbacks. While
most of these compounds kill cells by different mechanisms, they all share one common
characteristic. All of these compounds target rapidly proliferating cells with no differentiation
between healthy and diseased ones.(1, 8) The systemic activity of chemotherapeutics causes side
effects such as hair loss, fatigue, decrease in blood cell count, and appetite loss. Therefore, a
limitation of traditional chemotherapeutics is their upper dose limit that can be administered, above
which serious off target toxicity becomes a concern for the patient. As described earlier, one way
to overcome this barrier is through encapsulating chemotherapeutic drugs within nanoparticles
which rely upon passive accumulation in the tumor. An alternative strategy to passive targeting is
the concept of attaching a targeting ligand onto the surface of the nanoparticle. This approach,
called active targeting, can increase the interaction between nanoparticles and the targeted cell and
the likelihood of a more quantitative tumor targeted and specific uptake.(19-24)
Targeted nanomedicine offers the opportunity to treat patients in a more individualized
approach. To date, there is a wide assortment of biomarkers that have been exploited by researchers
to deliver a targeted payload to a tumor site. These functionalizations on the surface of the
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nanocarriers include monoclonal antibodies, aptamers, ligands for cell surface receptors, and small
peptides.(9, 25-28) Each of these is able to bind in a targeted manner to cellular specific biomarkers
such as cell surface receptors. Current receptors being exploited for targeted delivery include, but
are not limited to, folate receptor alpha and beta (FRα, FRβ), transferrin receptor, or integrin
receptors.(29-31) Certain surface receptors, such as FRα and transferrin receptor, are significantly
overexpressed in several cancers but display a very selective expression profile throughout the rest
of the body. For example, FRα is reported to be over-expressed in greater than 85% of ovarian
cancer patients and 80% of non-small cell lung cancers.(32, 33) Thus, attaching a ligand to the
surface of nanoparticles creates a homing-like mechanism to deliver their payload in a targeted
manner. When the nanoparticle binds to the receptor, a “Trojan-horse” type mechanism is used to
hijack the receptors’ natural ability to endocytose and to deliver the drug payload. This concept,
along with the advantages of FRα targeting is elaborated upon more thoroughly in Chapter 3.
Additionally, atomic force microscopy (AFM) techniques are utilized in Chapter 4 to assess the
interaction between ligand and receptor in relation to competitive inhibition of targeted
nanoparticles. Lastly, Chapter 5 addresses the nanoparticle biophysical changes that occur when
the targeting ligand folic acid is attached to the surface of the delivery vector. The FRα targeting
strategy is represented within Figure 1. Additionally, the AFM approach for analyzing ligandreceptor interaction can be seen in Figure 2.
There are four different isoforms of the folate receptor which can be found throughout the
body; α, β, γ, and δ. Each isoform shares a highly conserved amino acid sequence which ranges
between 68-79% similarity.(34, 35) All isoforms of the folate receptors have a high affinity for
binding multiple folate compounds including folic acid, reduced folates, and antifolates to provide
unidirectional transport into the cell. FR α and β have two N-glycosylation sites and bind folic acid
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with high affinity with an equilibrium dissociation constant (KD) of ~1 nM. These receptors bind
their ligands and internalize them into the cell via receptor mediated endocytosis via caveolae
coated pits.(34, 36-38) These pits completely evaginate into the cell and pinch off from the cellular
membrane to create an endosome. As the endosome matures from an early to a late endosome, the
pH inside the endosome drops considerably. Once the pH of the endosome has dropped, the ligand
will be released into the cytoplasm of the cell through pH-dependent anion transporters or diffuses
out of the intact endosomes.(33-35, 39) Substrates such as folic acid cannot be made de novo in
the body and thus are required to be taken up by the cells for purine synthesis.
The encoding gene for folate receptors is found on the 11q13.3-q13.5 chromosome.(33)
Of the four isoforms, FRα and β are a cysteine-rich glycophosphatidyl (GPI) anchored proteins
which have a select expression throughout the body.(34, 35, 40) Folate receptor alpha (FRα) is
expressed along the apical surface of the lung, the apical surface of the proximal tubules within
the kidney, as well as within the choroid plexus. Due to its expression profiles in healthy tissues
throughout the body, FRα is unable to recognize and bind circulating folates.(29, 40) However,
these receptors have also been found to be over-expressed within multiple cancers which have
direct access to the bloodstream; therefore, making them an attractive target for personalized
therapy approaches.(26, 41, 42) FRβ expression profiles are limited to hematopoietic cells, such
as activated macrophages, neutrophils, and the placenta.(43, 44)
Unlike the functions of FRα and β, the roles of FRγ and δ are lesser known. FRγ does not
contain a GPI-anchored signaling domain and has been cited to be a secretory protein whose
function is currently unknown.(45, 46) Lastly, FRδ plays an important role in fertilization of an
egg. FRδ is found on the surface of mammalian egg cells and can recognize the sperm counterparts.
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After recognition, FRδ expression is quickly decreased, possibly suggesting that FRδ also helps in
egg cells ability to recognize only one sperm and prevent the occurrence of polyspermy.(47)

Figure 1.1: Graphical abstract of FRα targeted delivery of siRNA.(48)
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Figure 1.2: Graphical abstract of AFM FRα modified cantilever (in blue). Cantilever binding to
folate decorated micelleplexes (bottom) without excess folic acid (red circles) (A) and excess folic
acid (B).
Although targeted therapy offers many advantages over standard chemotherapy, it does
have its limitations. One main challenge to this approach is that tumors are heterogeneous and it
can be difficult to find biomarkers that are uniquely specific to the cells within the tumor.
Additionally, inter-tumoral heterogeneity can arise creating more complexity.(49, 50) With
heterogeneous populations found in tumors, alternative delivery strategies are considered due to
their potent therapeutic effect and potential synergy they can offer to standard treatments.
Nanoparticles, with their high modularity, have the capabilities to deliver a wide variety of drugs
to various targets throughout the body. Very hydrophobic drugs, such as paclitaxel or cisplatin,
can be packaged inside the bilayer of liposomes, thus, allowing these drugs to be administered in
an aqueous formulation of a delivery vehicle.(51-53) Additionally, gene therapy based payloads,
such as messenger RNA (mRNA), plasmid DNA (pDNA), and small interfering RNA (siRNA)
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can be packaged inside polymeric nanoparticles through means of electrostatic condensation or
precipitation.(54, 55) These packaging strategies are beneficial for the successful delivery of
nucleic acids due to nucleic acids being large, negatively charged molecules and display poor
cellular uptake capabilities. Payloads such as siRNA offer several therapeutic benefits over
standard chemotherapy based drugs, which is why numerous companies are in the process of
translating siRNA nanomedicine into the clinic.
1.3 Introduction to siRNA and Delivery
RNA interference (RNAi) was discovered in 1998 by Andrew Fire and Craig Mello when
they first displayed the cells’ natural ability to use double-stranded RNA to silence gene expression
within the cytoplasm of the cell.(56, 57) They discovered that long double stranded RNA (dsRNA)
can be cleaved by a ribonuclease, termed dicer, which cuts the double-stranded RNA into small
interfering RNAs. These siRNAs can complex with the RNA induced silencing complex (RISC),
a protein complex with endonuclease activity, which in turn can recognize and cleave mRNA that
contains a homologous sequence. This decrease in functional mRNA leads to a transient protein
knockdown within the cell. Soon after Fire’s and Mello’s discovery, this concept was exploited by
researchers who demonstrated that synthetically made small interfering RNA (siRNA), delivered
into the cytoplasm, could utilize the same mechanism while also achieving a protein
knockdown.(16, 55, 56, 58) Synthetic siRNA molecules can be designed to recognize any target
mRNA sequence. Therefore, theoretically, if administered properly, siRNA has the ability to
silence any gene throughout the body. Due to its ease of modularity and its very potent therapeutic
effects within the cell, siRNA delivery remains a very promising tool in nanomedicine.
Unfortunately, one of the major hurdles of siRNA therapy is the delivery of siRNA into
the cytoplasm of the cell. Due to its large size and negative charge, naked siRNA cannot enter the
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cell efficiently to achieve its therapeutic effects.(58, 59) Furthermore, naked siRNA is quickly
cleared through the renal system and can easily be degraded in circulation by nucleases.(60)
Therefore, researchers have created ways to package siRNA molecules into a variety of
nanoparticles with the aim to increase its uptake profiles. Commonly used nanoparticles for siRNA
delivery are made of, but are not limited to, lipid based, polymeric, dendrimer, and cationic
materials. These types of nanomaterials are able to condense and protect the siRNA while aiding
in the uptake efficiency of siRNA and increasing its gene knockdown efficiency.(61-63) In order
to prolong the circulation profiles of the nanoparticles, and to increase the likelihood for them to
reach the target site, PEG can be attached to the outer surface of nanoparticles. Additionally, as
stated above, the surface of nanoparticles can be functionalized with targeting ligands such as folic
acid. Folic acid as a targeting ligand has shown the capability to deliver payloads to ovarian cancer
cells which overexpress the respective receptor. The ability to deliver siRNA to specific cells
through active targeting helps bolster the therapeutic potential of siRNA nanomedicines. Overall,
siRNA delivery has the ability to transiently knockdown specific genes which can give rise to
disease progression or those which are aberrantly expressed.
1.4 Ovarian Cancer
With approximately 22,400 new cases each year, ovarian cancer is ranked the 17th most
common cancer for women within the United States.(64, 65) Unfortunately, however, most of the
patients who get diagnosed are already at the late stages of the disease progression where the cancer
has already spread from the primary site of origination.(64, 66) For these patients, the survival
rate is considerably lower. As a whole, ovarian cancer has a cure rate of approximately 30%.
Ovarian cancer originates from three distinct areas: the ovary epithelium, fallopian tube
epithelium, as well as the surface of the peritoneum.(64, 67) Once a tumor is established, it has a
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fast disease progression with metastatic sites preferentially occurring within the peritoneum of the
abdominal cavity. When theses metastatic sites take hold, they can choke off vital organs.(64)
Standard treatment for ovarian cancers include tumor debulking, a full oophorectomy, and a
combinational treatment regimen of a platinum agent (e.g. carboplatin) and a taxane agent (e.g.
paclitaxel). (68, 69)
There are a few mutations that are common for ovarian cancer patients. It was estimated
by Endocyte and the American Cancer Society (ACS) that more than 85% of ovarian cancer
patients show a significant up-regulation of FRα.(70, 71) Additionally, as the histological grade of
the cancer increases from 1-4, a corresponding trend of increased FRα expression is observed as
well.(33, 71) This over-expression has been utilized by researchers and clinicians to help increase
treatment and imaging efficacy.(72) Two main genetic alterations commonly found in ovarian
cancer are p53 loss and BRCA 1 and 2 mutations.(73-78) Carrying a BRCA 1 or 2 mutation
predisposes patients to ovarian cancer, as it is known for breast cancer. These individuals have a
40-60% chance to develop ovarian cancer.(79) Similarly, more than 80% of ovarian cancer patients
that have serous ovarian carcinomas express a p53 mutation which ultimately loses its
function.(64) These two mutations can create treatment problems as the tumors are likely not to
respond to drugs and give rise to chemoresistant populations. Chapter 6 provides insight into FRα
targeted nanoparticle delivery of siRNA within a clinically relevant orthotopic ovarian cancer
mouse model using single-photon emission computed tomography (SPECT) and bioluminescence
imaging (BLI).
Reoccurring and chemotherapy resistant ovarian cancer is a major hurdle that has not yet
efficiently been addressed. Many ovarian cancer patients fall into either or both categories.
Response rates for second line therapies can be as low as 10-30%.(64) Multiple pathways have
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been cited to give rise to ovarian cancer chemoresistance. One mechanism of resistance is the overexpression of drug efflux pumps such as multi-drug resistance gene 1 (MDR1). (80-82) These
pumps are one of a family of P-glycoprotein pumps that can export the drugs out of the cell before
it can achieve its therapeutic effect.(83, 84) Additionally, anti-apoptotic proteins have been
identified to give rise to ovarian cancer chemoresistance. These proteins, such as BCL-2 and BCLxL, when overexpressed can inhibit efficacy of drugs by decreasing the likelihood of cells to
undergo programmed cell death once treated.(75, 85) Both examples provide significant hurdles
that need to be overcome in order to effectively treat ovarian cancer patients. Overcoming
chemotherapy resistance within ovarian cancer models by interfering with Toll-like receptor 4
signaling via FRα targeting is addressed in Chapter 3.
Toll like receptors plays a vital role in the innate immune system surveillance with the
ability to recognize bacterial pathogens.(86, 87) To date, 11 TLRs have been identified in humans
and namely expressed on various immune cells. The TLR family maintains a conserved
intracellular signaling domain along with a leucine-rich extracellular domain.(87, 88) TLRs are
transmembrane proteins that most commonly signal through a myeloid differentiation factor 88
(MyD88) dependent pathway and promote inflammation and immune response.(89) Toll like
receptor 4 (TLR4) can bind and recognize lipopolysaccharides (LPS) within bacterial cell walls
which, in turn, promotes the production of proinflammatory cytokines such as IL-6, IL-12, and
tumor necrosis factor-α (TNF-α).(88, 90) Several studies have demonstrated that increased
inflammation and cytokine production within a tumor microenvironment can lead to a harsher
microenvironment and promote tumor progression.(91-93) To date, TLR4 has been described to
be involved with immune system surveillance and activation. However, recent studies have
revealed a link of TLR4 activity with the tumor progression and chemotherapy resistance in
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epithelial ovarian cancers (EOC).(88-90, 94) This link is driven by two factors: the first one being
the expression of TLR4 and MyD88 dependent signaling in EOC, and secondly, PTX being
identified as a TLR4 ligand. Subsequently, TLR4 activity through the MyD88 signaling cascade
plays a role in EOC PTX chemotherapy resistance.(88, 90, 94) Therefore, it remains a promising
target for therapeutically overcoming PTX chemotherapy resistance.
Current research using nanoparticles is attempting to combat this issue. Chemotherapy
resistance has been more thoroughly studied in breast cancer. Therefore, within Chapter 2, we
explore the major mechanisms that give rise to chemotherapy resistance and how nanomedicine
can be utilized to combat and overcome them.
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CHAPTER 2 – TACKLING BREAST CANCER CHEMORESISTANCE WITH NANOFORMULATED SIRNA

Please note that this chapter has been taken and modified from the published Nature Gene
Therapy review article in 2016. The authors include myself and Dr. Olivia Merkel. I am the first
author on this review article. I performed the literature searches, compiled the literature, and wrote
the review.
S. Jones, OM. Merkel. “siRNA Utilization in Breast Cancer Resistance Treatment” Nature
Gene Therapy. 2016;23(12):821-8.

2.1 Introduction
Breast cancer is the leading cancer diagnosed in women and the second leading cause of
cancer related deaths in women. It is estimated that 1 in 8 women will be diagnosed with breast
cancer in their lifetime and over 40,000 women will die each year due to it (95). Early detection
is key for patients; with a greater than 90% five-year survival rate for patients diagnosed at stages
0, I or II. Approximately 10% of patients present with stages III and IV, where treatment options
are determined on an individual patient basis (96, 97). Neoadjuvent treatment can be used for
localized invasive breast cancer. These include but are not limited to Herceptin (Her2 positive
tumors only); a combination of an anthracycline-based and taxane based chemotherapy; hormone
replacement therapy with an aromatase inhibitor; or inhibitors of the cyclin-dependent kinase
(CDK) 4/6 (98). For advanced breast cancer, traditional chemotherapy and radiation can be used.
However, these patients may never be “cured” after the cancer has spread into distant organs.
Chemotherapy, radiation, bisphosphonates, Herceptin, and other treatments have all been used in
these cases to treat the disease but do not cure it.
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Current limitations to standard chemotherapy in the clinic are extensively researched.
Typical problems with chemotherapy include their systemic treatment, a lack of tumor targeting
and side effects in off-target tissues and organs, insufficient tumor deposition and penetration
which would be necessary to achieve cell killing. Additionally, chemotherapy drugs can be very
hydrophobic and poorly soluble which can limit their possible administration. Lastly, repeated
treatments with the same drugs can give rise to tumors that are comprised of cancer cells which
have become resistant to the drug. This phenomenon is called chemotherapy resistance. Resistance
can arise through several factors; however, the most commonly published resistance mechanisms
are associated with increased translation of anti-apoptotic proteins, such as Bcl-2, and of ATP
binding cassette (ABC) transporters – more specifically, a family member known as pglycoprotein (p-gp) drug efflux pumps (53, 99-101).
Since the discovery of RNA interference (RNAi), or small interfering RNA (siRNA),
researchers have been able to selectively inhibit the expression of proteins within the cell.
Considering that individual proteins have been described to give rise to multi-drug resistance
(MDR) in breast cancer, many researchers have pursued the idea of targeted delivery of siRNA to
combat and overcome chemotherapy resistance in cancer, and specifically in the context of breast
cancer (102, 103). However, delivering siRNA intracellularly and specifically to cancer cells to
knockdown the target gene can be difficult. Non-formulated, “naked” siRNA is easily degradable
by ubiquitous RNases, it is a macromolecule that does not readily cross membranes, and siRNA is
negatively charged and hydrophilic. Ongoing research has been evaluating the encapsulation of
siRNA inside various delivery vehicles, its delivery and targeting to cancer cells in order to knock
down oncogenes, genes associated with cell survival and anti-apoptosis, genes associated with
chemoresistance to resensitize resistant cells, and many others. The reader is referred to several
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excellent reviews which cover the current state of viral, non-viral, lipid, as well as other creative
delivery systems for siRNA therapy (16, 58, 104). Various mechanisms of chemotherapy
resistance and approaches to combat this problem with nanodelivery of siRNA have been
described (105). One important approach is depicted in Figure 2.1, showing how siRNA can be
coencapsulated with a chemotherapy drug to achieve maximum resensitization toward the drugs.
The siRNA delivered can be used to target known pathways which give rise to chemotherapy
resistance such as efflux pumps or anti-apoptotic protein Bcl-2. In this review, we are focusing on
nanoformulation of siRNA for the fight against breast cancer chemoresistance.

Figure 2.1: Combination approach of targeted delivery of siRNA and chemo drugs to the
cytoplasm of a cancer cell to treat chemotherapy resistant breast cancer. By encapsulating both
payloads with one nanoparticle, each drug is deposited inside the cell at the same time to achieve
synergistic cytotoxic effects, e.g. gene silencing of p-gp pumps.
2.2 siRNA Delivery Challenges and Innovative Carriers
Multiple challenges oppose effective siRNA delivery. Due to its negatively charged and
hydrophilic nature and susceptibility to degradation by nucleases, for successful delivery, siRNA
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needs to be packaged inside a carrier in order to mediate its potent effects. Ideally, a carrier needs
to be stable in circulation, have good cellular uptake and endosomal escape profiles, and be
biocompatible and biodegradable, as well as be inherently non-toxic to the healthy cells (105).
With a variety of “smart” vehicles being created and studied, these hurdles can be overcome.
Successful siRNA delivery is reflected by efficient downregulation of specific proteins which give
rise to multidrug resistance using nano-formulated siRNA.
Considering all the hurdles that need to be addressed in order to achieve safe and effective
siRNA therapy, an abundant and wide range of carriers is being studied. Effective siRNA carriers
for breast cancer therapy should have target specificity to the cancer cells which can be achieved
with a targeting ligand to a receptor specifically expressed or overexpressed on the cell surface of
breast cancer cells. Additionally, the final formulations of siRNA-bearing nanocarriers should
have suitable sizes, charge, solubility profiles, encapsulation efficiency, as well as translational
relevance in order to be potential candidates for clinical translation (106, 107). Wua et. al. and
Wong et. al. were able to successfully co-encapsulate doxorubicin and siRNA against p-gp (108,
109). However, Wua et. al. used a folic acid targeting ligand on a PEG-b-(PCL-g-PEI)-b-PCL
triblock copolymers which self-assembled into nanoparticles under 100 nm for delivery to MCF7 cells, while Wong et. al. utilized a polymer-lipid hybrid nanoparticle (PLN) (108, 109). These
dox loaded PLNs had an average size and zeta potential of 290 nm and -23.1 mV, respectively.
The delivery systems of both groups were able to knockdown p-gp while employing a targeted vs.
a non-targeted carrier system with different hydrodynamic diameters and zeta potentials.
Considering that optimal sizes are often reported to be below 260 nm in order to avoid macrophage
detection and phagocytosis, and optimal zeta potentials are described to be slightly positive to have
an inherent interaction with the cell surface (110-113), the PLN characteristics could pose a
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problem for in vivo delivery and efficacy. The use of folic acid on the surface of nanoparticles
offers several benefits. The binding affinity of folic acid to FRα is characterized by an equilibrium
dissociation constant being KD=1 nM (114). This allows for a very strong and specific binding to
the receptor. Coincidently, folate receptor alpha is primarily expressed on the epithelial surface
throughout the body (ex. kidney, choroid plexus, lung) while several cancers show a significant
overexpression of the receptor (29). This allows for folate receptor targeted nanoparticles to
achieve a higher selectivity in cellular uptake along with a higher binding affinity or avidity.
Another example of targeting a receptor on the cell surface was reported by Dou et. al (19). Their
group targeted the HER-2 receptor on breast cancer cells by using positively charged protamine
(F5-P) and attaching an anti-Her2 single-chain antibody fragment on the surface. The Her-2
targeting ligand displayed effective delivery to Her-2 positive cells BT474, but not to Her-2 null
cells MDA-MB-231 (19). Utilizing a targeted approach with a single chain antibody offers the
advantages of having a smaller size, of being cheaper and easier to produce, and the ability to
functionalize in order to increase half-life (115).
Modifications to widely known polymers have been used to increase the efficacy of the
latter or to increase their biocompatibility. Numerous groups have used polyethylene imine (PEI)
as the cationic portion of their respective nanocarriers to condense siRNA for delivery. However,
each group modified PEI differently in order to increase their carrier systems’ biocompatibility.
Navarro et. al. modified PEI with the phospholipid dioleoylphosphatidylethanolamine which
resulted in particles of 127-187 nm in size, along with the ability to co-encapsulate p-gp siRNA
and doxorubicin (116). In attempts to make PEI more biocompatible and to evade detection by the
immune system, a common modification is the PEGylation of PEI. Meng et al. and Essex et. al.
both PEGylated PEI in order to functionalize either a mesoporous silica nanoparticle with PEI-
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PEG, or a DOPE-modified phospholipid PEI, respectively (117, 118). Meng’s silica based
nanoparticle achieved greater than 70% reduction of p-gp mRNA in vivo, as well as decreased off
target cardiotoxicity after systemic doxorubicin treatment. On the other hand, by modifying a low
molecular weight PEI with PEG, Essex et. al. exhibited an increase in circulation half-life of the
nanocarriers which led to a deposition of 8% of the injected dose of siRNA in the tumor (117,
118). Lastly, low molecular weight PEI was designed by Lin et. al. with different alkylation groups
and formed nanocarriers with clustered iron oxide nanoparticles. These nanocarriers were 80-130
nm in size with a zeta potential of +44 mV and were able to be imaged in vivo. Lin’s iron oxide
nanocarriers achieved a 50-60% downregulation of MDR1 in vivo after local administration (119).
Novel delivery devices and polymers have also been engineered and tested. Song et. al.,
for example, developed 270 nm thiolated glycol chitosan nanoparticles for anti-MDR1 siRNA
delivery. Thiolating the nanoparticles helped increase their binding affinity and cross linking to
form nano-complexes. This complex can be intravenously administered and shows 2.7x higher
tumor targeting efficiency compared to non-chitosan-based nanoparticles (102). A unique
approach to increasing doxorubicin’s efficiency in treating triple negative breast cancer is the use
of a layer-by-layer (LbL) nanoparticle film formation by alternately depositing siRNA and polyL-arginine in layers atop a doxorubicin-loaded liposome. These nanoparticles were 120 nm in size
with a zeta potential of -56 mV and could impressively hold 3,500 siRNA molecules per particle.
In addition, the LbL nanoparticles had a circulation half-life of 28 hours, reduced MDR1 levels in
the tumor by 80%, and increased doxorubicin’s cell killing efficacy 4-fold (120). This approach,
along with the Segovia et. al. approach of an oligo-peptide terminated pBAE nanoparticles
embedded within a hydrogel scaffold, can lead to an increased half-life and a controlled release
mechanism of siRNA to achieve a more sustained knockdown (121). Ultimately, several types of
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carriers, ranging from well-established building blocks to novel compounds, have been studied
and have shown promise. With all of the sophisticated carrier systems that have been developed,
there has been a movement away from single payload delivery of siRNA to a co-delivery approach
of multiple payloads to the cancer cell.
2.3 Common Targets to Overcome Resistance
In breast cancer research, several types of proteins are reported to lead to multidrug
resistance. However, the most commonly studied form of MDR is caused by the overexpression
of ABC transporters (122). In total, over 45 ABC transporter genes have been identified (123).
These transporters actively transport various drugs through the plasma membrane and outside the
cell. The most widely studied ABC transporter is ABCB1/MDR-1. Overexpression of MDR-1
can lead to an increase in the cells’ resistance to certain drugs that are substrates to this efflux
pump. The substrates for MDR-1 include, but are not limited to, generic chemotherapeutic agents
such as anthracyclines, taxanes, and vinca alkaloids (109). However, even newer cancer drugs
such as Gleevec (imatinib) can be a substrate (123). Numerous research groups around the globe
have extensively studied the role of MDR1 in breast cancer (83, 103, 124, 125). Many of these
groups have shown the effectiveness of inhibiting the overexpression of MDR1 with siRNA in
order to resensitize breast cancer cells to various chemotherapeutic substrates of the protein pump.
Other ABC family member transporters have been linked to giving rise to drug resistance in breast
cancer. As demonstrated by Liang et. al., the inhibition of MRP-1/ABCC1 renders MCF-7 cells
sensitive to doxorubicin (126). Furthermore, breast cancer resistance protein BCRP/ABCG2 was
suppressed with siRNA in order to confer an increase in sensitivity to drugs such as methotrexate,
doxorubicin, flavopiridol, and anthracyclines (127-129).
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Additionally, several prosurvival and anti-apoptotic proteins have been linked to
chemoresistance in breast cancer. Besides drug efflux pumps such as MDR1, prosurvival and antiapoptotic proteins are the second most studied area in the breast cancer resistance field (53).
Survivin, a small anti-apoptotic protein, can cause cells to avoid apoptosis when treated with
paclitaxel. Salzano et. al described that when survivin is downregulated via siRNA treatment,
cells became strongly resensitized to paclitaxel treatment and underwent significant inhibition of
cell growth (130). Similar results were found with doxorubicin by Tang et. al. (51). By the same
token, BCL-2, an anti-apoptotic protooncogene is overexpressed in at least 70% of breast cancers
(131). By silencing more than 85% of BCL-2 expression in MCF-7 cells, Akar et. al. achieved
efficient inhibition of cell growth and increased cell death (131). Other groups such as Li et. al.
have studied NF-ΚB and its role in breast cancer chemoresistance (132). By co-delivering
doxorubicin and siRNA against NF-ΚB, a significant decrease in doxorubicin’s IC50 value was
observed. Specifically, 80% of cells underwent apoptosis, and a greater than 95% positive synergy
between the treatment with doxorubicin and anti-NF-ΚB siRNA was observed (132).
Besides the inhibition of MDR1 and anti-apoptotic proteins with siRNA, numerous other
proteins have been published and linked to MDR within breast cancer. Liu et. al. revealed that
fatty acid synthase (FASN) was overexpressed in breast cancers and gave rise to palmitic acid
production which resulted in a decrease in apoptotic levels. Their work elucidates a potential new
target for siRNA therapy to overcome chemotherapy resistance (133). Additionally, Gouazé et.
al. provided a link to MDR through an overexpression of glucosylceramide synthase (GCS). By
knocking down GCS, MCF7 cells exhibited a restored sensitivity to doxorubicin, vinblastine and
paclitaxel (134). Members of the kinesin family have been linked to chemoresistance by Singel et.
al. Two independent groups have shown that by knocking down the expression of Kif11 and Kif14,
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resistance can be overcome in triple negative breast cancer (135, 136). This increase in kinesin
family member proteins can be considered a potential biomarker for high-risk breast cancer tissue,
according to Singel et. al. (135). Lastly, inhibition of angiogenesis in the context of breast cancer
has been studied by knocking down VEGF with nano-formulated siRNA. Successful inhibition of
VEGF was shown to inhibit the growth of tumor spheroids in vitro, while also showing efficacy
in vivo. When combined with low dose doxorubicin, tumor microvessel density was inhibited,
along with an increase in overall survival (137). Although less studied compared to MDR-1 or
BCL-2, these alternative targets hold promise in the battle to overcome breast cancer resistance.
2.4 Epigenetic Targets
In an approach to better understand the development of chemoresistance, histone
modifying and DNA methylating enzymes, so-called “epigenetic enzymes” have been reported to
play important roles not only in cancer development (138, 139), but also in cancer chemoresistance
(140). Calcagno et al. described that histone hyper acetylation is the reason for upregulation of
ABCG2 in doxorubicin-selected cancer cell lines, including MCF7 breast cancer cells, and
mediates their resistance. The authors employed Oligofectamine, a commercially available
transfection reagent, to deliver siRNA against ABCG2 and observed that a 40-fold decrease in the
ABCG2 levels led to 85% restored sensitivity compared to the parental MCF7 cells (140). But
epigenetic changes can also cause chemoresistance via pathways independent of p-glycoproteins.
As described above, pro-survival signaling can prevent the effectiveness of chemotherapy also.
Accordingly, Almeida et al. reported that NFκB signaling can cause histone modifications which
in turn mediate chemoresistance in head and neck squamous cell carcinoma (HNSCC) via histone
deacetylation. The authors showed that knockdown of IKKα and IKKβ, which represses NFκB,
resulted in induced acetylation of tumor histones and reduced chemoresistance against cisplatin
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(141). Even though this study was conducted in HNSCC cells, similar pathways may be found in
breast cancer cells, as well. In breast cancer, however, other epigenetic changes have already been
described. Mungamuri et al. investigated epigenetic changes that lead to overexpression of Her2/neu, an EGFR family receptor. The authors observed that methylation of H3K4me3 mediates
resistance toward trastuzumab and that silencing of Wdr5 with shRNA, one of the four structural
components of the H3K4 methyltransferase complex, decreased Her-2/neu levels and
chemoresistance (142). shRNA was also used to silence DNA methyltransferase 3b (DNMT3b) in
hypermethylator breast cancer cell lines BT549, and Hs578T and caused sensitization toward
doxorubicin, paclitaxel, and 5-fluorouracil (143). DNMT3b and DNMT1 were also the subject of
other studies that used commercially available transfection reagents to deliver siRNA (144, 145).
However, to our knowledge, so far no studies have been published employing nanoformulated
siRNA to silence epigenetic targets.
2.5 Co-delivery of Payloads and Alternative Approaches
Recent literature has stated that simultaneous delivery of siRNA and a chemotherapeutic
agent yields more synergistic results and more cell killing than separate or stand alone treatment
(53). This technique of encapsulating chemotherapeutic drugs within carriers offers the advantages
of encapsulating poorly soluble drugs, eliminating off target effects caused by harmful organic
solvents needed to dissolve hydrophobic drugs and replacing the use of viscous emulsions.
Encapsulating chemotherapeutic agents within the core of a micelle or liposome allows for the
opportunity to add a targeting ligand to change the delivery profile from systemic non-targeted to
targeted therapy. Additionally, delivering both payloads at the same time ensures that both agents
reach the tumor simultaneously instead of relying on the pharmacokinetic circulation profiles, and
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targeting efficiency of each separate drug. Several groups have used this approach to their
advantage to overcome resistance in breast cancer.
Due to the frequent overexpression of p-gp in breast cancer, several groups have coencapsulated anti-siRNA p-gp with doxorubicin. Examples of this strategy were described by
Wua et al. and Wong et. al. Both groups demonstrate that co-delivery of both payloads can reduce
off target toxicity and resensitize MCF-7 and MDA-435 cell lines (108, 109). Using a different
carrier, Jiang et. al. synthesized a modified RGD (argininine-glycine-aspartic acid) targeted
peptide liposome encapsulating p-gp siRNA and doxorubicin. These liposomes were less than 200
nm in size and ex vivo imaging studies showed the accumulation of siRNA and dox within the
tumors at the same site. Furthermore, co-delivery of these two agents showed significant inhibitory
effects on tumor growth (146). Peptide-based targeting moieties, such as integrin targeting RGD
can bind to their respective receptors throughout the body. Peptides inherently are easy to
synthesize, biocompatible, and smaller than antibodies, and have a wide variety of targeting
receptors (147). A tabulated summary of co-delivery approaches is shown in Table 2.1, adapted
from Gandhi et al. (105). This table depicts various approaches utilizing nanoparticles to co-deliver
a chemotherapeutic drug, along with a nucleic acid based payload in order to treat a variety of
cancers. These results emphasize the potent synergy between co-administration versus single
dosing.
An alternative approach to overcoming resistance is packaging two separate siRNA
sequences for different targets, as well as encapsulating selenium. Zheng et al., prepared layered
double hydroxide (LDH) nanoparticles that were 116 nm in size and were able to selectively
deliver siRNA against p-gp and b-tubulin III. This approach was shown to inhibit cell mitosis,
spindle formation but also induced apoptosis in MCF-7/ADR cells (148). Additionally, other
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groups have described the approach of using two siRNA sequences to silence multiple ABC
transporters in MCF-7 cells. In a study by Li et al., ABCG2 and ABCB1 sequences were
simultaneously delivered inside a pH-sensitive carbonate apatite nanoparticle. The dual targeted
siRNA approach led to an enhanced toxicity (above 45-50% cell killing) when treated with
cisplatin, paclitaxel and doxorubicin. While the single delivery of siRNA did slightly resensitize
the cells, the dual targeted siRNA approach had a greater cytotoxicity (149).

Table 2.1
Co-delivery of siRNA in combination with chemotherapeutic drug and/or nucleic acid based reagent for the
treatment of cancer.
siRNA/
miRNA
siRNA
targeting
BCL2 and
MRP-1
siRNA
targeting
P-gp

Type of
nanocarrier

Cell lines

CIS

Mesoporous
silica
nanoparticle

A549 human
lung
adenocarcinoma

In vivo
model
Murine
A549 lung
cancer
Orthotopic
model

DOX

mesoporous
silica
nanoparticles

MDR KB-V1
human cervical
carcinoma

Drug

DOX/

Targeting

Targeting
moiety

Ref.

Active

LHRH
peptide

(13)

–

Passive

–

(62)

MCF-7/MDR—
breast cancer

Murine
MCF7/MDR
breast
cancer
Xenograft
model

Passive

–

(27)

siRNA
targeting
P-gp

DOX

PEI-PEG
functionalized
mesoporous
silica
nanoparticles

siRNA
targeting
mTERT

PTX

HTCC
nanoparticles

LLC—lewis
lung carcinoma

–

Passive

–

(63)

DOX

G(4)PAMAMPEG-DOPE
dendrimers

C166 cells—
yolk sac
endothelial

–

Passive

–

(64)

siRNA
targeting
GFP
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siRNA
targeting
Luc gene

siRNA
targeting
BCL-2

DOX

Docetax
el

(G3) poly (llysine) OAS
dendrimer

PEG-PLLPLLeu
cationic
micelles

U-87
glioblastoma

Active

RGD
peptide

–

(13)

–

Murine
MCF-7
breast
cancer
Xenograft
model

Passive

–

(65)

Passive

–

(13)

SAHA

TLO cationic
liposomes

KB epithelial
cancer

Murine KB
epithelial
cancer
Xenograft
model

PTX

PDMAEMA–
PCL–
PDMAEMA
cationic
micelles

PC-3 human
prostate cancer
and MDA-MB435-GFP breast
cancer

–

Passive

–

(66)

MDR NCI/ADRRES ovarian
tumor

Murine
NCI/ADRRES ovarian
cancer
xenograft
model

Passive

–

(67)

DOX

LiposomepolycationDNA
nanoparticles

HT-1080
fibrosarcoma

Murine HT1080
fibrosarcom
a xenograft
model

Active

PEGylate
d NGR
(aspargine
-glycinearginine)

(68)

siRNA
targeting
BCL2 and
MRP-1

DOX

DOTAP
cationic lipid
nanoparticles

MDR lung
cancerMDR
A2780/AD
ovarian cancer

–

Passive

–

(13)

siRNA
targeting
MCl-1

MEK
inhibito
r
PD0325
90

Cationic
liposomes

KB epithelial
cancer

Murine KB
epithelial
cancer
xenograft
model

Passive

–

(69)

CIS

PEI complexes

–

Passive

–

(13)

siRNA
targeting
MCL-1
and GL2

siRNA
targeting
VEGF

siRNA
targeting
VEGF and
c-Myc

siRNA
targeting cMyc

siRNA
targeting

DOX

Lipid
polycation
DNA
nanoparticles

Murine
A549
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VEGFR
and EGFR

siRNA
targeting X
linked
inhibitor of
apoptosis

siRNA
targeting
BCL-2

siRNA
targeting
P-gp

siRNA
targeting
MCL-1

siRNA
targeting
Plk1

siRNA
targeting
BCl-2

iMdr-1shRNA
iSurvivinshRNA

NSCLC
xenograft
model

PTX

DOX

PTX

PTX

PTX

S-1

DOX

Deoxycholic
acid-PEI
complexes

Cationic PEIPCl
nanoparticles

PLGA-PEI
nanoparticles

Cationic solid
lipid
nanoparticles

PEG-b-PCL-bPPEEA
micelleplex

Lipoplexes

Poly (b-amino
esters) based
nanoparticles

HCT-116
colorectal cancer

Murine
HCT-116
xenograft
model

Passive

–

(70)

C6 Glioma Bel7402 human
hepatoma

Murine C6
glioma
xenograft
model

Active

Folic acid

(71)

JC mouse
mammary cancer

Murine
BALB/c JC
breast
cancer
xenograft
model

Active

Biotin

(72)

KB epithelial
cancer

Murine KB
epithelial
cancer
xenograft
model

Passive

–

(73)

MDA-MB-435
breast cancer

Murine
MDA-MB435 s breast
cancer
xenograft
model

Passive

–

(74)

DLD-1
colorectal
adenocarcinoma

Murine
DLD-1
colorectal
adenocarcin
oma
xenograft
model

Passive

–

(75)

Passive

–

(42)

MCF-7 human
breast
adenocarcinoma

Murine
BALB/c
MDR MCF7 breast
adenocarcin
oma

27
xenograft
model

siRNA
targeting
HMD2<co
mma>cMyc

siRNA
targeting cMyc and
MDM2

VEGF
siRNA

VEGFR
mir-24a

Lipid coated
calcium
nanoparticles

Liposomepolycationhyaluronic
acid

A549
adenocarcinoma
and H460 lung
carcinoma

Murine
A549 and
H460
NSCLC
xenograft
model

Passive

–

(76)

–

Murine
B16F10
melanoma
xenograft
model

Active

scFv

(77)

2.6 Animal Models
In order to move the various delivery systems, siRNA targets, and disease states closer to
the clinic, numerous animal models have been employed to investigate overcoming multidrug
resistance in a more complex in vivo setting. For the past four decades, several previous models
have been utilized in vivo for breast cancer research (102, 108, 121). Current breast cancer models
which are applied can be spontaneously forming tumors, mainly in larger animals, genetically
modified models, and xenografts. Additionally, all of the various subtypes of breast cancer such
as triple negative, invasive ductle carcinoma or inflammatory breast cancer are studied. However,
new models needed to be developed in order to specifically analyze the re-sensitization of
chemotherapy resistant cells in laboratory animals, mainly in mice.
Numerous research groups have created isogenic cell lines that are sensitive and resistant
to various chemotherapeutic agents. Montazeri et al. used a xenograft nu/nu nude mouse model
with MDA435 sensitive and resistance cells injected subcutaneously into the right flank of the
mice (150). This model, along with the authors’ work delivering VEGF siRNA and doxorubicin
to mice, helped elucidate a decrease in tumor blood vessels which allowed for an increase in life
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span of the tumor bearing mice. Commonly, MCF-7 cells are used in breast cancer in vivo
xenograft models due to being extensively researched, being easily available, and for having
resistance to commonly used agents such as doxorubicin. A multitude of independent groups have
all utilized MCF-7 cells to study chemotherapy resistance and demonstrate their treatments
efficacy on overcoming MDR in vivo (102, 119, 137, 151, 152). Similarly, triple negative breast
cancer cell lines such as MDA-MB-231 and MDA-MB-468 can be injected into immunesuppressed mice in order to study the response of triple negative breast cancer to siRNA therapy
(107, 153-155). Besides varying cell lines in order to study a wide variety of breast cancer
subtypes, different injection sites have been described. While the most common injection site for
studies employing nano-formulated siRNA to tackle chemoresistance in breast cancer is the
subcutaneous area at the flank (102, 150, 154), other models mimic metastases in the axilla region
(137, 152), or primary orthotopic tumors in the mammary fat pad of the mice (107, 119, 153). So
far, no spontaneous tumors or genetic models have been used for siRNA delivery to breast cancer
in the fight against chemoresistance. The lack of more relevant models may explain the large
amount of pre-clinical but the very small amount of clinical studies.
2.7 Clinical Trials of siRNA Utilized in Breast Cancer Treatment
Since the discovery of siRNA, researchers have been trying to transition this technology to
the clinic. Advances have been made since the discovery of the RNAi mechanism, however, the
transition into clinical trials and into the clinic has remained challenging. There have only been a
handful of RNAi based clinical trials translated into the clinic for treatment of solid tumors, and
hardly any for breast cancer. In 2008, Calando Pharmaceuticals started a clinical trial with their
drug CALAA-01 for solid tumors, including breast cancer (24). Their study used a transferrin
targeted cyclodextrin-containing polymer which carried an anti-R2 siRNA sequence. Transferrin-
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targeting utilizes a recycling pathway involving a clatherin-coated pits method of internalizataion
which can be exploited to help delivery payloads into the cell while also achieving a tumor
targeting approach. Several cancers such as breast, pancreas, colon, lung, and bladder have
demonstrated an increased expression of transferrin receptors, including several drug resistant
tumors (24). This transferrin-targeted clinic trial was performed to study the safety and tolerability
of a nanoparticle and siRNA based injection in patients and has been subsequently terminated due
to not meeting their primary or secondary outcome measures (156). Lately, M.D. Anderson Cancer
Center has been recruiting participants for their EphA2 gene targeting study using a liposomal
siRNA delivery agent. This study also assesses the safety of their liposomal formulation. Data such
as dose-limiting toxicity and hematologic toxicity are being recorded (157). On the other hand,
ever since the discovery of ABC transporters, such as MDR1, several clinical trial studies have
investigated inhibitors of ABC transporters. These clinical trials range from the early 1990s until
recently. Although these trials do not include siRNA, but rather small-molecule inhibitors of the
transporter pumps, they have been studied in several cancers, including breast cancer, and have
been shown to increase overall survival in patients (100). The knowledge obtained through these
clinical trials could in fact be a promising basis for subsequent trials with siRNA for the inhibition
of ABC transporters. Overall, siRNA based therapies have not yet reached the clinic, but with
further development of multiple targets, sophisticated delivery systems, and combination
treatments, hopefully a breakthrough can be achieved.
2.8 Conclusion and Outlook
Resistance to chemotherapy is a challenging obstacle that needs to be addressed and
overcome in the clinic. One mechanism that has been used to resensitize cells has been targeted
delivery of siRNA. Since the discovery of RNA interference, researchers have been trying to
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exploit its benefits in order to provide therapeutic gene knockdown of target proteins. This
approach yields several advantages, especially in combination with standard chemotherapy. For
years it has been known that several proteins (namely ABC transporters and anti-apoptotic factors)
are over-expressed in breast cancer leading to resistance toward chemotherapy drugs such as
doxorubicin or paclitaxel. Effective siRNA delivery can selectively knock down the overexpression of such proteins, thus resensitizing the cells to treatment. While this review touched
heavily upon resistant mechanisms derived from MDR expression, anti-apoptotic factors,
angiogenesis, and epigenetic factors, there are a variety of alternative pathways and factors that
can give rise to multidrug resistance. Due to the scope of this review, those factors such as tumor
microenvironment mediated drug resistance will not be addressed in this chapter. However, in
order to effectively deliver siRNA, a carrier needs to be used. One of the major advantages is that
these carriers can encapsulate multiple payloads for a combination treatment. It has been shown
that combination treatment of drugs such as doxorubicin and siRNA have a greater therapeutic
efficacy than the delivery of single agents. This approach has shown significant promise both in
vitro and in vivo. Albeit multiple studies have been shown to achieve significant therapeutic
efficacy with nanoformulated siRNA therapies, there are hurdles that need to be addressed in the
future. For a more in depth analysis on the toxicity and off target effects of siRNA and
nanoparticles, the authors refer the reader to several in depth reviews on the matter (158-161).
The transition of siRNA therapy into the clinic has yet to be achieved. Only a handful of
clinical trials have used siRNA, and only a small fraction included breast cancer patients. It is
expected that with newer targeted delivery agents, the most common hurdles for specific and
efficient siRNA delivery can be overcome. If successful, siRNA treatment has a promising future
in the clinic, especially for chemoresistant breast cancer patients.
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CHAPTER 3 – FOLATE RECEPTOR TARGETED DELIVERY OF SIRNA AND
PACLITAXEL TO OVARIAN CANCER CELLS VIA FOLATE CONJUGATED
TRIBLOCK CO-POLYMER TO OVERCOME TLR4 DRIVEN CHEMOTHERAPY
RESISTANCE

Please note that the entirety of this chapter has been published as a research article in
Biomacromolecules in 2015. The Authors include myself, Vincent Lizzio, and Olivia Merkel.
Within this publication, I designed and executed the experiments, as well as wrote the chapter.
S. Jones, V. Lizzio, OM. Merkel. “Folate Receptor Targeted Delivery of siRNA and Paclitaxel to
Ovarian Cancer Cells via Folate Conjugated Triblock Co-polymer to Overcome Chemotherapy
Resistance”. Biomacromolecules 2015, doi: 10.1021/acs.biomac.5b01189.

3.1 Introduction
While healthy tissues outside of the kidneys, choroid plexus, lung generally do not express
an abundance of folate receptor-α (FR-α) exposed to the bloodstream, several cancers have been
found to significantly over express FR-α which are. Most notable, in approximately 85-90% of
ovarian cancers, there is an over expression of FR-α with an increasing expression as the
histological grade of the cancer increases.(69, 70, 162, 163) Outside of a full oophorectomy for
early stage patients, treatments for late stage ovarian cancer includes radiation and a combination
of platinum and taxane chemotherapeutic agents. Often times, late stage ovarian cancer patients
experience a reoccurrence of their disease where resistance to first line treatment is seen.(164) To
overcome challenges seen within the clinic, such as chemotherapy resistance, relapse of the
disease, and off target toxicity, we are taking advantage of the over-expressed FR-α commonly
observed in ovarian cancer patients by using folate receptor-targeted nanoparticles. Targeted
nanoparticle delivery, formulated and designed specifically for enhanced tumor targeting and
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uptake tackling chemoresistance could therefore become a novel approach for treating
chemotherapy refractory ovarian cancer.
A new theory to treating cancer eventually within the clinic is the use of nanoparticles to
deliver a targeted payload to the tumor, while decreasing uptake of the drug inside healthy tissues.
Both Doxil and Abraxane are nanopartcles that are currently being used within the clinic to treat
cancer.(68, 165) However, both of these nanoparticle formulations solely rely upon the enhanced
permeation and retention effect (EPR effect) to passively target the tumor by means of
extravasation out of the tumor’s leaky blood vasculature.(14, 166) A targeted delivery, such as
demonstrated within this dissertation, can be achieved by attaching a targeting ligand to the surface
of the nanoparticle to increase its interaction with the tumor cell.(26, 167-169) The folate receptor
is an excellent receptor to target tumors due to its nature of receptor-ligand interaction. FR-α is
an internalizing transmembrane receptor which will endocytose once folic acid, its ligand, binds,
and the receptor-ligand complex is internalized. The ligand, and anything conjugated to it is
subsequently deposited into the cytoplasm, while the receptor is recycled back to the cell
surface.(170-172)

This provides a selective gate to deliver chemotherapeutics, but also

macromolecules such as therapeutic RNA (siRNA) can be delivered into the cytoplasm of the cell
where they can achieve their effect.(170) In order to overcome the hurdles commonly seen with
ovarian cancer treatment, such as relapse and resistance, a wide variety of combinational therapies
that include siRNA are currently being studied.(74, 173-178) However, our own approach
incorporates targeted delivery of siRNA to ovarian cancer cells for therapeutic knock down of
specific oncogenes that give rise to chemotherapy resistance, such as TLR4.(88, 90, 94, 179) We
hypothesize that knock down of these proteins re-sensitizes ovarian cancer cells toward first-line
chemotherapeutic agents. Our results show that folate-decorated nanoparticles can effectively
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deliver siRNA into the cancer cells and achieve a drastic and sustained knockdown of TLR4. Our
approach of using a tri-block copolymer that consists of polyethyleneimine-graftpolycaprolactone-block-poly(ethylene

glycol),

or

folate-coupled

PEI-g-PCL-b-PEG-Fol,

overcomes typical obstacles of siRNA delivery, such as rapid clearance and degradation in
circulation. PEI-g-PCL-b-PEG polymers have been shown to form stable micelles with siRNA
that exhibit enhanced circulation time, and folate coupled PEI-g-PCL-b-PEG-Fol conjugates have
been reported to transfect receptor overexpressing cells in a targeted manner.(59, 180-186) Within
the polymer, PEI electro-statically condenses and shields the siRNA from degradation by
nucleases, while the conjugated folic acid ligand on the particle surface provides specificity
towards cells that over-express FR. In addition, the PCL block increases the hydrophobic content
of the nanoparticle, which forms the inner core of the micelle where paclitaxel (PTX) can be
encapsulated for combination therapy with the same particle.(180) Lastly, the addition of PEG
increases the biocompatibility and acts as a stealth mechanism to avoid macrophage detection of
the nanoparticles.(184) Collectively, these four components are hypothesized to effectively
encapsulate their payload and yield a targeted delivery to the cancer cells of interest.
Altogether, our strategy within this project is to create an effective, targeted siRNA therapy
to meet the following goals: 1) develop a biocompatible folate-decorated nanoparticle which can
deliver siRNA in a targeted fashion to ovarian cancer cells that over-express FR-α; 2) achieve a
targeted tumor uptake and specificity; 3) accomplish improved pharmacokinetic parameters such
as bioavailability and prolonged circulation; and 4) overcome the barrier of chemotherapy
resistance. In response to the aforementioned strategy, we hypothesize that by effectively
delivering siRNA against TLR4 with our folate conjugated tri-block co-polymer to ovarian cancer
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cells, we can achieve a targeted therapeutic effect in FR-overexpressing cells, decrease off-target
toxicity, and overcome chemotherapy resistance in combination with PTX.
3.2 Materials and Methods
3.2.1 Reagents
Hetero-bifunctional poly(ethylene glycol) (HO-PEG-COOH, 3.5 and 5 kDa), as well as
monofunctional poly(ethylene glycol) (CH3-PEG-COOH, 5 kDa) was purchased from JenKem
Technologies (Plano, TX, USA). Hyper branched polyethylenimine (hyPEI, 25k Da) was obtained
from BASF (Ludwigshafen, Germany). All other regents for synthesis were obtained from SigmaAldrich (St. Louis, MO, USA) and used without further modification. Dicer substrate doublestranded siRNA (DsiRNA) targeting the Enhanced Green Fluorescent Protein gene (EGFP siRNA,
25/27), siRNA for Toll-Like Receptor 4 (TLR4), and a scrambled nonspecific control (siNegCon)
DsiRNA as well as Alexa Fluor-488 and TYE-563 labeled siRNA, were purchased from Integrated
DNA Technologies (IDT, Coralville, IA, USA). Dulbecco’s Modified Eagle’s Medium (10x)
without folic acid, Dulbecco’s phosphate buffered saline (PBS), heat-inactivated fetal bovine
serum (FBS), D-(+)-glucose, sodium bicarbonate, sodium pyruvate, 2-mercaptoethanol, dimethyl
sulfoxide (DMSO, ≥99.7%), ethylenediaminetetraacetic acid (EDTA, 99.4−100.06%), trypan blue
(0.4%, sterile filtered), and luciferin were purchased from Sigma-Aldrich (St. Louis, MO, USA).
3.2.2 Synthesis of Tri-block Copolymers and Characterization
The overall reaction scheme, adjusted from Liu et al, (187) can be found in Supplementary
Scheme 1. The tri-block copolymers were synthesized by a six step reaction process consisting of
coupling an azido functionalized folic acid (molecule A) with a heterobifunctional acrylate-PCLb-PEG-alkyne (molecule B) via click chemistry reaction. This was followed by coupling the
previous product of acrylate-PCL-b-PEG-Fol (molecule C) with hy-PEI (25 kDa), as previously
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described.(187) A total of six different conjugates were synthesized consisting of two different
PEG lengths (3.5 kDa or 5 kDa), varying grafting densities of PCL-b-PEG-Fol (10 µmol or 30
µmol per 10 µmol of PEI), as well as one null folate conjugate (Table 1). Compounds synthesized
were characterized by 1H NMR, UV spectroscopy, and a folate composition assay.
3.2.3 Folate Composition Assay
A UV spectroscopy assay was used for determining the folic acid concentration within
each sample. Each sample was read in triplicates on a Synergy 2 microplate reader (BioTek
Instruments, Winooski, VT, USA). Folic acid standards were dissolved in DMSO at a
concentration of 2, 1, 0.5, 0.25, 0.125 and 0 mg/mL. Conjugates were weighed out and dissolved
in water. Afterwards, 100 µL of each sample was added to a 96 transparent well plate and read at
360 nm. Blank values of DMSO and water were used to eliminate any background signal. Results
were analyzed by Graphpad Prism 5.0 and are displayed as mean values.
3.2.4 Cell Culture
SKOV-3 cells are a human ovarian cancer cell line and were obtained from ATCC (LG
Promochem, Wesel, Germany). The SKOV-3/LUC cell line was transfected to stably express the
reporter gene luciferase as described before.(188) SKOV-3 ovarian cancer cells were cultured in
folate-free DMEM cell culture medium (Sigma-Aldrich) supplemented with 0.584 gm/L of Lglutamine, 3.7 gm/L sodium bicarbonate, 10% fetal bovine serum (Thermo Scientific Hyclone),
and 1% penicillin/streptomycin. Cells were grown in 75 cm2 cell culture flasks (Thermo Scientific)
at 37 °C and 5% CO2 and passaged every 2-3 days when they had reached confluency.
A549 cells are a human adenocarcinoma alveolar based lung cancer cell line and were
obtained from ATCC (LG Promochem, Wesel, Germany). A549 lung adenocarcinoma cells were
cultured in DMEM cell culture medium (Sigma-Aldrich) and supplemented with 10% fetal bovine
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serum and 1% penicillin/streptomycin. Cells were grown in 75 cm2 cell culture flasks at 37 °C and
5% CO2 and passaged twice a week when they reached confluency.
3.2.5 Preparation of PEI-g-PCL-b-PEG-Fol Micelleplexes
Each polymer was dissolved in water to yield a 1 mg/mL concentration based upon the PEI
25 kDa content. Once dissolved, samples were filtered through a 0.22 μm filter for sterilization. In
order to prepare the micelleplexes, a specific ratio between the amine groups found within the
polymer (N) and the phosphate groups of the siRNA (P) was chosen. The N/P ratios were
calculated based upon the formula seen below:
m (polymer) = n(siRNA) x 52 x MW (protonable units) x N/P ratio
In the equation listed above, m refers to the mass of the polymer needed, n refers to the amount of
siRNA used per well, 52 represents the amount of phosphate groups within one 25/27 nucleotide
siRNA molecule, the MW represents the molecular weight of the protonable unit found within the
polymer (43.1 g/mol for hy-PEI), and the N/P is the desired ratio between amine groups on the
polymer and phosphate groups on the siRNA.
3.2.6 SYBR Gold and Heparin Assays
The SYBR gold assay was used to assess the ability of each conjugate to successfully
condense siRNA at varying N/P ratios (0-20). SYBR Gold is a fluorescent dye that intercalates
with uncomplexed double-stranded nucleic acids and experiences a more than 1000-fold
fluorescence enhancement upon intercalation. However, once siRNA is condensed within the
micelleplex, the dye can no longer intercalate and exhibits very weak fluorescence. All conjugates
were tested against hy-PEI (25 kDa) as a positive control. At varying N/P ratios (0-20), 50 μL of
polymer dilution and 50 μL of 1 µM EGFP siRNA were added to each well in a total of 100 μL of
a 5% glucose solution. Once mixed, solutions were incubated for 20 minutes at room temperature.
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Afterwards, 30 μL of a 4x SYBR Gold solution (Life Technologies, Carlsbad, CA, USA) were
added to each well and incubated in the dark for 10 minutes at room temperature. Samples were
measured in triplicates for fluorescence at 495 nm (excitation) and 537 nm (emission) on a Synergy
2 microplate reader (BioTek Instruments, Winooski, VT, USA). Samples were normalized based
upon the following criteria. The fluorescence level of 100 percent free siRNA was calculated based
upon the fluorescence of free siRNA, non-condensed, with SYBR Gold dye. The fluorescence of
zero percent free siRNA was calculated with SYBR Gold dye in glucose solution only at the
absence of siRNA. Results were analyzed by Graphpad Prism 5.0 and are displayed as mean values
and standard deviation.
Similarly, heparin assays were used to determine the stability of the micelleplexes the
conjugates formed at a physiologically relevant pH (7.4), as well as at a lower pH to resemble the
late endosome (4.5). The lowest N/P ratios which showed full condensation for each polymer (N/P
5) were used for testing the stability against increasing amounts of heparin (0-1.0 I.U.). The
samples at pH 7.4 were made in 5% glucose solution while the samples measured at pH 4.5 were
made in sodium acetate buffer. Samples were prepared as described for the SYBR Gold assay with
the exception of adding 10 μL of Heparin solution at various concentrations (0-1 international unit
(IU) per well). Samples were incubated for varying time points (30 min-4 hours) at room
temperature. Afterwards, fluorescence was measured in triplicates at 495 nm (excitation) and 537
nm (emission) on a Synergy 2 microplate reader (BioTek Instruments, Winooski, VT, USA).
Results of the heparin assays were analyzed as described for the SYBR Gold assays.
3.2.7 Hydrodynamic Diameter and Zeta (ζ) Potential Measurements
Measurements of the hydrodynamic diameters of micelleplexes were performed by
dynamic light scattering (DLS) using a Zetasizer Nano

ZS

(Malvern

Instruments

Inc.,
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Malvern, UK). Micelleplexes were made as described above and measured at N/P 5, 6, and 7,
complexing 40 pmol of scrambled siRNA. Samples were diluted with 5% glucose to a total
volume of 75 μL within a disposable cuvette. Each sample was read in triplicates with each run
consisting of 15 scans. Results are represented as average size (nm) ± standard deviation. The
samples were then diluted with 5% glucose to 800 μL, and transferred to disposable capillary cells,
and ζ-potential measurements were taken. ζ-potential measurements were read in triplicates by
laser Doppler anemometry (LDA), with each run consisting of 30 scans. Results are shown in mV
± standard deviation.
3.2.8 Transmission Electron Microscopy (TEM)
Transmission Electron Microscopy (TEM) was used in order to assess the size and
morphology of the micelleplexes after siRNA condensation. For TEM analysis, micelleplexes
were made, as described above, in a total volume of 20 μL of 5% glucose containing 20 pmol of
siRNA. Samples were added dropwise to a copper-coated grid, air dried and imaged with a
transmission electron microscope (JEOL 2010 TEM, JEOL, Tokyo, Japan).
3.2.9 Cellular Uptake of Micelleplexes by Flow Cytometry
In 24-well plates (Corning Incorporated, Corning, NY) 60,000 SKOV-3 cells were seeded
and incubated overnight at 37 °C and 5% CO2. In each experiment, freshly made micelleplexes
containing 50 pmol of AF488 siRNA at varying N/P ratios were added per well. Negative controls
consisted of blank/untreated cells, and cells treated with free siRNA. Positive control cells were
transfected with Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) following standard
protocol. Unless otherwise stated, cells were transfected for 4 hours in 37 °C and 5% CO2 with
50 μL of micelleplex solution containing 50 pmol siRNA within a total volume of 500 μL of serum
containing cell culture media. In order to quench any extracellular fluorescence, the cells were
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incubated with 100 μL of 0.4% Trypan Blue (Fisher Scientific). Results were compared between
cells treated with and without Trypan Blue in order to gain insight into each polymer’s uptake
profile. Cells were then washed twice with 1X PBS + 2 mM EDTA, trypsinized and spun down at
350 g for 5 min. After centrifugation, the supernatant was decanted, and the cells were washed
twice with 1X PBS + 2 mM EDTA. Samples were analyzed via flow cytometry (Applied
Biosystems Attune Acoustic Focusing Cytometer), and the Median Fluorescence Intensity (MFI)
was collected and recorded. Samples were run in triplicates, with each sample consisting of a
minimum of 10,000 viable cells. The siRNA was excited at 488 nm, and emission detected using
a 530/30 band-pass filter set. Analysis and presentation of the data were performed by GraphPad
Prism 5.0 software calculating mean values and standard deviations.
3.2.10 Monensin Assay
To determine the extent of siRNA being trapped within the endosome, a monensin assay
was utilized with flow cytometry. In 24-well plates 60,000 SKOV-3 cells were seeded and
incubated overnight at 37 °C and 5% CO2. Freshly made micelleplexes containing 50 pmol of
AF488 siRNA were added per well. Negative controls consisted of blank/untreated cells. Cells
were transfected for 24 hours in 37 °C and 5% CO2 with 50 μL of micelleplex solution containing
50 pmol siRNA within a total volume of 500 μL of serum containing cell culture media. In order
to quench any extracellular fluorescence, certain cells were incubated with 100 μL of 0.4% Trypan
Blue while others were treated with monensin. Results were compared between cells treated with
and without Trypan Blue and monensin in order to gain insight into each polymer’s uptake profile.
Cells were then washed twice with 1X PBS + 2 mM EDTA, trypsinized and spun down at 350 g
for 5 min. After centrifugation, the supernatant was decanted, and the cells were washed once
with 1X PBS + 2 mM EDTA and incubated at 4 ˚C for 30 minutes with 50 µM monensin.
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Afterwards, cells were washed once with 1X PBS + 2 mM EDTA and were analyzed via flow
cytometry; the Median Fluorescence Intensity (MFI) was collected and recorded for each sample.
Samples were run in triplicates, with each sample consisting of a minimum of 10,000 viable cells.
The siRNA was excited at 488 nm, and emission detected using a 530/30 band-pass filter set.
Analysis and presentation of the data were performed by GraphPad Prism 5.0 software calculating
mean values and standard deviations.
3.2.11 Confocal Scanning Laser Microscopy
SKOV-3 cells were seeded in a Permanox 8 chamber slide (Nunc, Fisher Scientific,
Waltham, MA, USA) at a density of 25,000 cells in a total volume of 300 μL and allowed to
incubate over-night in 37 °C and 5% CO2. Micelleplexes were made as described above using 40
pmol of labeled siRNA. After incubating the cells with the micelleplexes for 4, 12, or 24 h, the
supernatants were decanted. Following this, the cells were washed with 300 μL of PBS for 2-3
minutes each while shaking. Afterwards, cells were fixed with 4% paraformaldehyde solution in
PBS for 20 minutes at room temperature. This solution was then discarded, and cells were washed
twice with 300 μL of PBS for 2-3 minutes each while shaking. The nucleus was stained with DAPI
at a concentration of 175 ng/mL (Life Technologies, Carlsbad, CA, USA) for 20 minutes at room
temperature while shaking. Cells were then washed twice with 300 μL of PBS. The chambers
were then removed, the slides were blotted to remove any excess wash solution with a Kimwipe,
and 1 drop of Fluorsave (CalBiochem, San Diegeo, CA, USA) was added per coverslip. The
coverslips were mounted and allowed to sit for 1-2 hours in the dark. For excitation of TYE-563,
an excitation wavelength of 570 nm was used while emission was detected with a spectral detector
at 590 nm. DAPI staining was excited with a UV laser that had an excitation wavelength of 364
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nm, and emission was detected at 385 nm. Images were recorded using a Zeiss LSM 780 confocal
microscope and overlaid with brightfield light to gain information about cellular structures.
3.2.12 Protein Knockdown by Western Blot and Luciferase Assay
SKOV-3 and A549 cells were seeded in 6 well plates with a seeding density of 300,000
cells per well and allowed to attach overnight at 37 °C and 5% CO2. For the assessment of TLR4
expression, SKOV-3 and A549 cells were harvested after 24 hours of incubation. For transfection
of SKOV-3 cells, micelleplexes were formed as previously described containing 100 pmol of
TLR4-targeted siRNA. Cells were incubated with micelleplexes for 48 and 72 hours to assess
protein knockdown. Afterwards, they were washed twice with ice cold PBS, followed by a 2
minute incubation in 100 μL of RIPA lysis buffer. The lysis solution was collected, transferred to
a conical tube, and pipetted up and down to ensure complete cell lysis. Cells were incubated on
ice for 30 minutes, followed by sonication and centrifugation at 15,000 g for 20 minutes at 4 °C.
Once centrifuged, the pellet was discarded and samples were analyzed via a Pierce BCA Protein
Assay Kit (Life Technologies, Carlsbad, CA, USA) to determine the protein concentration.
The samples were prepared for loading the 10% polyacrylamide gel by denaturing 30 μg
of protein by adding 1X final concentration loading buffer (4% SDS, 10% 2-mercaptoethanol,
20% glycerol, 0.004% bromophenol blue, and 0.125 M Tris-HC), β-mercaptoethanol, and by
diluting them to 35 μL with a radioimmunoprecipitation assay buffer (RIPA). Samples were added
to a dry heat bath (at 95 °C) for five minutes before loading onto the gel. Once loaded, samples
were run at 110 V for approximately 1-2 hours at room temperature. The gel was then transferred
to a PVDF membrane by running at 0.4 A current for 1 hour at room temperature. In order to keep
the box cold, it was placed on ice. The membrane was then blocked in 5% milk in phosphate
buffered saline containing Tween-20 (PBST) for 1 hour at room temperature followed by overnight
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incubation with 1:1000 diluted primary anti-TLR4 antibody 76B357.1 (Abcam, Cambridge, MA,
USA) at 4 °C. On the next day, the membrane was washed three times for 10 minutes each with
PBST, followed by incubation with a secondary antibody (goat anti mouse IgG-HRP SC-2005
diluted 1:10,000) (Santa Cruz Biotechnology, Dallas, Texas, USA). Samples were incubated at
room temperature for 1 hour. This was lastly followed by another set of three washes of PBST for
10 minutes each. Afterwards, the membrane was imaged using an ImageQuant LAS4000.
Membranes were also probed for β-actin with a mouse monoclonal antibody 3700P (Cell
Signalling Technology, Beverly, Massachusetts, USA) in order to test for proper loading controls.
Protein knockdown was also measured with a luciferase knockdown experiment. SKOV3/LUC cells which have a NF-ΚB binding site on the CMV luciferase promoter were used in this
experiment. In 24 well plates, 60,000 SKOV-3/LUC cells were seeded per well and incubated
overnight at 37 °C and 5% CO2. Micelleplexes were made as described previously with 50 pmol
of TLR4 targeted or scrambled siRNA. Cells were incubated at 37 °C and 5% CO 2 with the
micelleplexes for 24 hours before adding 1000 nM Paclitaxel to each well for an incubation period
of 48 hours. After 48 hours, cells were washed twice with 200 μL of PBS and treated with 300 μL
of lysis buffer (Cell Culture Lysis Reagent, CCLR, Promega, Madison, WI, USA) per well. Each
well was scraped with a pipette to effectively dislodge cell debris on the bottom of the well. The
plate was then rocked for 5 minutes at room temperature. Cell lystates were transferred to conical
tubes and set on ice. Each tube was vortexed for 10-15 seconds and then centrifuged at 12,000 g
for 2 minutes at 4 °C. The supernatant was collected, and 20 μL of each sample was added to a
white 96-well plate to be analyzed for luminescence using a Synergy 2 microplate reader (BioTek
Instruments, Winooski, VT, USA). Each well was injected with 100 μL of luciferase assay reagent
containing 10 mM luciferin (Sigma-Aldrich, St. Louis, MO, USA) by the plate reader immediately
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before the measurement. Samples were measured in triplicates and analyzed using GraphPad
Prism 5.0 software.
3.2.13 MTT Assays
SKOV-3 cells were seeded at a density of 10,000 cells per well in 200 µL of medium in a
96 well plate and incubated overnight at 37 °C and 5% CO2. Lipofectamine and each conjugate
were diluted to varying concentrations from 0-16 µg mL-1 and added to SKOV-3 cells and
incubated for 24 hours at 37 °C and 5% CO2. Upon 24 hours of incubation, 20 µL of a sterile 5
mg/mL MTT solution was added to the cells and incubated for 4 hours at 37 °C and 5% CO2. The
media was then removed and 200 µL of DMSO was added to each well for 10 minutes. The plate’s
absorbance was read at 540 nm using a Synergy 2 microplate reader (BioTek Instruments,
Winooski, VT, USA). The percentage of viable cells was calculated by the ratio of absorbance of
treated cells compared with untreated cells. Samples were measured in triplicates and analyzed
using GraphPad Prism 5.0 software.
For assessment of resensitization of SKOV-3 cells toward PTX, SKOV-3 cells were
transfected with the micelleplex containing 780 nmol TLR4 siRNA within a T-75 flask for 24
hours at 37 °C and 5% CO2 – day 0. On day 1, 6,000 SKOV-3 cells were seeded per well within a
96 well plate for the MTT assay in 200 µL of media. Subsequently on day 2, the cells were treated
with PTX at concentrations ranging from 0-1000 µM for 48 hours in 200 µL of media. Upon 48
hour incubation, on day 5, 20 µL of a sterile 5 mg/mL MTT solution was added to the cells in
serum-free media and incubated for 4 hours at 37 °C and 5% CO2. The media was then removed
and 200 µL of DMSO was added to each well for 10 minutes. The absorbance of each well was
read at 540 nm using a Synergy 2 microplate reader (BioTek Instruments, Winooski, VT, USA).
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Samples were run in triplicate and the data was analyzed with GraphPad Prism 5.0 software for
IC50 values.
3.2.14 Annexin Assays
SKOV-3 cells were seeded at 60,000 cells per well in 24 well plates and incubated
overnight at 37 °C and 5% CO2. Micelleplexes were made as described previously with 50 pmol
of TLR4 targeted or scrambled siRNA. Cells were incubated at 37 °C and 5% CO2 with the
micelleplexes for 24 hours before adding paclitaxel (0-1000 nM). Cells were incubated for another
48 hours. Afterwards, cells were washed with PBS while keeping each supernatant. Cells were
trypsinized for 3-5 minutes, fresh media was added to each well, and the supernatant was added to
each tube. Samples were centrifuged at 350 g for 10 min, and the supernatants were decanted.
According to the Alexa Fluor 488 Annexin V/Dead Cell Apoptosis Kit, 1X Annexin Binding
Buffer was prepared consisting of 10 mM HEPES/NaOH, 140 mM NaCl, and 2.5 mM CaCl 2 at
pH 7.4. Cells were resuspended in 100 μL of 1X Annexin Binding Buffer followed by the addition
of 5 μL of Alexa Flour 488 annexin V and 1 μL of 100 μg/mL of Propidium Iodine (PI). Cells
were incubated at room temperature for 15 minutes and then diluted with 400 μL of 1X binding
buffer. Samples were kept on ice and analyzed by flow cytometry at excitation of 488 nm and
emission at 530 nm. Samples were measured in triplicates and analyzed using GraphPad Prism 5.0
software.
2.2.16 Statistics
All statistical analyses within this dissertation were performed in triplicates. Results are
given as mean values ± standard deviation (SD) values. GraphPad Prism 5.0 software was utilized
to address significance by means of either a one or two-way ANOVA.
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3.3 Results and Discussion
3.3.1 Synthesis of PEI-PCL-b-PEG-Fol Conjugates
The first step in this project was to synthesize several tri-block co-polymers and to
characterize them via several criteria. Two different molecular weight blocks of heterobifunctional PEG chains were used in order to start the synthesis, namely 3.5 kDa and 5 kDa. Both
were heterobifunctional with a hydroxyl and carboxylic acid group at either end. Two different
groups of co-polymers were synthesized with either molecular weight of PEG. Additionally, the
grafting degree of PCL-b-PEG-Fol was varied in terms of two different molar ratios per fixed
amount of PEI, namely equimolar or 3-fold molar excess. One co-polymer was synthesized to bear
10 μmol of the grafted PCL-b-PEG-folate chains per 10 μmol of PEI, and the other one was grafted
with 30 μmol per 10 μmol of PEI. Furthermore, we synthesized a PEI-g-PCL-b-PEG null folate
polymer which had a monofunctional mPEG chain and no folic acid attached, and a mixed
conjugate which had both 3.5 kDa and 5 kDa PEG blocks in the PCL-b-PEG-folate chains.
Interestingly, the feed ratio of PCL-b-PEG-folate chains did not have a significant influence on
the polymers’ final structure. Both equimolar ratios and 3-fold excess yielded in copolymers with
statistically about 5 PCL-b-PEG-folate chains per molecule PEI. It is possible that especially in
the reactions of equimolar ratios a large amount of unreacted PEI or PEI with just one PCL-bPEG-folate chain were present but were lost during the purification of the polymers by
ultrafiltration with a 30 kDa MWCO membrane. A folate concentration assay was performed on
each of the five conjugates which were made with folic acid attached to the PCL-PEG chain. The
average amount of folate was 1.313x10-5 mol folate/mg of polymer. This was similar, and in some
cases higher, than what has been previously reported in the literature.(187) Table 1 describes each
polymer’s composition along with its corresponding and designated name. Diagrams of these
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polymers can be seen in Scheme 1 (Supplementary data). Furthermore, conjugates were
successfully characterized by 1H NMR (D2O) as described before;(187, 189, 190) and the spectra
were as follows: δ (ppm) = 8.6, 8.0, 7.6, 6.8 peaks characterizing the folate terminus; strong singlet
peak at 3.6 (OCH2CH2O); and a broad but weak peak 1.6-1.2 (COCH2CH2CH2CH2CH2O)
(Supplementary Spectrum 1).

Name

PEG Chain

PCL Chain

Hy-PEI

Feed Ratio of

Statistical

Folate

Size (kDa)

Size (kDa)

(kDa)

PCL-b-PEG(-

(final grafting

(mol per mg

folate)

degree)

polymer)

3.5k 10 µmol

3.5

1000

25

10 µmol

5

2.4E-06

3.5k 30 µmol

3.5

1000

25

30 µmol

5.5

3.1E-06

5k 10 µmol

5

1000

25

10 µmol

5

1.2E-05

5k 30 µmol

5

1000

25

30 µmol

4.7

8.9E-06

Mixed

3.5 and 5

1000

25

10 µmol

0.5

3.9E-05

5

1000

25

10 µmol

2.5

0

Conjugate
Null Folate

Table 3.1: All six conjugates synthesized with the proposed scheme.
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Schematic Table 3.2: Schematic representation of all synthesized folate decorated conjugates. Numbers 1-6 are
all screened for siRNA condensation as shown in figure 3.1. Red depicts PCL, while blue and yellow signify PEG and
folic acid, respectively.

3.3.2 siRNA Condensation Ability and Retention
As explained above, our approach utilizes a PEI block to electrostatically condense and
protect the siRNA from nuclease degradation in vitro and in vivo. Therefore, we tested whether
the tri-block co-polymers were still able to effectively condense the siRNA compared to
unmodified, hyperbranched hy-PEI as described previously.(191) In order to do this, SYBR Gold
assays were carried out with each polymer at varying polymer:siRNA (N/P) ratios ranging from
0-20. Figure 3.1 A shows that the grafting of PCL-PEG-Fol did not decrease the co-polymers’
ability to condense the siRNA. In order to mimimize toxic side effects that could result from an
excess of free polymer in the micelleplex suspension, the ideal N/P ratio was defined as the lowest
one which fully condenses the siRNA. The SYBR Gold assays showed the optimal N/P ratios of
all conjugates to be between 5 and 7. Therefore, these N/P ratios were continuously used for all
subsequent experiments.

48

Additionally, the appropriate retention and release of siRNA are critical for effective
delivery. Therefore, heparin assays were utilized in order to mimic release of the siRNA during
circulation (pH 7.4) and in the late endosome (pH 4.5).(183, 192) Heparin is a polyanion and in
the presence of the micelleplexes can be used to mimic competition for the electrostatic binding
with the polymer. It is known that the presence of polyanions in serum can cause premature release
of the siRNA from merely electrostatically self-assembled polyplexes.(193) Each conjugate was
tested at N/P 5 in the presence of increasing amounts of heparin (0-1.0 I.U.). These data, seen in
Figure 3.1 B, demonstrate that the copolymers only released 3-12% of the total siRNA in presence
of the competing poly-anion heparin at pH 7.4, whereas PEI polyplexes released up to 20% siRNA
in the concentration range of heparin tested here. Conversely, micelleplexes need to have good
release profiles at low pH values in order to be released from the polymer to achieve optimal
protein knockdown. Based upon our hypothesis that our micelleplexes are internalized within the
cell by means of folate receptor-mediated endocytosis, the micelleplexes have to escape out of an
endocytic vesicle to deposit the siRNA into the cytoplasm. Thus, the same heparin assay was run
with similar conditions as before, except at pH 4.5 to mimic the pH of the late endosome. Figure
3.1 C demonstrates that all micelleplexes were able to successfully release more than 95% of the
siR2.NA, while unmodified PEI only released about 50%. Collectively, these data indicate that all
six co-polymers would not only be stable in circulation (see release at pH 7.4, Figure 3.1 B), but
could efficiently release siRNA into the cytoplasm upon being endocytosed (see release at pH 4.5,
Figure 3.1 C). Release of siRNA is into the cytoplasm is hypothesized to occur due to the “proton
sponge” effect which results in bursting of the endosome and subsequent siRNA deposition into
the cytoplasm. Evidence for siRNA deposition and action within the cytoplasm is reflected in the
protein knockdown data that is discussed later in this dissertation. Similar assays were performed
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to assess siRNA release over time while in the presence of heparin. It was found that after 30
minutes, the release profiles did not change, but were comparable to the curves in Figure 3.1 C
(Data not shown).
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Figure 3.1 A-C: SYBR Gold assays for each conjugate in comparison to PEI. The conjugates’ abilities to
electrostatically condense siRNA were analyzed from N/P 0-20 (A). Heparin assays at pH 7.4 mimic the pH during in
vivo circulation. Each conjugate was tested at N/P 5 and incubated in the presence of heparin for 30 minutes (B).
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Heparin assays at pH 4.5 mimic the late endosome. Each conjugate was tested at N/P 5 and incubated in the presence
of heparin for 30 minutes (C).

3.3.3 Characterizing nanoparticle morphology, hydrodynamic diameter, and zeta potential
Two important characteristics for nanoparticle delivery are their sizes and zeta potentials.
An effective carrier should form nanoparticles within the nanometer scale with a slightly positive
zeta potential to increase the likelihood of cell binding and consecutive endocytosis.(178, 181,
194-197) Maintaining small sizes of nanoparticles is important for permeation out of the blood
vessels and into the tumor as well as avoiding detection from the host’s natural defense
mechanisms, such as macrophages. In the lung, an optimal size to avoid macrophage detection and
subsequent endocytosis is 260 nm (196, 198). However, optimal sizes of nanoparticles that are
administered intravenously should also be below 260 nm, if not smaller, in order to avoid
macrophage detection and phagocytosis, along with other side effects.(194, 195, 197) Here,
micelleplex formulations with 50 pmol of siRNA at N/P 5, 6, and 7 were characterized by dynamic
light scattering (DLS). As seen in Figure 3.2 A, at N/P 5, the hydrodynamic diameters were all
below 150 nm, and slightly increased as the N/P ratio increased. At the higher N/P ratios, (6 and
7) the hydrodynamic diameters were either at or below 260 nm. The sizes determined here with
DLS measurement are smaller than other folic acid chitosan low molecular weight PEI delivery
systems reported in literature (220-250 nm).(199) Conversely, other previously published folic
acid targeted delivery systems utilizing platinum based nanoparticles have much smaller
hydrodynamic diameters.(200) Collectively, this suggests that our micelleplexes have adequate
sizes to evade the host immune system and easily permeate out of the blood vessel and into the
tumor interstitium and correspond adequately with what is published.
Furthermore, the zeta potentials of the micelleplexes are important for delivery as the cell
membrane carries a slight negative charge. If the micelleplexes are negatively charged, they can
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be electrostatically repelled by the cell membrane, and the siRNA uptake would suffer.
Conversely, with a slight positive charge to the micelleplex, attraction between the cell membrane
and micelleplexes is expected which helps promote binding to the cell membrane and non-specific,
adsorptive uptake. However, a micelleplex that is strongly positively charged can be toxic to the
cells, which is a common problem with polycation delivery vectors for siRNA. Ideally, this
toxicity should be avoided. In case of targeted nanoparticles, a strong positive zeta potential is not
necessary, since uptake is promoted by receptor-mediated endocytosis. A slight positive charge,
however, can be helpful to orient the particles in close proximity of the cell membrane and
receptor. In our experiments, the corresponding zeta potentials for every micelleplex at every N/P
ratio were all positive, and below +20 mV. Although there has not been a reported threshold for
cationic polymers zeta potential in correlation to toxicity, generally the less cationic nanoparticles
are, the fewer cytotoxic effects will be seen within the cell. Most N/P formulations for each
micelleplex were around +8-12 mV; corroborating other nanoparticle formulations which are
published.(201) Figure 3.2 B represent the average zeta potential for each micelleplex containing
siRNA. Cytotoxicity studies were carried out with an MTT assay comparing lipofectamine, a
known toxic transfection reagent, against our conjugates. The MTT assay was carried out at
concentrations at which lipofectamine was used for transfections. However, our conjugates are
used at much lower concentrations and additionally exhibit higher IC50 values, thus suggesting that
there is little toxicity concerns when transfecting with our folate-decorated micelleplexes
(supplementary Figure 3.1). This has been seen in literature with similar PEI-PEG/siRNA
delivery systems.(188) Based upon the data acquired from zeta potential measurements, our
micelleplexes should exhibit a slight attraction to the cell membrane and not be inherently toxic.
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Additionally, TEM was used to validate our findings obtained with dynamic light scattering
in terms of micelleplex sizes. TEM imaging serves to learn more about the size but also the
morphology of our micelleplexes. As presented in Figure 3.2 C-D, the sizes determined by TEM
corroborate extremely well with DLS measurements. In addition, the micelle formation of the inner
core and outer corona is clearly shown. Concluding these results, all conjugates formed
micelleplexes with the siRNA with adequate sizes (100-200 nm) and zeta potentials (+8-12mV).
Based on these data, our micelleplexes contain optimal characteristics to condense siRNA and
allow for interaction with the cellular membrane.

B

A

C

D
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Figure 3.2: Characterizing nanoparticle morphology, size, and zeta potential. Each micelleplex’s hydrodynamic
diameter was tested at N/P 5, 6, and 7 with 50 pmol of siRNA (A). Each micelleplex formulation was then diluted to
measure zeta potentials via LDA (B). TEM images of 5k 30 µmol (C) and mixed conjugate (D) are shown.

3.3.4 Assessing siRNA uptake and targeted delivery
After the appropriate characterizations were performed to assess our micelleplexes’ size,
zeta potentials, and siRNA release/retention profiles, flow cytometry was utilized to perform
siRNA delivery studies. For all siRNA uptake flow cytometry experiments, unless otherwise
stated, Alexa fluor 488 labeled siRNA was used. In order to identify which conjugate worked the
best, all folate decorated micelleplexes were tested against one another, as well as compared with
PEI and lipofectamine. As seen in Figure 3.3 A, comparable results to PEI were obtained, while
slightly less transfection efficiency was seen in comparison to lipofectamine. Although there
seemed to be no statistical difference in the initial screen between all conjugates, we did notice a
trend that the 10 µmol conjugates performed better than their 30 µmol counterparts. Due to this,
the three most promising conjugates appeared to be PEI grafted with 10 μmol of the chains
containing 3.5 kDa PEG (3.5k 10 μmol), PEI grafted with 10 μmol of the chains containing 5 kDa
PEG (5k 10 μmol), and the mixed conjugate. With this small selection, we determined the optimal
N/P ratio for each conjugate’s siRNA delivery. Due to the smaller sizes obtained at N/P 5 and no
difference in uptake with higher N/P ratios, siRNA was formulated with the co-polymers
mentioned at N/P 5, which may also reduce any possible toxicity seen with excess polymer at
increasing N/P ratios (Data not shown). Once delivery conditions were optimal, folate-decorated
conjugates were compared against a null folate conjugate to assess targeted FRα-mediated uptake.
First, a time course analysis was carried out comparing the three best folate-decorated conjugates
and the null-folate conjugate seen in Figure 3.3 B. Each micelleplex was transfected and allowed
to incubate for 24, 48, 72, and 96 hours before harvesting cells for flow cytometry. At each time
point, every folate-decorated conjugate outperformed the null folate polymer in SKOV-3 FRα
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positive cells. This led us to believe that there are two possible mechanisms for uptake of our
micelleplexes. As one possibility, non-receptor mediated, but charge-mediated adsorptive
endocytosis across the cellular membrane could occur due to sedimentation of the micelleplexes
over a period of time and might be promoted by their amphiphilic properties. Secondly, the folate
decorated micellepexes are able to be endocytosed utilizing the folate receptor mediated
endocytosis pathway. With this in mind, we hypothesized that our folate decorated micelleplexes
can take advantage of both mechanisms, thus resulting in a more significant uptake over time.
The next step was to test whether the uptake that was demonstrated in Figure 3.3 B was
folate receptor driven. To answer this question, two experiments were performed. First, we
analyzed the micelleplexes’ siRNA delivery at 37˚ C and 4˚C. When cells are incubated at 4˚C,
the lower temperature inhibits active uptake such as FRα mediated endocytosis, but leaves
receptor-mediated binding or charge-mediated binding to the cell still an available option for cell
associated fluorescence. Figure 3.3 C shows that significant inhibition of active uptake occurs for
SKOV-3 cells incubated with folate decorated micelleplexes at 4˚C in comparison to 37 ˚C.
Conversely, the folate null micelleplexes showed little decrease between the two conditions, thus
suggesting no receptor-mediated but possibly adsorptive endocytosis was inhibited for this
conjugate. Most interestingly, the uptake efficacy of the targeted formulation (3.5k 10 μmol) was
significantly higher than that of the non-targeted micelleplexes (Null folate) if incubated at 37˚ C.
However, if incubated at 4˚ C, the uptake of both formulations was comparable. Additionally,
competitive inhibition of receptor-mediated uptake was analyzed after pre-incubating SKOV-3
cells with an excess of the receptor substrate, free folic acid (FF).
The recycling rates of FRα vary depending upon the tissue and tumor cell line. However,
on average, the in vivo recycling rate is just under 5.7 hours, and recycling of a receptor previously
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blocked with free folic acid renders the former available for binding folate-conjugated
nanoparticles.(202) Therefore, our studies were performed at early time points with or without preincubation of free folic acid to get a better picture of whether the targeted micelleplexes are binding
with FRα.(70, 202) Figure 3.3 D demonstrates that when excess free folic acid was added (20 µg),
there is no significant drop in siRNA uptake for neither the folate decorated micelleplex nor the
non-folate micelleplex. Excess folic acid concentrations were used based upon previous studies
with similar concentrations and findings.(167, 203, 204) Benoit et. al. did not observe any
competitive inhibition in the presence of 10 µg/mL of free folic acid.(167) Conversely, at higher
concentrations, above 1 mM, uptake was inhibited as shown by Arima et. al.(203) Tied into the
fact that a non-specific inhibition was seen across the board with our folate-decorated
micelleplexes, as well as the non-decorated ones at concentrations above 1 mM of free folic acid
per well (data not shown), we have seen a different result of competitive uptake than that reported
by Arima et. al. The lack of competition with low amounts of free folic acid could be due to the
fact that our micelleplexes are multivalent, and thus have a stronger binding avidity to the receptor
when compared to the affinity of a monovalent folic acid to the receptor. Therefore, it is expected
that the folate-decorated micelleplexes will easily out compete folic acid for the folate receptors
binding sites. At higher concentrations of free folic acid, uptake can be inhibited but the observed
inhibition is not necessarily an inhibition of receptor mediated endocytosis.
Taken together, these results imply that uptake of these micelleplexes by means of
diffusion does not explain the difference of targeted vs. non-targeted formulations, while the
folate-decorated micelleplexes are able to utilize FRα-mediated uptake for siRNA delivery if 1)
energy-dependent endocytosis is possible, and 2) the receptor is not blocked by free competing
ligand. These data were further reinforced by confocal microscopy showing significantly more
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siRNA deposition within the cell by the folate-decorated nanoparticles. As seen in Figure 3.4, all
folate-decorated nanoparticles (C-E) were able to effectively delivery siRNA more efficiently than
their null folate counterpart (F). At first glance PEI seemed to deliver a significantly larger amount
of siRNA to the cells. However, the fluorescence may arise from PEI complexes merely bound to
the surface of the cell due to the strong electrostatic interaction and not effectively being
endocytosed into the cell. When analyzed with flow cytometry and using trypan blue to quench
the extracellular fluoresecence, the MFI for PEI drops significantly in comparison to targeted
micelleplexes, indicating that a higher percentage of polyplexes is not internalized but only cellbound. Additionally, PEI/siRNA polyplexes that are taken up into an endosome may not release
siRNA as efficiently into the cytoplasm as the micelleplexes do due to the very strong binding of
the polymer to siRNA (Figure 3.1 C). Taken together, these results appear different from the flow
cytometry data in Figure 3.3 A. Due to CLSM being a different type of measurement revealing
information on spatial siRNA deposition in the cell, it is not surprising that there is a discrepancy
seen here. This could also be attributed to self-quenching of the fluorescently labeled siRNA
molecules when in close proximity to other fluorophores which could be stronger for the Tye-563
dye than observed with Alexa Fluor 488.(205) However, our CLSM data strengthen our previous
observations that folate decorated micelleplexes can utilize a receptor-mediated mode of uptake
while the null folate micelleplexes cannot, thus resulting in greater siRNA delivery ability.
To determine if the micelleplexes are taken up by endocytosis into acidic vesicles, a
monensin assay was performed. Fluorescence was measured after transfection in three distinct
ways: without any treatment for total fluorescence, after treatment with trypan blue to quench any
extracellular fluorescence, as well as after treatment with monensin to quench any fluorescence
located within acidic vesicles. With this technique, we are able to elucidate where in the cell the
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fluorescent signal originates from. As shown in Figure 3.3 E, the majority of the fluorescence is
intracellular for both folate-targeted and non-targeted micelleplexes. At 24 h, the overall uptake
was higher for targeted vs. non-targeted micelleplexes, which is in line with Figure 3.3B.
Interestingly, a higher extent of targeted particles was trafficked into acidic vesicles compared to
non-targeted ones. This observation can be explained by the intracellular trafficking of the folate
receptor which can either be recycled at the early endosome stage or ripen to a late endosome.
Most importantly, however, the targeted micelleplexes are shown to be more efficient in terms of
delivery to the cytoplasm, which is the site of action for siRNA. These results are also in line with
our observations based on confocal microscopy which, especially in Figure 3.4D, show siRNA in
the cytoplasm, rather than in vesicles. The percentage of particles that is trapped in vesicles,
however, may not result in a bright signal in the CLSM images, however, and therefore explain
the discrepancy with the flow cytometric results.
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Figure 3.3: siRNA uptake studies using flow cytometry. Uptake study across all folate decorated conjugates using
Alexa Fluor 488 for 4 hrs (A). Time course uptake study with the three most promising conjugates against folate null
conjugate (B). Uptake in SKOV-3 cells incubated for 2 or 4 hrs at 37 ˚C versus 4 ˚C (C). Uptake study with and
without an excess of free folic acid to determine competitive inhibition of binding (D). Uptake study with trypan blue
and monensin treatment to assess localization of siRNA (E). Significance values were determined with a two-way
ANOVA. *** = p < 0.05, **** = p < 0.01
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Figure 3.4: siRNA uptake studies using confocal laser scanning microscopy. Uptake study across the three most
promising folate decorated conjugates compared to hy-PEI and null folate for 4 hrs. Cell nuclei are stained with DAPI.
In order, images are of blank cells (A), PEI treated (B), 3.5k 10 µmol (C), 5k 10 µmol (D), mixed conjugate (E) and
null folate (F).

3.3.5 Protein Knockdown in vitro and Resensitization Towards Paclitaxel Treatment
Ultimately, the main goal of siRNA delivery is to be able to achieve protein knockdown.
Furthermore, our objective was to mediate protein knockdown in a targeted manner to achieve
PTX re-sensitization. For preliminary experiments, we chose SKOV-3 cells that are PTX resistant
and FRα over-expressing, in comparison to a PTX sensitive cell line, here A549, which have only
a basal FRα expression. The TLR4 expression in both cell lines was assessed via Western Blot
analysis and found to be about 4-fold increased in SKOV-3 cells, as compared to A549 cells, seen
in Figure 3.5 A. Previous literature studying ovarian cancer suggests that a rise in TLR4
expression leads to increased chemo-resistance.(88-90, 94) Subsequently, we transfected SKOV3 cells with siRNA against TLR4 using the 3.5k 10 μmol conjugate and lipofectamine as a positive
control and determined the gene knockdown after 48 and 72 hours via Western blot analysis.
Figure 3.5 B shows significant knockdown of TLR4 at 48 hours and knockout at 72 hours for both
lipofectamine and the 3.5k 10 μmol conjugate.
To further elucidate the impact of TLR4 knockdown, we used a SKOV-3 luciferase cell
line with luciferase expression controlled by a CMV promoter with a NF-ΚB binding site. In this
cell culture model, NF-ΚB activation results in enhanced luciferase activity. Combined with the
fact that PTX treatment causes NF-ΚB activation downstream through activating the TLR4
pathway, this model allows determining the effects of TLR4 knockdown on chemosensitivity of
SKOV-3 cells toward PTX through measuring luciferase expression.(89) Figure 3.5 C shows that
the luciferase expression of SKOV-3/LUC cells is clearly upregulated upon treatment with PTX,
unless TLR4 is down regulated upon TLR4 knockdown by the 3.5k 10 μmol micelleplex. In this
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case, a dramatic decrease in luciferase expression is observed compared to cells not treated with
PTX. However, cells treated with PTX upon transfection with a scrambled siRNA or polymer only
showed an increase of luciferase expression, thus demonstrating no knockdown of TLR4 occurred.
Interestingly, TLR4 knockdown did not affect the basal luciferase expression of SKOV-3/LUC
cells when this expression was not triggered by treatment with PTX. Thus, Figure 3.5
demonstrates three processes: 1) if SKOV-3 cells are treated with PTX, NF-KB is activated and
pro-survival genes may be activated; 2) if TLR4 is knocked down, NF-ΚB activation is inhibited;
and 3) NF-KB is not necessary for basal luciferase expression but strongly triggers the latter. Taken
together, Figure 3.5 demonstrates that the 3.5k 10 μmol conjugate is able to successfully
knockdown TLR4 protein with a therapeutically relevant effect on PTX treatment.

Figure 3.5 A: Western blot. Western Blot analysis of TLR4 levels within SKOV-3 and A549 cells.

Figure 3.5 B: Western blot. Western Blot analysis of TLR4 knockdown at 24 and 48 hours using
lipofectamine and 3.5k 10µmol.
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Figure 3.5 C: Luciferase assay. Luciferase assay in SKOV-3/LUC cells assessing TLR4 knockdown on
luciferase expression 48 hrs post transfection when treated with 1000 µM of PTX. Significance values were
determined with a two-way ANOVA.*** = p < 0.05.

Lastly, cells were transfected with the 3.5k 10 μmol conjugate containing TLR4 siRNA,
followed by treatment with PTX in order to assess SKOV-3 re-sensitization to PTX. MTT cell
viability assays confirmed that TLR4 knockdown resulted in a decrease in IC50 value for PTX in
comparison to cells not transfected with micelleplexes containing TLR4 siRNA (Figure 3.6 A).
Their corresponding IC50 values were 9.34 and 21.72 nM, respectively. In addition, cells were
analyzed via flow cytometry to assess the percentage of apoptotic cells between different
treatments. Figure 3.6 A/B shows that pre-treatment with 3.5k 10 μmol micelleplexes containing
TLR4 siRNA caused a re-sensitization of SKOV-3 cells at varying concentrations of PTX. This
effect was most drastic at higher PTX concentrations. At 1000 nM, only 27% and 23% of cells
were apoptotic or dead if the cells underwent no pre-treatment or if they were transfected with 3.5k
10 μmol conjugate containing scrambled siRNA, respectively. Conversely, when TLR4 specific
siRNA was used, more than double the cells stained positive for annexin V binding to phosphatidyl
serine on the cellular surface - a marker of apoptosis. Collectively, SKOV-3 cells that were pre-
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treated with 3.5k 10 μmol micelleplexes containing TLR4 siRNA before PTX treatment resulted
in a significant increase in cell death. A loss in TLR4 activity has been cited in the literature render
SKOV3 cells sensitive to PTX treatment. Szajnik et. al showed that by using siRNA to knockdown
TLR4 there was a 2-3 fold increase in cell death upon PTX treatment.(90) Other groups using
shRNA to stably knock down TLR4 have displayed similar resensitization, namely a 3-fold
increase in caspase activity, upon PTX treatment. (88) Our results are in line with these published
results; however, our approach utilizes a targeted micelleplex delivery system to focus the TLR4
knockdown to cells that overexpress FRα.
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Figure 3.6 A: MTT assay. MTT assay of SKOV-3 cells after TLR4 knockdown at 48 hours.
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Figure 3.6 B: Annexin Flow cytometry stain. Flow cytometry analysis of cell death via Annexin V staining for
apoptosis.

3.4 CONCLUSION
The over-expression of FRα in ovarian cancer cells offers the ability to specifically target
and deliver siRNA in a Trojan-horse like mechanism explicitly to these cancer cells. Utilizing
polymer based siRNA delivery systems for therapeutic purposes offers a very wide range of
possibilities due to the modularity of this approach. Theoretically, as long as a sequence is
available for a protein’s mRNA, complementary siRNA sequences can be made against that
protein to abrogate its expression.

The delivery system discussed in this chapter has the

opportunity and ability to target cancer cells through FRα overexpression for example found in
ovarian cancer cells. Furthermore, targeted micelleplexes, as seen here, have the ability to provide
beneficial therapy to patients while decreasing off target toxicity which is commonly seen with
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most chemotherapy treatments. Our tri-block co-polymer, consisting of PEI-PCL-b-PEG-Fol has
shown impressive ability to condense and protect siRNA, along with favorable release profiles at
acidic pH values as found in late endosomal vesicles. Furthermore, several physical techniques
such as DLS, and TEM were utilized to show adequate sizes (100-200nm), zeta potentials (0-30
mV), and a core-corona structure. Utilizing fluorescently labeled siRNA and flow cytometry,
transfection conditions were optimized, and the micelleplexes were demonstrated to utilize FRmediated endocytosis for cellular uptake. Protein knockdown with 3.5k 10 μmol micelleplexes
was analyzed by Western blots and luciferase assays. Both demonstrated efficient protein
knockdown of TLR4. Upon knockdown of TLR4, a re-sensitization occurred for SKOV-3 cells
to PTX treatment and a significant increase in apoptotic cells was detected with flow cytometry.
This approach displays similar therapeutic effects to those in the published literature but utilizes a
targeted delivery mechanism. Collectively, these findings based on cell culture models suggest the
feasibility of targeted gene knockdown of TLR4 and re-sensitization of PTX resistant cells toward
PTX therapy. Currently, in vivo targeting and therapeutic efficacy are being tested.
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CHAPTER 4 – REVISITING THE VALUE OF COMPETITION ASSAYS IN FOLATE
RECEPTOR-MEDIATED DRUG DELIVERY

Please note that this chapter has been modified from the submitted entry in 2017. The
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experiments, as well as wrote the manuscript.
Steven K. Jones, Anwesha Sarkar, Daniel P. Feldmann, Peter Hoffmann, Olivia M. Merkel,
Revisiting the value of competition assays in folate receptor-mediated drug delivery, Biomaterials,
Volume

138,

September

2017,

Pages

35-45,

ISSN

0142-9612,

https://doi.org/10.1016/j.biomaterials.2017.05.034.

4.1 INTRODUCTION
Smart personalized cancer therapies utilize the molecular profiles of the tumor of
individual patients as the basis of treatment and can selectively target malignant cells over healthy
ones. A promising approach, which has already been utilized by drugs approved by the FDA, is
based on targeting cellular receptors which are over-expressed on the surface of malignant cells.
Several studies have been described which utilize receptor targeting to deliver a wide variety of
payloads to multiple disease states.(206, 207) Several cancers such as ovarian cancer, non-small
cell lung cancer, kidney cancer, and colorectal cancer have a significant over-expression of folate
receptor alpha (FRα) (32, 41, 71). In ovarian cancer patients, it has been noted that as the
histological grade of the cancer increases, so do the FRα expression levels (37). Several factors
have made FRα over-expression in malignant cells a promising target for receptor targeted drug
delivery: one being very low expression throughout the rest of the body, healthy tissues expressing
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FRα on the apical side of the cell therefore not accessible to the bloodstream, and malignant cells
displaying high degrees of overexpression that can be targeted through the bloodstream.(32, 37,
114) Furthermore, once FRα binds its ligand, it internalizes the receptor-ligand complex via
receptor-mediated endocytosis. This process has the capability to endocytose the ligand and what
is conjugated to it. Therefore, FRα internalization can be exploited by hijacking the internalization
process with a drug payload which is conjugated to folic acid (FA). (208, 209) Currently, several
approaches to FRα-guided imaging and therapies are being utilized clinically and tested in clinical
studies.
However, in order to improve and better understand FRα drug targeting, the mechanics
behind the ligand-receptor interaction need to be better understood. With a variety of targeting
strategies for FRα, the need to comprehend the advantages and disadvantages to designing a FRαtargeted approach is necessary and will lead to more successful therapeutic approaches. One key
aspect that has been studied is the need for having a monovalent versus multivalent drug conjugate.
Several studies, including the clinical studies performed by Endocyte have proven that monovalent
studies can be successful and deliver their drug payload specifically to cells which over-express
FRα, while decreasing any unwanted and off target side effects.(210-213) Conversely, many
studies such as the ones by Silpe et. al. and Stella et. al., have demonstrated that a multivalent
approach yields a more advantageous system.(41, 214) In the latter studies, the principle idea of
adding multiple folic acid molecules on the surface of the drug carrier is aimed at promoting higher
binding avidity and affinity to FRα than a monovalent folic acid delivery system. This idea relies
on the fact that several FRα cluster on the cell surface within lipid rafts, and therefore, multiple
ligands binding to multiple receptors increase and prolong ligand-receptor interactions and
therefore increase the FRα internalization with the drug.(214-216) Studies performed by Silpe et.
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al. and Leistra et. al. revealed that with multiple ligand binding domains, the binding strength to
the receptor of the folic acid drug conjugates can increase from to several orders of magnitude up
to 1,000-fold, respectively (214, 215). Conversely, it has been shown that multivalent agents, such
as the nanobodies used by Movahedi et al. bind more strongly to off-target tissues.(28) There are
abundant nanocarrier delivery systems that have been used for FR-targeted delivery of a payload,
such as siRNA. Of these systems, previous studies with block copolymers consisting of three
components, namely polyethylene imine (PEI), polycaprolactone (PCL), and poly ethylene glycol
(PEG), or PEI-PCL-PEG, have demonstrated effective siRNA delivery. Previous in vitro and in
vivo work has shown that micelles made of PEI-PCL-PEG can effectively shield and condense
nucleic acids in so-called micelleplexes at suitable sizes and zeta potentials, co-encapsulate
hydrophobic drugs with the siRNA, achieve substantial knockdown of the target protein, and have
stable and long circulation profiles within the bloodstream.(180, 181, 183, 217) Additionally, when
this PEI-PCL-PEG platform was further modified with a folic acid targeting moiety, the selfassembling nanoparticles can selectively target and deliver siRNA to cancer cells which overexpress FRα. (25, 48) Moreover, these FRα targeted nanoparticles exhibited stable circulation
profiles as well as accumulation in FRα positive ovarian cancer xenografts, which was not
achieved with the non-targeted formulation. (25)
This chapter focuses on better understanding the interaction of these multivalent FRα
targeted nanoparticles with the receptor. In order to advance nanoparticle and small molecule
therapies which utilize receptor-mediated drug delivery, a thorough understanding of the receptorligand interaction is imperative. Here, we assess this interaction with multiple in vitro cell-based
and biophysical techniques including atomic force microscopy and flow cytometry. Collectively,
we are demonstrating that excess monovalent free folic acid cannot outcompete targeted
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multivalent micelleplexes for the binding to the clustered FRα and that by adding multiple ligands
to the surface of the nanoparticle, a higher binding avidity is achieved. Additionally, the presence
of high concentrations of competing ligand can cause instability problems or aggregation of the
delivery system. These effects must be taken into consideration while validating targeted delivery
with nanoparticles. Here, we demonstrate that pretreatment with excess ligand may not be the best
approach in determining the specificity of targeting effects and alternative approaches are offered.
4.2 MATERIALS AND METHODS
4.2.1 Materials: PEI-PCL-PEG and PEI-PCL-PEG-FA copolymers were synthesized as described
before.(48) Briefly, ring opening polymerization of polycaprolactone (PCL) and heterobifunctional (HO-PEG-COOH, 3.5 and 5 kDa) PEG was performed for the targeted polymer. For
non-targeted PEI-PCL-PEG, monofunctional (CH3-PEG-COOH, 5 kDa) PEG (JenKem
Technologies, United States) was used instead. Acrylate-PCL-b-PEG-alkyne or acrylate-PCL-bmPEG was reacted with hyper branched polyethylenimine (hyPEI, 25k Da, BASF, Ludwigshafen,
Germany) in a Michael addition, and azido functionalized folic acid was coupled to the alkynemodified PEG in a click reaction. Firefly luciferase (FLuc) dicer substrate double-stranded siRNA
(DsiRNA), and Alexa Fluor-488-labeled siRNA were purchased from Integrated DNA
Technologies (IDT, Coralville, IA).
4.2.2 Preparation of PEI-g-PCL-b-PEG-Fol micelleplexes for in vitro use: Each polymer was
dissolved in sterile water to yield a 1 mg/mL concentration of the PEI block of the polymer. Once
dissolved, samples were filtered through a 0.22 μm filter for sterilization. In order to prepare the
micelleplexes, a specific ratio of the amine groups found within the polymer (N) to the phosphate
groups of the siRNA (P) was chosen, as described before. (48)
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To prepare the micelleplexes, equal volumes of diluted polymer and siRNA were pipetted
together, vortexed quickly, and incubated at room temperature for 20 minutes. After 20 minutes,
the freshly formed polyplexes were characterized or used in cell culture experiments.
4.2.3 Hydrodynamic Diameter and Zeta (ζ) Potential Measurements: Measurements of the
hydrodynamic diameters of micelleplexes were performed by dynamic light scattering (DLS)
using a Zetasizer Nano ZS (Malvern Instruments Inc., Malvern, UK), as described previously. (48)
Micelleplexes were made as described above in 1X PBS and measured at N/P 5 complexing with
40 pmol of siRNA. Samples were diluted with 1X PBS solution to a total volume of 75 μL within
a disposable cuvette. Each sample was read in triplicate with each run consisting of 15 scans.
Results are represented as average size (nm) ± standard deviation. The samples were then diluted
with 1X PBS to a final volume of 800 μL, and transferred to a disposable capillary cell where ζpotential measurements were performed. ζ-potential measurements were read in triplicates by laser
Doppler anemometry (LDA), with each run consisting of 30 scans. Results are shown in average
mV ± standard deviation.
4.2.4 Cell Culture: SKOV-3 and IGROV-1 cell lines are human ovarian cancer cell lines which
were obtained from ATTC (LG Promochem, Wesel, Germany). Additionally, SKOV-3/LUC cells
stably expressing the reporter gene luciferase were established as described before.(188) All three
ovarian cancer cell lines were cultured in folate free DMEM cell culture medium (Sigma-Aldrich)
supplemented with L-glutamine, sodium bicarbonate, 10% fetal bovine serum (Thermo Scientific
Hyclone), and 1% penicillin/streptomycin. Cells were allowed to grow at 37 °C and 5% CO2 and
were passaged every 2-3 days when they had reached confluency.
4.3.5 Folate Receptor Alpha Receptor Expression Profiles by Flow Cytometry: Human
ovarian cancer SKOV-3 and IGROV cells were grown in folate free DMEM medium and
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subcultured as described previously.(48) For receptor expression experiments, 200,000 cells were
harvested per tube and centrifuged at 350 g for 5 min. After the cells were pelleted, the supernatant
was decanted, and the cells were washed twice with 1X PBS + 2 mM EDTA. Following an
additional centrifugation step, 20 µL of primary monoclonal mouse anti-human Folate Receptor α
antibody (MOV18 Enzo Life Sciences, Farmingdale, NY, USA) was added to their appropriate
tubes. Samples were vortexed and incubated for 25 minutes at 4˚ C in the dark. Cells were washed
with 1X PBS + 2 mM EDTA, centrifuged and washed one more time. The supernatant was
decanted and 20 µL of a secondary goat anti-mouse IgG pacific blue conjugate antibody
(Invitrogen, Carlsbad, CA, USA) was added to the tubes. After addition, samples were vortexed
and incubated for 25 minutes at 4˚ C in the dark. Following this incubation step, samples were
washed with 1X PBS + 2 mM EDTA twice. Samples were analyzed via flow cytometry (Applied
Biosystems Attune Acoustic Focusing Cytometer), and the Median Fluorescence Intensity (MFI)
was recorded. Samples were run in triplicate, with each sample consisting of a minimum of 10,000
viable cells. The secondary antibody was excited at 410 nm, and emission detected using a 450/40
band-pass filter set. Analysis and presentation of the data was performed in the GraphPad Prism
5.0 software calculating mean values and standard deviations.
4.2.6 Cellular Uptake of Micelleplexes by Flow Cytometry: In a 24-well plate (Corning
Incorporated, Corning, NY), 60,000 SKOV-3 cells were seeded and incubated overnight at 37 °C
and 5% CO2. In order to remove any folic acid in the well, cells were washed two times with ice
cold acid wash solution (150 mM NaCl, 10 mM sodium acetate, pH 3.5), followed by three washes
with ice cold HBSS buffer (pH 7.4). Afterwards, serum-free and folate-free DMEM media (SigmaAldrich, St. Louis, MO, USA) was added to each well for samples treated in the absence of folic
acid to avoid any source of folic acid. Samples that were treated with excess free folic acid (in
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varying concentrations) were treated with serum-free DMEM media containing the specific
quantity of folic acid.

Samples were incubated in the new media for 30 minutes before

transfection. For transfection, 50 µL of freshly made micelleplexes containing 50 pmol of AF488
siRNA at varying N/P ratios were added per well. Negative controls consisted of blank/untreated
cells while positive control cells were transfected with Lipofectamine 2000 (Life Technologies,
Carlsbad, CA, USA) following the supplier’s standard transfection protocol. Unless otherwise
stated, cells were transfected for 4 hours in 37 °C and 5% CO2 with 50 μL of micelleplex solution
containing 50 pmol siRNA within a total volume of 500 μL of serum free and folate free DMEM
media (Sigma-Aldrich, St. Louis, MO, USA). After incubation, media was removed, and 100 μL
of 0.4% Trypan Blue (Fisher Scientific, Waltham, MA, USA) was added to each well in order to
quench any extracellular fluorescence. Cells were then washed twice with 1X PBS + 2 mM EDTA,
trypsinized and spun down at 350 g for 5 min. After centrifugation, the supernatant was decanted,
and the cells were washed twice with 1X PBS + 2 mM EDTA. Samples were analyzed via flow
cytometry, and the Median Fluorescence Intensity (MFI) was recorded. Samples were run in
triplicate, with each sample consisting of a minimum of 10,000 viable cells. The siRNA was
excited at 488 nm, and emission detected using a 530/30 band-pass filter set. Analysis and
presentation of the data were performed in GraphPad Prism 5.0 software calculating mean values
and standard deviations.
4.2.7 Protein Knockdown by Luciferase Assay: Protein knockdown was measured with
luciferase knockdown experiments. SKOV-3/LUC cells stably transfected with a CMV-luciferase
plasmid were used in this experiment. In 24 well plates, 60,000 SKOV-3/LUC cells were seeded
per well and incubated overnight at 37 °C and 5% CO2. To remove any folic acid in the wells,
cells were washed two times with ice cold acid wash solution as described above, followed by
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three washes with ice cold HBSS buffer. Afterwards, serum-free and folate-free DMEM media
was added to each well for samples treated in the absence of folic acid. Samples that were tested
in the presence of excess free folic acid were treated with serum-free DMEM media containing the
specific quantity of folic acid in order to match the concentrations used in the uptake studies.
Samples were incubated in the new media for 30 minutes before transfections. Micelleplexes were
made as described previously with 50 pmol of luciferase targeted siRNA. Cells were incubated at
37 °C and 5% CO2. After 48 hours, cells were washed twice with 200 μL of PBS and treated with
300 μL of lysis buffer (Cell Culture Lysis Reagent, CCLR, Promega, Madison, WI, USA) per well.
Each well was scraped with a pipette to effectively dislodge cell debris on the bottom of the well.
The plate was then rocked for 5 minutes at room temperature. Cell lysates were transferred to
conical tubes and set on ice. Each tube was vortexed for 10-15 seconds and then centrifuged at
12,000 g for 2 minutes at 4 °C. The supernatants were collected, and 20 μL of each sample was
added to a white 96-well plate to be analyzed for luminescence using a Synergy 2 microplate reader
(BioTek Instruments, Winooski, VT, USA). Each well was injected with 100 μL of luciferase
assay reagent containing 10 mM luciferin (Sigma-Aldrich, St. Louis, MO, USA) by the plate
reader immediately before the measurement. Samples were measured in triplicate and analyzed
using GraphPad Prism 5.0 software representing average values and standard deviations.
4.2.8 Monensin Assay: To determine the extent of siRNA being trapped within the endosome, a
monensin assay was utilized and analyzed via flow cytometry. In 24-well plates, 60,000 SKOV3 cells were seeded and incubated overnight at 37 °C and 5% CO2. Freshly made micelleplexes
containing 50 pmol of AF488 siRNA were added per well. Negative controls consisted of
blank/untreated cells. Cells were transfected for 24 hours in 37 °C and 5% CO2 with 50 μL of
micelleplex solution containing 50 pmol siRNA within a total volume of 500 μL of serum-
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containing cell culture media. In order to quench any extracellular fluorescence, triplicates of cells
were incubated with 100 μL of 0.4% Trypan Blue while other triplicates were treated with 50 µM
monensin. Cells were then washed twice with 1X PBS + 2 mM EDTA, trypsinized and spun down
at 350 g for 5 min. After centrifugation, the supernatant was decanted, and the cells were washed
once with 1X PBS + 2 mM EDTA and incubated at 4 ˚C for 30 minutes with 50 µM monensin.
Afterwards, cells were washed once with 1X PBS + 2 mM EDTA and were analyzed via flow
cytometry; the Median Fluorescence Intensity (MFI) was recorded for each sample. Samples were
run in triplicate, with each sample consisting of a minimum of 10,000 viable cells. The siRNA was
excited at 488 nm, and emission detected using a 530/30 band-pass filter set. Analysis and
presentation of the data were performed in the GraphPad Prism 5.0 software calculating mean
values and standard deviations. Results were compared between cells treated with and without
Trypan Blue and monensin in order to gain insight on the targeted and non-targeted micelleplex
uptake profile.
All statistical analyses within this chapter were performed in triplicates. Results are given
as mean values ± standard deviation (SD) values. GraphPad Prism 5.0 software was utilized to
address significance by means of either a one or two-way ANOVA.
4.2.9 Atomic Force Microscopy (AFM): Atomic Force Microscopy was used in order to assess
the size and morphology of the micelleplexes after siRNA condensation. Additionally, binding
events of folate decorated polyplexes compared to folic acid on a folate receptor-modified
cantilever were measured as described below. For AFM size and morphology measurements,
micelleplexes were prepared at N/P 5 with 40 pmol of non-fluorescent siRNA in a total volume of
20 μL in 5% glucose. That suspension was added to a glass coverslip and let dry overnight. Lastly,
micelleplexes for AFM force measurements with a FRα-modified cantilever were prepared as
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described above with 75-fold higher amounts of siRNA and polymer in order to obtain a 3 mL
suspension with the same polymer and siRNA concentration in 5% glucose solution, as used for
all other AFM experiments.
4.2.10 Modification of Cantilevers with Folate Receptor: Cantilevers (MLCT-Bio, Bruker)
were incubated within a cleaning solution (Cell cleaning solvent for UV/VIS, Agilent
Technologies) for 2 h. The cantilevers were cleaned with ultra deionized water afterwards. Organic
contaminants were removed through ozone treatment for 20 min. Afterwards, 5 mL of a 1 mM
solution of silane PEG NHS (3400 Da, ThermoScientific) in 95% ethanol and 5% DI water was
prepared, and the cantilever was incubated in this solution for 2 h. After rinsing, the cantilever was
incubated in a solution of 0.15 mL recombinant human folate receptor α (FOLR1) protein (EZ
Biosystems, College Park, MD, USA) for 1 h. Afterwards, the cantilever was preserved in 1×PBS
solution until the experiments were performed within the following 24 h.
4.2.11 Immobilization of Folic Acid or Folate-Decorated Particles on the Substrate: Small
silicon square pieces (15×15 mm) were rinsed with ultra DI water and UV glued to the bottom of
a 60 mm sterile petri dish. The petri dish and substrate were further cleaned with DI water. The
silicon substrate was incubated in a 5 mL solution of 1 mM silane PEG NHS (3400 Da, Thermo
Scientific) in 95% Ethanol and 5% DI water for 2 h, followed by incubation in either 5 mL DMSO
solution of 5 mg/mL folic acid or a suspension of folate decorated particles (16.38 µM of folic
acid) for 5 h. The substrate was then washed with DI water and preserved in 1× PBS buffer until
the experiment was performed.

4.3 Results and Discussion
The strategic design of the targeting aspect of the triblock copolymers used here for siRNA
delivery relies upon the inherent over-expression of FRα in a variety of cancers. The American
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Cancer Society (ACS) estimates that over 85% of ovarian cancers significantly over-express FRα,
and that the expression has a positive correlation with the histological grade of the cancer. (37)
Therefore, FRα levels have been studied in ovarian cancer cell lines such as IGROV-1 and SKOV3 also by others. Both cell lines show significantly upregulated FRα expression levels when
compared to normal epithelial tissues and other cancerous cell lines such as A549 adenocarcinomia
alveolar basal epithelial cells. (33, 218). Figure 4.1 shows FRα expression levels in the specific
cell lines used here and clearly demonstrates that both ovarian cancer cell lines IGROV1 and
SKOV-3 showed an increase in FRα status. It should be noted that with varying FRα expression
profiles, the receptor recycling rate does not change between cell lines. Therefore, SKOV-3 cells
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were utilized in all in vitro experiments to be consistent with previously published results.(25, 48)

Figure 4.1. Folate Receptor Alpha (FRα) Expression for Ovarian Cancer Cell Lines: Two ovarian
cancer cell lines which are known to over-express FRα were tested for their FRα expression levels
via flow cytometry compared to a lung cancer cell line which is known to express only basal levels
of FRα. Each sample was stained with a primary FRα specific antibody followed by a fluorescent
secondary antibody, Significance values were determined with a two-way ANOVA.***p<0.05.
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For successful delivery with nanoparticles, two important characteristics that need to be
considered are their hydrodynamic diameters and zeta potentials. The polymers used here for
nanoparticle formation were previously characterized by 1H NMR, UV spectroscopy, and
absorbance measurements. (48) The polymers used in this study were selected for the following
reasons: 1) the targeted polymer previously showed the most efficient intracellular delivery of
siRNA; 2) the polymer termed “mixed conjugate” contains, which contains 3.5 and 5 kDa PEG
chains, also comprises the highest folic acid weight percentage; 3) a null folate conjugate not
containing any folic acid was necessary as a negative control. (48) Due to the conditions required
for AFM force measurements, the hydrodynamic diameters and zeta potentials of micelleplexes
prepared with all three polymers were determined in PBS buffer. As shown in Figure 4.2 A, in all
cases, hydrodynamic diameters were slightly larger than observed in 5% glucose solution (48) but
still at or below the 260 nm threshold reported in the literature to favor evasion of recognition by
macrophages. (110-112) It was not surprising that the hydrodynamic diameter increased when
changing the dispersant from 5% glucose to a buffer with higher ionic strength where the
hydrodynamic diameter is affected by the presence of a larger amount of counter ions that move
with the diffusing particles. The sizes of the micelleplexes are comparable with other folate
receptor-targeted nanoparticles. Bhattacharya, Li, and Esmaeili et. al. all have successfully
prepared nanoparticles around 100-200 nm in size, while others such as Krais and Su et. al.
reported sizes greater than 300 nm. (22, 219-222) Interestingly, the polydispersity indices (PDIs)
were smaller than observed in glucose dispersion with 0.11, 0.12, and 0.04 for targeted, mixed
conjugate, and null folate micelleplexes, respectively. The low PDI for each micelleplex confirms
that size distribution around the average hydrodynamic diameter is very narrow, and that no large
aggregates were observed. The same suspensions were utilized for zeta potential measurements.
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The micelleplexes made with all three conjugates had a slightly positive charge, between +1.5 and
+3 mV as shown in Figure 4.2 B. This positive charge can support the initial interaction between
the negatively charged cellular membrane and the positive charge of the outer shell of the
micelleplex but should not over shadow the desired targeting effect of the folic acid ligand. Taken
together, in PBS, the three chosen conjugate formulations had hydrodynamic diameters and zeta
potentials that were comparable to previous findings, which demonstrates initial promise towards
an effective siRNA nanoparticle delivery approach based on size and zeta potential criteria.
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Figure 4.2. Hydrodynamic diameter (with polydispersity index, PDI, measurements) and Zeta
Potential Measurements: Micelleplexes made of three different triblock copolymers were analyzed
by dynamic light scattering (DLS) and LDA at N/P ratio 5 in PBS. Formulations made with two
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folate decorated copolymers (targeted and mixed conjugate) as well as a null folate copolymer
were analyzed. Hydrodynamic diameters and PDIs are presented in Figure 4.2 A, and zeta
potentials are shown in Figure 4.2 B. Error bars represent stand deviation of error between
triplicates.
When assessing receptor targeting, a common way to determine specificity and receptormediated endocytosis is to inhibit the uptake with an excess of the free endogenous ligand of the
receptor. (48, 167, 203, 204, 223, 224) Accordingly, in regard to folate receptor targeting, free
folic acid has been used as the substrate to demonstrate competitive inhibition for the binding and
internalization for folate decorated therapies. Within recent literature, concentrations of excess
folic acid used to inhibit nanoparticle binding and uptake have ranged from as low as 100 µM up
to 5 mM. However, due to folic acid being a small molecule with only one possible binding
interaction with the receptor, and the nanoparticles used here being multivalent, the aim of this
project was to better understand the potential inhibition of nanoparticle binding to the folate
receptor that free folic acid can mediate. Therefore, we used a concentration range of free folic
acid that covers the concentrations reported in the literature. As shown in Figure 4.3, we compared
micelleplexes made with the targeted polymer against null folate micelleplexes with and without
excess competing free folic acid. Hypothetically, the folic acid-decorated micelleplexes would
experience an inhibition in their uptake via FRα in the presence of an excess folic acid, while the
null folate conjugates uptake profiles would not be affected. However, due to the multivalent
nature of the conjugates, we did not expect strong inhibition of their binding or uptake due to their
stronger binding avidity to FRα compared to monovalent folic acid. As described in our previous
work, as well as in Figure 4.3 A, only a slight inhibition of uptake of the targeted nanoparticles is
observed, while the uptake of the null folate micelleplexes is unaffected at low excess FA
concentrations. (48) This slight inhibition at low concentrations corroborates what has been
demonstrated by the Stayton group. (167) However, as the concentration of the free folic acid
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increased to 500 µM and above (Figure 4.3 B-D), not only was the targeted nanoparticle uptake
diminished, but also that of the null folate nanoparticles. It should be noted that uptake was studied
4 h past transfection. After such a short incubation time, the full targeting advantage of the targeted
micelleplexes over the null folate ones is not yet expected. Collectively, the data in Figure 4.3
illustrate that at low concentrations of folic acid, a minor inhibition of the targeted micelleplexes
occurred, while not affecting the null folate micelleplexes which are taken up by routes other than
receptor-mediated endocytosis.
Alternatively, when treated with higher concentrations of free folic acid, it is possible that
the hydrophobic folic acid destabilizes all micelles, no matter if they are targeted or not, which
leads to decreased siRNA delivery for all nanoparticles.(5) It is also possible that the DMSOcontaining solvent in which folic acid is dissolved changes the viscosity of the media, the micelle
stability, or affects the cells. This decrease in nanoparticle uptake of targeted and non-targeted
formulations after addition of high amounts of FA to the system has been observed before with
folate targeted liposomes by Lee et al.(5) In order to overcome the stronger binding affinity
observed in the case of multivalent particles, excess amounts of folic acid, above 1 mM were
required. However, at these high concentrations, inhibition of the uptake of non-targeted liposomes
was measured as well, which corroborates the results shown here in Figures 4.3 B-D. (5, 225) Lee
et al. reasoned that with excess folic acid in solution, a disruption of the cationic lipid/nucleic acid
complex stability occurred. Also in the case of our micelles, disruption and premature release of
siRNA in the presence of excess folic acid was considered but was not observed (data not shown).
However, at excess folic acid concentrations as low as 250 µM, hydrodynamic diameters of higher
than 600 nm were measured, and steadily continued to increase with the folic acid concentration.
These hydrodynamic diameters measured by DLS clearly suggest that aggregation is occurring in
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the presence of free folic acid. It should be noted, however, that folic acid has been described to
form dimers and trimers at higher concentrations within a system. These dimers and trimers, if
formed, are then unable to bind to FRα to compete with the uptake of targeted nanoparticles. (226)
Therefore, as shown in the literature, higher concentrations of folic acid on the surface of
multivalent FA-modified nanoparticle may not necessarily yield a greater targeting advantage but
rather hinder the targeting system. Reddy et. al. revealed that only 0.03 molar percent of folic acid
on a liposome is needed to gain a targeting advantage. With higher molar percentages of FA on
the surface of nanoparticles, it is possible that the problem of FA dimer and trimer formation is
encountered. (225) The binding advantage of multivalent particles was demonstrated in uptake
studies using SKOV-3 cells in vitro. However, when an excess concentration of free folic acid is
used to saturate the receptors to outcompete for the binding of the targeted micelleplexes, no
competition is detected. This observation falls in line with the hypothesis that multivalent
micelleplexes cannot easily be displaced from FRα binding sites by monovalent folic acid. In
comparison to the studies performed by Liu et. al. who showed efficient uptake inhibition at low
excess amounts of FA added, the micelles demonstrated here carry more FA on their surface.(25)
The discrepancy in competitive inhibition can therefore be explained by the difference in valency
which determines the affinity and avidity with the receptor and the ability of these multivalent
nanoparticles to be displaced by a monovalent ligand or not. Similar observations have been
reported not only in vitro, but even in vivo.(28) However, when high amounts of folic acid are
added to the system, the decrease in uptake affects both targeted and non-targeted formulations.
This suggests that the inhibition occurring is not due to blocking the receptor binding, but perhaps
affecting all nanoparticle uptake due to a cellular event or a physical destabilization of the cationic
condensation of the nucleic acids, or aggregation of the micelles, as Reddy hypothesized.(225)
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Further experiments should therefore be performed in parallel to competiton studies to better
understand this effect. Thus, when performing competitive inhibition studies, the concentration of
folic acid in the experiment should be considered and optimized for maintained stability of the
delivery system. Furthermore, competition assays may not necessarily be the most efficient route
of addressing receptor targeting specificity; especially if the delivery system’s physical and
chemical properties are affected due to the presence of excess ligand.
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Figure 4.3. Micelleplex Competitive Uptake Studies Using Flow Cytometry (A-D): Uptake
Studies in SKOV-3 cells compared for targeted and null folate micelleplexes at varying

83

concentrations of free folic acid. Samples were run in triplicates. Significance values were
determined with a two-way ANOVA.*p<0.05, ***p<0.01.

After assessing the uptake profiles with and without excess free folic acid, the next step
was to determine whether or not protein knockdown was affected by the inhibited uptake. We
hypothesized that if the uptake is inhibited for the folate receptor-targeted micelleplexes, the
knockdown of protein should be inhibited as well. By performing this test, we were able to assess
whether the slightly inhibited uptake was reflected in only a slightly inhibited pharmacologic effect
or if uptake mechanisms other than receptor-mediated endocytosis would skew the uptake results
but would lead to endosomal entrapment of the particles, taken up by mechanisms other than
receptor-mediated endocytosis reflected in a large inhibition of gene knockdown. SKOV-3/LUC
cells were incubated with and without 250 µM and 1 mM of free folic acid, while being transfected
with siRNA against Firefly Luciferase. After 48 hours, the luciferase knockdown was analyzed. In
both data sets, the targeted micelleplexes achieved a significantly greater protein knockdown than
the non-targeted micelleplexes. The more efficient gene knockdown mediated by the targeted
micelleplexes could be due to the recycling parameters of FRα. The majority of FRα, once it binds
and internalizes the ligand, will be recycled back to the cell surface. (202) This prevents many
micelleplexes from becoming trapped inside the endosome and counteracts the degradation of the
siRNA before it can cause protein knockdown. It is also possible that exocytosed particles may be
endocytosed again at a later time point. Data shown in Figure 4.4 A demonstrate that when there
was little uptake inhibition with 250 µM free folic acid, as shown in Figure 4.3 A, there was no
knockdown inhibition. This demonstrates that over a prolonged time period, although a slight
uptake inhibition occurred at 250 µM excess folic acid after 4 hours, the overall multivalent
binding approach eventually overcomes whatever slight inhibition occurs early on and therefore
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negates any offset in knockdown expected. Conversely, Figure 4.4 B demonstrates that a large
excess folic acid (1 mM) can not only inhibit the uptake of both targeted and non-targeted
nanoparticles, it can also impede the subsequent knockdown of luciferase as it generally inhibits
nanoparticle uptake, no matter if the intended mechanism would have been receptor-mediated
endocytosis or other uptake mechanisms. These data agree with the uptake results, demonstrating
that uptake and knockdown seem to be inhibited when high concentrations of folic acid are added
to the system due to micelle aggregation or a possible decrease in their stability. It should be noted
that due to the relatively slow recycling rate of FRα, most folate receptor ligands remain on the
cell surface or recycle through the cell without unloading their cargo into the cytoplasm.(202) The
release from the receptor is expected to occur in the endosome after receptor-mediated
endocytosis. Therefore, it may take longer for the targeted particles to achieve knockdown, and
only a slight benefit of receptor targeting regarding gene knockdown is observed at 48 h post
transfection versus non-targeted micelleplexes.
Theoretically, if the folate-decorated micelleplexes bind with FRα and become
internalized, the receptor, ligand and nanoparticle will be taken up into the early endosome and
undergo the endosomal ripening process starting from early endosomes and eventually merging
with lysosomes. However, since the mechanism of action of the RNAi machinery is within the
cytoplasm, the micelleplexes were designed to escape the endosome. A monensin assay is able to
delineate where the siRNA loaded micelleplexes are located after transfection. With trypan blue
treatment in addition to monensin, observations can be made as to where specifically the siRNA
loaded micelleplexes are localized after transfection. As shown in Figure 4.5, after 48 hours, the
folic acid-decorated particles (targeted) display significantly higher association with SKOV-3 cells
than the null folate particles. However, much of the siRNA seems to be present extracellularly and
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intravesicularly. The small difference of intracellular siRNA after delivery between the targeted
versus non-targeted micelleplexes at the 48 h time point clearly explains the small benefit of
targeting on gene knockdown efficacy at the same time point. These data could be explained by
the relatively slow recycling kinetic of FRα. As most FRα is recycled back to the cell surface with
the folic acid ligand still attached to the receptor, this represents a challenge for FRα mediated
targeting strategies. If drugs are not able to escape the endosome after their first internalization,
they do not reach the cytoplasm of the cell on first pass into the cell. The recycling of the targeted
nanoparticles back to the cell surface, combined with the slow internalization kinetics of FRα,
could explain the increased extracellular and intravesicular signals detected over time. However,
these tri-block micelleplexes were designed to hijack the cells’ natural receptor-mediated
endocytosis mechanism and to escape the endosome to deliver siRNA to the cytoplasm. Receptormediated internalization can only be utilized by the folate decorated particles. It has been
previously demonstrated that the uptake profiles of receptor mediated endocytosis is slower than
adsorptive endocytosis and that the targeting benefit of these polyplexes is more clearly observed
at later time points.(48) Additionally, it has been shown that FRα endocytosis of folic acid and
FRα-targeted nanoparticles utilize caveolae mediated endocytosis within lipid rafts, whereas nontargeted particles are likely to enter the cell via clathrin-coated pits through adsorptive
endocytosis.(227) Due to the nature of the different uptake mechanisms, the difference in
intravesicular signal could be attributed to the uptake kinetics of the particles. Non-targeted
particles may enter the cell at a faster rate than via the FRα mechanisms but may not be able to
escape the endosome as efficiently as their targeted counterparts. Therefore, it is likely that the
non-targeted particles were degraded within 48-hour past transfection. This hypothesis is
supported by the results in Figure 4.4 A where the targeted particles demonstrated a more efficient
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knockdown profile. These differences in kinetic and uptake mechanistic profiles can help explain
the difference between their compartmental distribution shown in Figure 4.5.
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Figure 4.4. Luciferase Knockdown under Competition: Luciferase assay in SKOV-3/LUC cells
assessing firefly luciferase knockdown 48 h post transfection at 250 µM (A), and 1 mM (B) of free
folic acid. Samples were run in triplicates. Significance values were determined with a two-way
ANOVA. *** p< 0.05
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Figure 4.5. Monensin uptake assay: Uptake study with trypan blue and monensin treatment to
assess localization of siRNA within SKOV-3 cells 48 h after transfection. Samples were run in
triplicates.

To measure size and morphology of the conjugates, we imaged randomly dispersed
micelleplexes which were air-dried on a glass coverslip. A uniform particle polydispersity with an
average particle size of 152± 22 nm was observed, as shown in Figure 4.6. These sizes are
consistent with the hydrodynamic diameters of micelleplexes determined in previously published
work using a DLS.(48) These sizes, albeit slightly smaller than in Figure 4.2 A, are in agreement
with the hydrodynamic diameters of micelleplexes prepared in 5% glucose instead of a PBS
solution, emphasizing the role of counter ions diffusing with the particles in a higher ionic strength
dispersant which increase their hydrodynamic diameters.
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Figure 4.6. AFM images of micelleplexes: Topographical image of micelleplexes on a 25*25 mm
glass coverslip with scan size of 10 μm.
In order to assess and compare binding probability of FRα with folic acid and folatedecorated micelleplexes, we performed AFM force measurements. The AFM cantilever was first
functionalized with an active FRα and experiments were run with varying substrates on a glass
cover slip. Control experiments were performed with folate receptors on the cantilever tip and a
clean non-functionalized silicon substrate. In this case, there was little to no specific adhesion to
the receptor; the binding probability for a blank substrate was 0.009. Next, over 1000 force
measurements were recorded for each substrate with the FRα-modified cantilever. In each case,
the binding probability was determined by the number of force curves that show at least one rupture
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event divided by the total number of force measurements performed on the substrate. The binding
probability for folic acid-modified substrates to the folate receptors attached to the cantilever was
0.462. Conversely, the binding probability for the folate-decorated micelleplexes to the active
folate receptors attached to the cantilever was 0.573. The rupture force distributions on both folic
acid and folate-decorated micelleplexes at a 2 µm/s retract speed were also recorded. Rupture force
histograms for folic acid and folate-decorated micelleplexes are shown in Figure 4.7 A and B,
respectively. For folate-decorated micelleplexes, we found a most probable rupture force of 215.8
pN. This binding force was significantly (p<10-22) higher compared to the most probable rupture
force of 78.6 pN, which was observed for free folic acid only. This large difference is most likely
due to multiple bonds formed on the folate-decorated micelleplexes, leading to a higher binding
probability and binding avidity of the multivalent folate-decorated micelleplexes versus the
affinity of folic acid to FRα. It should be noted that the same type of cantilever was functionalized
under identical conditions for both experiments.
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Figure 4.7. (a) Rupture force histogram plotted for substrate functionalized with free folic acid,
(b) Rupture force histogram for substrate functionalized with folate-decorated nanoparticles.
Multiple studies have tried to use a competitive inhibition setup to demonstrate that the
addition of free folic acid to the system outcompetes the folate-decorated nanoparticles regarding
the binding to FRα. With this in mind, the kinetics of bond formation were observed between a
FRα decorated cantilever and folate decorated micelleplexes. During the experiment, repetitive
injections of free folic acid were added at fixed concentrations into the measurement cell. Figure
4.8 shows the binding probability of the decorated micelleplexes with FRα versus the injected folic
acid concentration. Based on the cell uptake study shown in Figure 4.3, we hypothesized that low
excess amounts of free folic acid could only slightly decrease the binding probability of
multivalent folate decorated micelleplexes having multiple binding sites on the cantilever.
Therefore, we expected that they could not be displaced efficiently from the receptor by
monovalent folic acid. Accordingly, it was observed that injection of free folic acid into the flow
cell did not decrease the binding probability significantly until about 250-300 µM free FA.
However, as the concentrations of free folic acid increased, a precipitous decrease of the binding
probability was observed. These results are in full agreement with the uptake study in Figure 4.3
A-D. Earlier published work with free folic acid around 100 µM showed no significant inhibition
of siRNA uptake between targeted and non-targeted micelleplexes, which can be explained by the
results in Figure 4.8. At 250 µM, a slight inhibition of binding probability can be observed
correlated with a significant decrease in siRNA uptake for the targeted micelleplexes, but
unchanged uptake in the non-targeted formulation. At this concentration, an optimal excess
concentration seemed to be reached where the free folic acid inhibited the folate receptor
dependent endocytosis while not decreasing micelleplex stability. Even if increased average
hydrodynamic diameters of the particles were observed at this concentration of free folic acid,
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apparently not all particles had aggregated and a large amount of particles was still in the size
range for efficient endocytosis. As demonstrated at higher concentrations above 250 µM, the
binding probability significantly drops in cell culture as the uptake of both targeted and nontargeted formulations was significantly inhibited. Overall, the precipitous drop of binding
probability above 250 µM of free folic acid can easily be explained by micelleplex instability or
aggregation in the presence of high concentrations of free folic acid. In case of dissociation of the
micelleplexes, the valency is decreased from multivalent complexes to monovalent conjugates
which can be displaced from the receptor by the presence of excess monovalent ligand. In case of
aggregation, targeting ligands are lost in the core of the aggregates, and in cell culture, they reach
sizes that are no longer conducive for endocytosis.
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Figure 4.8. Binding probability versus concentration of folic acid after injecting folic acid in the
flow cell of a substrate functionalized with folate-decorated nanoparticles with a folate receptor
functionalized cantilever tip.
Limits of this AFM-based approach failed to take into account, or to verify, the clustering
of FRα. On the apical surface of the cell, FRα tends to cluster together on lipid rafts which can not
be mimicked through this AFM-based approach. In a biological state, if the FRα clusters together,
the multivalency of folate decorated micelleplexes can utilize the proximity of other FRαs to create
a tighter binding when compared to a free standing FRα. Unfortunately, with functionalizing the
cantilever with FRα, receptor clustering can only be aimed for by adjusting the receptor
concentration used for the functionalization.(36, 39) Lastly, in in vitro and in vivo experiments
with FRα-expressing cells, the addition of free folic acid can have several pharmacological effects
on the cells which could inhibit binding and uptake. However, with the AMF approach, we can
only address any biophysical effects of receptor binding that happen.
4.4 Summary and Conclusion
Targeted therapy has been on the forefront of developing new treatment options for cancer
in the clinic. The ability to selectively target cancer cells while avoiding toxicity toward healthy
tissues has become the ideal outcome of drug delivery. Since the development of the field of
nanomedicine in the late 2000’s, the ability to easily modulate and alter delivery systems to fit the
needs of one disease profile is achievable. It has been shown that multiple cell surface receptors
are significantly over-expressed within a variety of disease states such as cancer and or
inflammatory diseases. Examples of such receptors are folate receptor alpha and beta, HER-2,
transferrin, and integrin receptors (30, 31, 48, 228). However, to target these receptors, specifically
FRα, we believe that more optimization in the models is needed in order to confidently claim that
receptor targeting is being utilized when a ligand is added to a nanoparticle. Multiple experiments
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other than the excess addition of the targeting ligand, as discussed in this chapter, can further
elucidate the multivalent targeting advantage gained when a targeting ligand (e.g., folic acid) is
added to a drug delivery system. Here, FRα binding properties of micelleplexes made with folatetargeted triblock copolymers were evaluated. The sizes and zeta potentials of the micelleplexes
were verified with DLS and AFM in a PBS suspension and compared with previously published
results.(48) The sizes obtained with both techniques were within the range of 200-250 nm with a
slightly positive zeta potential. The hydrodynamic diameters were slightly larger than previously
reported due to the change in dispersant from 5% glucose to PBS. AFM data with a modified
cantilever demonstrated that the multivalent micelleplexes bind at a higher probability and a with
a stronger force than free folic acid. Receptor-mediated endocytosis and knockdown kinetics were
studied with the monensin assay and luciferase assay. Due to the slow rate of FRα recycling, and
the time required to observe protein knockdown with siRNA, later time points of 48 h post
transfection were assessed. As shown, the targeted micelleplexes resulted in a greater
accumulation in the cytoplasm over time which leads to a significant targeting advantage to
luciferase knockdown after 48 hours when compared to the non-targeted micelleplex.
Additionally, due to the slow recycling of the FRα over time as well as the propensity of the
receptor to recycle back to the surface with its cargo, greater amounts of the micelleplexes were
found extracellularly and intravesicularly over time. This difference could be greater for periods
longer than 48 hours if particles are still located on the outer surface of the cell or not yet released
from the intracellular vesicles after 48 h. Collectively, these data suggest that a simple design of
adding excess folic acid ligand to an uptake study may not prove or disprove receptor-mediated
endocytosis. Further studies, as described here, should be carried out to investigate a targeting
advantage that is gained through ligand conjugation. In this chapter, the targeted micelleplexes
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have a higher degree of binding and stronger binding than folic acid. This results in an inherent
targeting advantage that cannot be overcome by adding excess ligand into the solution without
jeopardizing the entire system. Currently, further biophysical approaches are being carried out to
further assess the biophysical changes of triblock copolymer interaction with siRNA when a
targeting ligand is conjugated and the differences of cellular interactions of targeted and nontargeted micelleplexes.
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CHAPTER 5 – AN INSIGHT INTO THE BIOPHYSICAL CHARACTERISTICS OF
FOLATE RECEPTOR ALPHA TARGETED SIRNA MICELLEPLEXES
5.1 INTRODUCTION
The number of nanomedicine publications has grown exponentially since the early 2000’s.
Within this field, nanoparticle therapies for drug delivery have only become more sophisticated.
The first nanoparticle-based therapies to be approved in the clinic were doxil and abraxane. Both
are non-targeted towards any tumor specific biomarker and solely relied upon passive uptake to
treat cancer.(7, 18) Now, nanoparticles in the clinical pipeline include multiple delivery vectors
such as liposomes, silica or gold nanoparticles, or polymeric micelles. These nanoparticles are
used as imaging agents, and a wide variety of them are cancer therapeutics for solid and liquid
tumors, as well as for auto-immune diseases.(3) Intelligently designed nanoparticle therapies
could be one approach to overcome the complexities of diseases such as cancer. These
nanoparticles are optimized in order to deliver the most payload possible to the target site.
Polymeric nanoparticles, which can be easily modified, allow for multiple disease states to be
targeted with various targeting ligands.(23, 41, 114, 204, 229-231) Nanoparticles have a wide
variety of payloads that can be encapsulated or covalently attached. One of the types of payloads
that researchers have utilized for nanoparticle delivery is the group of nucleic-acid based
therapeutics, including mainly DNA and RNA, but also modifications such as peptide nucleic acids
(PNAs) and locked nucleic acids (LNAs). Researchers have used gene delivery to introduce new
genes or knock out specific genes in a safe and efficient way. After discovery of short interfering
RNA (siRNA) in the late 1990’s, it has been heavily investigated for its therapeutic properties to
silence aberrant gene expression. However, naked siRNA is not able to circulate long in the
bloodstream due to being renally excreted within minutes and being easily degraded by
endonucleases.(60) Therefore, carriers are needed to safely deliver siRNA into cells in order to
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achieve its promising therapeutic potential. However, these carriers ideally need to be stable to
avoid premature release of the payload, allow for long circulation, have a low toxicity and
immunogenicity profile, and to be biodegradable.
Since the discovery of the potential of nucleic acid and gene delivery, a special focus on
developing a variety of nucleic acid vectors has developed. Researchers have created viral and
non-viral delivery systems, all of which have shown considerable potential. Non-viral
nanoparticles are comprised of lipids, peptides, polymers or blends and conjugates of the latter.(54,
232) Here, we chose to utilize a polymer-based nanoparticle delivery system with three
components: polyethyleneimine (PEI), polycaprolactone (PCL), and poly(ethylene glycol) (PEG).
The rationale for including PEI within the polymer backbone was its ability to electrostatically
condense siRNA and provide the resulting polyplexes with a net positive charge for interaction
with the cell membrane and intracellular delivery. PCL drives micelle formation and increases the
hydrophobic content of the polymer.(62) However, a major disadvantage of high molecular weight
PEI is its marked toxicity.(116, 117, 233) Therefore, PEG was added to the backbone in order to
increase the biocompatibility, while also aiding in macrophage phagocytosis avoidance.(234) As
previously reported, this triblock co-polymer effectively delivers siRNA and mediates protein
knockdown. (48)
In order to target gene therapy to cancer cells and not healthy dividing cells, researchers
have been exploiting options for conjugating targeting ligands on the surface of their nanoparticles.
This creates homing mechanism which allows for the selective targeting of diseased cells over
healthy ones. There have been several targeted therapies that have made their way into the clinic
in the form of antibody-drug conjugates, or antibodies/antibody fragments.(27, 235, 236)
Examples of these therapies are Herceptin, Zevalin, and Avastin which have all been approved by
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the FDA.(19, 228, 237) Strategies to create targeted nanoparticles rely upon the same concept as
attaching targeting ligands to small molecules, proteins, or antibodies/antibody fragments.
However, attaching a ligand to a drug or a nanoparticle can affect many parameters such as
molecular weight, hydrodynamic diameters, hydrophilicity, hydrophobicity, interaction with
excipients, and many more. Therefore, here, we explore the biophysical effects of attaching folic
acid targeting ligands on the surface of our micelleplex siRNA delivery system.
The benefits of using these targeted nanoparticles need to be better understood, and the
effects of the targeting ligands can play a role in changing important properties of the
nanoparticles. Several targeted nanoparticle drug delivery papers have been published which
compare payload delivery efficiencies between their targeted and non-targeted delivery vectors.
However, simple additions of any component within the nanoparticle structure can have drastic
effects on the size, shape, charge, drug loading efficiency, and other physical or chemical
parameters. All of these can either enhance or be detrimental to drug delivery. The same
principle can be applied to a targeting ligand, in this case folic acid. Therefore, we sought to
address whether or not a simple comparison between a targeted and non-targeted nanoparticle is
truly a fair assessment. Accordingly, we assessed several biophysical properties of the different
micelleplexes to determine if any basic biophysical property changes with the addition of a folic
acid targeting ligand.
5.2 MATERIALS AND METHODS
5.2.1 Materials.

Hetero-bifunctional poly(ethylene glycol) (HO-PEG-COOH), as well as

monofunctional (CH3-PEG-COOH, 5 kDa), were purchased from JenKem Technologies (Plano,
TX, United States) and utilized for chemical synthesis of siRNA delivery vectors. Hyper branched
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polyethylenimine (hyPEI, 25k Da) (BASF) was included in the overall synthesis of the tri-block
copolymer. All other chemical regents for synthesis were obtained from Sigma-Aldrich and used
without any modification. Dicer substrate double-stranded siRNA (DsiRNA) targeting the
Enhanced Green Fluorescent Protein gene (EGFP siRNA, 25/27), firefly luciferase (luc siRNA,
25/27), and a scrambled nonspecific control (siNegCon, 25/27) siRNA were purchased from
Integrated DNA Technologies (IDT, Coralville, IA).
5.2.2 Synthesis of Tri-block Copolymers and Characterization. The tri-block copolymers
consisting of PEI-PCL-PEG and PEI-PCL-PEG-Folic acid were synthesized based upon a
previously published approach applying ring opening polymerizations, Michael’s addition
reactions, and folic acid decoration onto the triblock copolymer via click chemistry reaction.(48)
Here, a targeted polymer with 3.5 kDa PEG chain length, a non-targeted one with 3.5 kDa PEG
chain length, as well as a polymer with higher folic acid grafting degrees and mixed 3.5 kDa and
5 kDa PEG chains (mixed conjugate) were synthesized and characterized by 1H NMR, UV
spectroscopy, and a folate composition assay, as described before.(48)
5.2.3 Preparation of PEI-PCL-PEG-Fol micelleplexes. Each polymer was dissolved in water at
1 mg/mL based on the PEI content and sterilized with filtration. Polymers were stored at -4 ˚C.
Micelleplexes were created using the same equation, as described before with these triblock copolymers.(48)
To prepare the micelleplexes, equal volume amounts of polymer and siRNA were added
together, vortexed, and incubated at room temperature for 20 minutes. Once the micelleplexes had
been formed, suspensions were added to the samples for respective experiments.
5.2.4 Cell Culture. SKOV-3/LUC cell line is a human ovarian cancer cell line which was obtained
by stably transfecting SKOV-3 cells, obtained from ATTC (LG Promochem, Wesel, Germany),
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with a pCMV-luciferase plasmid. SKOV-3/LUC cells were cultured in folate free DMEM cell
culture medium (Sigma-Aldrich) supplemented with L-glutamine, sodium bicarbonate, 10% fetal
bovine serum (Thermo Scientific Hyclone), and 1% penicillin/streptomycin. Cells were allowed
to grow in 37 °C and 5% CO2, incubators and passaged when they reached confluency.
5.2.5 Transmission Electron Microscopy (TEM). Transmission Electron Microscopy was
utilized to assess the size and morphology of the micelleplexes after siRNA condensation, as well
as assessing localization of siRNA within micelleplex structure. For TEM size and morphology
measurements, micelleplexes were made, as described above in a total volume of 20 μL in 5%
glucose. TEM Samples were added dropwise to a copper-coated grid and imaged with a JEM 2010
transmission electron microscope (JEOL, Tokyo, Japan).
5.2.6 Fluorescent Correlation Spectroscopy. Micelleplex stability in serum was analyzed by
fluorescent correlation spectroscopy (FCS) on a two photon Miatai spectraphysics Zeiss axiovert
200 inverted microscope platform (Oberkochen, Germany) using 100 femtosecond excitation, 80
megahertz laser at 780 nm with a 488 nm filter. The FCS protocol and analysis method was adapted
based on a previously published approach. (193, 238) Micelleplexes were made in 10 mM HEPES
buffer containing 1.6 µM AlexaFluor-488 labeled siRNA as described above. Within an 8 chamber
slide (Nunc, Fisher Scientific, Waltham, MA, USA), serum, free AlexaFluor-488, and AlexaFluor488 containing micelleplexes were made as described earlier. Micelleplexes were made at various
N/P ratios (5, 10, 15) and analyzed with 10% and 90% FBS for 85 minutes each. Data points were
collected every 1/100 of a second using a correlator from ISS (Champaign, IL, USA). In the
graphed results, each data point represents the average of 500 seconds. Samples were normalized
to 0-100% free siRNA where free serum represents the baseline, 0% fluorescence, while free
siRNA represents 100% fluorescence. The data were analyzed using GraphPad Prism 5.0 software.
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5.2.7 Circular Dichroism. Circular dichroism was performed on each micelleplex formulation to
gain insight on the siRNA complexation and condensation behavior. For analysis, 2 nmol of
siRNA within 100 µL of 10 mM HEPES buffer solution was mixed with 100 µL of each polymer
solution at variable N/P ratios (N/P 1, 3, 5, 7, 10, 15, and 20). Samples were incubated for 20
minutes, followed by a 1:1 dilution with 10 mM HEPES buffer at pH 7.4. Following dilution, the
samples were pipetted into a 0.2 cm quartz cuvette and analyzed on a Jasco J-1500 CD
Spectrometer (Easton, MD, USA). Five scans were collected for each sample at 20 ˚C at 200
nm/min between 200-320 nm at a response time of 1 s and bandwidth/data pitch of 1 nm.(191)
5.2.8 Tensiometry. Critical micelle concentration (CMC) of each polymer was recorded on a KSV
tensiometer while following and adapting a previous approach.(239) Samples were diluted at
various concentrations (0.01-2 mg/mL) with water and loaded into a 0.55 mm gauge needle. Once
the tip of the needle was placed within the center of the screen, the plunger was depressed until a
full drop of the sample was formed. Data collection occurred at 25 ˚C and automated software
(KSV 2001) analyzed the formation of the droplet for the surface tension. Results were recorded
and analyzed in GraphPad Prism 5.0. Theoretic hydrophilic-lipophilic balance (HLB) values were
calculated according to Griffin’s method.(240) Since all polymers are highly hydrophilic, their
ionic nature was not further taken into consideration but the HLB values were solely calculated to
assess the difference in hydrophobic content.
5.2.9 Luciferase Knockdown. SKOV-3/LUC cells stably expressing luciferase were used in this
experiment. In 24 well plates, 60,000 SKOV-3/LUC cells were seeded per well and incubated
overnight at 37 °C and 5% CO2. Micelleplexes of the targeted polymer were made, as described
previously with 50 pmol of luciferase targeted siRNA. SKOV-3/LUC cells were incubated at 37
°C and 5% CO2. After predetermined time points (24 h, 48 h, 72 h), cells were washed twice with
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200 μL of PBS and treated with 300 μL of lysis buffer (Cell Culture Lysis Reagent, CCLR,
Promega, Madison, WI, USA). Afterwards, each well was scraped with a pipette to effectively
dislodge cell debris from the bottom of the well. The plate was then rocked at room temperature
for 5 minutes. Cell lysates were pipetted out of the well plate and transferred to 0.5 mL Eppendorf
tubes and placed on ice. Each tube was vortexed for 10-15 seconds and then centrifuged at 12,000
g for 2 minutes at 4 °C. The supernatant was collected, and 20 μL of each sample was added to a
white 96-well plate to be analyzed for luminescence using a Synergy 2 microplate reader (BioTek
Instruments, Winooski, VT, USA). Each well was injected with 100 μL of luciferase assay reagent
containing 10 mM luciferin (Sigma-Aldrich, St. Louis, MO, USA) by the plate reader immediately
before the measurement. Samples were measured in triplicate and analyzed with a two-way
ANOVA using GraphPad Prism 5.0 software representing average values and standard deviations.
5.3 RESULTS AND DISCUSSION
Several tri-block copolymer consisting of polyethyleneimine-graft-polycaprolactoneblock-poly(ethylene glycol) copolymers were previously synthesized and descriptions along with
basic characterizations have been previously published. (48) The previously published results
showed the presence of folic acid did not cause any notable changes to the hydrodynamic diameter
of the micelles, while the zeta potential with the folic acid made the micelles slightly more neutral
than their non-targeted counterpart.(48) This result was also observed with variations of this
triblock copolymer, as demonstrated by Liu et al. as well as other with other folic acid modified
delivery systems.(25, 241) Although size and zeta potential can by themselves have an effect on
the drug delivery capability of nanoparticles, this study takes a closer look at additional biophysical
properties of these targeted, folic acid decorated micelleplexes, and their non-targeted
counterparts. To begin, TEM images were taken of both targeted and non-targeted micelles as
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shown in Figure 5.1 to confirm sizes, micelle structure formation, and shape and were consistent
with previous results.(48) No noticeable differences were found between any of the triblock
formulations when complexed with siRNA.

A

B

Figure 5.1: Characterizing Nanoparticle Size and Morphology. Micelle size and morphology
was tested at N/P 5, with 40 pmol of EGFP siRNA by TEM. TEM samples were fixed on a grid
for imaging. TEM images of null folate (A) and targeted micelleplexes (B) are shown above.
Once the micellar structure was confirmed, the siRNA binding properties within the
micelleplexes were investigated with and without folic acid conjugated to the terminal end of the
triblock co-polymer. In order to assess and characterize different conjugates’ ability to condense
siRNA, circular dichroism was performed. CD analysis can distinguish secondary and tertiary
structure conformational changes within the siRNA backbone when it is electrostatically
complexed within the micelleplex.(191, 233, 242) Changes in the chemical composition of the
conjugates could theoretically change siRNA complexation and condensation behavior. At each
N/P ratio, all CD spectra obtained from each conjugate at 264 nm showed a red shift, as well as an
increase in the Cotton effect compared to free siRNA, without any noticeable change in the
polarization degree after N/P 1. Similarly, a decrease in the polarization profile of free siRNA was
observed at each polymer and N/P ratio at 210 nm. These were unlike the results obtained by
Merkel et al. and O’Mahony et al. where they experienced a decrease in the cotton effect when
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siRNA was electrostatically condensed within the polyplexes.(191, 242) However, the complexed
siRNA within micelleplexes still contained the notable positive band at 260 nm and a negative
band at 210 nm. This is indicative of the A-form of the molecule that is needed to be loaded into
the RISC complex for mRNA degradation.(242) Therefore, we can conclude that every
conjugate’s PEI block was able to interact and complex with the siRNA backbone which is
reflected in the change of the optical profile. Due to the similarity of optical profiles between the
unmodified PEI and each triblock micelleplexes, we can deduce that the complexation of siRNA
and change in its base stacking is a result of electrostatic interactions between PEI and the
phosphates within the siRNA backbone which was not affected by the PEG or PCL blocks. Based
on the CD results described here, the attachment of PCL-PEG or PCL-PEG-FOL did not seem to
alter the siRNA interaction with PEI or the backbone of the molecule within the micelleplexes.
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Figure 5.2: Circular Dichroism of Micelleplexes. Circular dichroism spectra of siRNA
condensed within increasing polymer concentration in 10 mM HEPES buffer at pH 7.4
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To build upon the studies previously published, further testing of micellar formations was
carried out by tensiometry to determine the critical micelle concentration (CMC). Due to the
amphiphilic nature of the triblock co-polymers, they have a thermodynamic driving force to create
micelles. When increasing concentrations of amphiphilic polymers are added into an aqueous
solution, the polymer chains start to aggregate into an organized structure with their hydrophobic
polymer chains oriented towards the core of the micelle when the CMC is reached.(243, 244) In
addition to the electrostatic interactions that occur with PEI, this process also aids in the protection
and encapsulation of nucleic acids at the interface of the inner core and outer corona layer of the
micelle for gene delivery. High CMC values indicate that the carrier will easily disassemble before
it delivers the payload. Generally, micelles with high CMCs immediately dissociate more readily
and their payload is prematurely released when they are injected into the body due to the dilution
in the blood. As shown in Table 1, the CMC values of three conjugates were obtained via
tensiometry across a broad range of dilutions. Interestingly, the targeted conjugate, as well as the
non-targeted conjugate had very similar CMC, which were 23 µg/mL and 16 µg/mL respectively.
The CMC values for these two tri-block copolymers, with and without folic acid modification, are
greater than those described by Zheng et al. who reported values ranging between 62-512 µg/L for
very similar copolymers.(181) Although they used a shorter hydrophobic chain, their polymers
displayed lower CMCs as the grafting degree of the hydrophobic chain increased. In comparison
with the targeted and non-targeted polymers, the mixed targeted conjugate in the panel investigated
here had a 5 fold higher CMC at 105 µg/mL. Based on the polymers’ statistical PEG-PCL grafting
degrees, the hydrophilic content of the mixed conjugate was greater than that of the other two
polymers, as reflected in its high theoretical HLB value in Table 1. As seen in previous studies,
the grafting degree of PEG-PCL is lower than that of the targeted and non-targeted conjugates.
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Therefore, overall, the PCL content decreased in the mixed conjugate. With a greater
hydrophilicity, and decreased amphilicity of the conjugate, its solubility in water is higher and the
thermodynamic driving force for forming micelles only comes into play at a higher concentration.
The higher hydrophilicity of the mixed conjugate would be one explanation for its higher CMC
value. However, it should also be noted that the mixed conjugate has a fifteen-fold higher folic
acid concentrations than the targeted conjugate.(48) As described in previous studies, increased
amounts of folic acid, as present in the mixed conjugate, have been shown to lead to instability or
aggregation of micelles. (245) Since the presence of folic acid in the targeted conjugate did not
strongly affect the CMC values, it appears that an optimal folic acid was obtained here which could
help achieve a targeting effect without affecting micelle formation and stability. This CMC
analysis suggests that the addition of a targeting ligand, such as folic acid, can have an effect on
the CMC of the resultant micelles.

CMC
(mg/mL)

Theoretical
HLB Values
16.67

Polymer
Targeted
0.023
Conjugate
Mixed
19.61
0.105
Conjugate
18.18
0.016
Null Folate
Table 5.1: Critical Micelle Concentration and Theoretical HLB value. Critical micelle
concentration (CMC) and calculated Hydrophilic-Lipophilic-Balance (HLB) ratio of each polymer
in water was measured by tensiometry.
Once the micelles were formed, their stability in the presence of 10% serum (mimicking
in-vitro conditions) and 90% serum (mimicking in-vivo conditions) was investigated with
fluorescence correlation spectroscopy (FCS). The release of the encapsulated drug, in this case
AlexaFluor-488 labeled siRNA, was monitored over time and results are depicted in Figure 5.3.
The siRNA release was measured for each micelleplex over the course of 90 minutes, with
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measurements taken every 1/100 of a second for multiple N/P ratios. The release of siRNA over
time did not increase for any of the conjugates in 10% serum; however as the N/P ratio increased
from 5 to 15, greater stability and better condensation of the siRNA micelleplexes was observed
at any given time point. Each conjugate, with the exception of the targeted conjugate at N/P 5,
released approximately 5-15% of the total siRNA loaded into the system. However, with 90%
serum in the system, the targeted and mixed micelleplexes showed a lower ability to retain siRNA.
Compared to the unmodified PEI and the mixed conjugate micelleplexes, the targeted and null
folate micelleplexes displayed a greater ability to protect the siRNA from release. The mixed
conjugate micelleplexes appeared to exhibit poorer siRNA retention than any other micelleplex.
This observation could be related to the CMC value being greater for the mixed conjugate than the
others. It is worth noting that the null folate non-targeted micelleplexes at 90% serum exhibited
the best siRNA retention profiles across all N/P ratios with 15% release at N/P 5 and no measurable
release at N/P 15. This creates a trend where increasing folic acid attached to the surface of the
micelleplexes worsens the siRNA retention profiles. Therefore, as more folic acid attached disrupts
the micelleplex formation and stability, these micelleplexes are more prone to siRNA release when
serum is present in higher concentrations. Based on the CMC and FCS results, it becomes obvious
that greater folic acid amounts on the surface of the micelles will not aid in the receptor targeting,
but instead can become detrimental to the micelle stability in circulation and payload retention.
This result may be more noticeable in vivo where higher serum concentrations are present and
where the dilution of the micelleplexes into the bloodstream may cause the payload to be
prematurely released.
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Figure 5.3: Fluorescent Correlation Spectroscopy of Micelleplexes. The stability of
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mixelleplexes was tested in 10 and 90% FBS in 10 mM HEPES for 80 minutes. The siRNA
complexes of each conjugate were analyzed at N/P ratios 5, 10, and 15.
After comprehensive biophysical characteristics of each micelleplex formulation, their
efficacy, both in terms of siRNA uptake and protein knockdown, was evaluated in vitro for
correlation with biophysical parameters. Flow cytometry uptake results of AF488 siRNA are
presented in Figure 5.4. As shown, free siRNA cannot enter the cell very efficiently due to it being
negatively charged and hydrophilic.(16, 56) However, when electrostatically packaged inside the
micelleplexes, efficient siRNA delivery was achieved. Figure 5.4 demonstrates that the conjugates
perform similarly as the unmodified PEI, confirming previous work.(48) However, the biophysical
characterization offered above can help further explain these in vitro results. It is worth noting that
the benefit of FRα targeting and receptor mediated uptake becomes more prominent at later time
points beyond 4 hours.(48) At time points beyond 4 hours, the targeted micelleplexes outperform
the null folate micelleplexes.(48) The significantly decreased uptake obtained after transfection
with the mixed conjugate could be related to the increased folic acid concentration on the surface
of the micelleplexes. Studies performed by Reddy et al and Ciuchi et al. demonstrated that very
little folic acid on the surface of liposomes is needed in order to achieve receptor targeting, namely
0.033 molar percent. Furthermore, if more folic acid is added to the surface, this can lead to dimer
and timer forming between the folic acid ligands resulting in the inability of the ligands to bind to
FRα and even to precipitation of the liposomes.(225, 226) Consequently, the decrease in siRNA
uptake by the mixed conjugate’s micelleplexes in comparison to the targeted micelleplexes can be
explained.

111

***

80000

***
***

60000
40000
20000

PE
I
C
on
M
ju
ix
ga
ed
te
C
on
ju
ga
te
N
ul
lF
ol
at
e

Ta
rg
et
ed

si
R
N

Fr
ee

B

A

0
la
nk

Median Fluorescence Intensity

Uptake of AF488 siRNA

Figure 5.4: Alexa-fluor 488 siRNA uptake. siRNA uptake mediated by each polymer in SKOV3 cells. Cells were transfected with 50 pmol of AF488 siRNA for 4 h and analyzed via flow
cytometry. Results were analyzed by Prism. Samples were run in triplicates. Significance values
were determined with a two-way ANOVA.*** p<0.05.

Once the micelleplexes are taken up into the cell, the siRNA needs to be released into the
cytoplasm in order to achieve mRNA and subsequently protein knockdown. SKOV-3/LUC cells
were transfected in order to evaluate protein knockdown over time and to demonstrate the
micelleplexes’ functionality in vitro. After time points of 72 and 96 hours, luciferase expression
was analyzed. Due to the poor stability and uptake profiles of the mixed conjugate micelleplexes,
they were not tested in vitro for luciferase gene knockdown. The targeted micelleplexes achieved
a greater knockdown than the null folate micelleplexes at each time point. After 72 hours, the
targeted micelleplexes achieved greater than 65% protein knockdown while the non-targeted null
folate micelleplexes, achieved a maximum of 45% knockdown. Luciferase knockdown results with
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the siRNA containing micelleplexes were comparable to knockdown described by Meyer et al.
who achieved about 60-80% luciferase knockdown utilizing a PEGylated polycation to deliver
siRNA. (246) Due to the micelleplexes being amphiphilic, they can efficiently enter cells (Figure
5.4) and be released from the endosome.(181) Therefore, we expected knockdown to occur with
or without the targeting ligand. With this in mind, it is likely that there is an optimal concentration
of folic acid that can be added to the micelleplexes to achieve a targeting benefit without
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significantly affecting their biophysical properties in a deleterious aspect.

Figure 5.5: Luciferase Knockdown Assay. Knock down of luciferase in SKOV-3/LUC cells by
3.5k 10 µmol conjugate with 100 pmol of siRNA. Cells were transfected for 72 and 96 hours and
harvested for a luciferase assay. Samples were run in triplicates. Significance values were
determined with a two-way ANOVA. * p<0.05, ** p<0.01, *** p<0.001 compared to non-treated
cells.
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5.4 SUMMARY AND CONCLUSION
Lately, there has been an increased focus on personalized therapies in the clinic. In this
regard, therapeutic nanotechnology has taken the approach of attaching targeting ligands onto
nanoparticles to target disease specific cells by attaching substrates such as antibodies, small
molecules, or proteins.(21, 231, 247, 248) These ligands can be used to target cell surface receptors
such as integrin receptors, transferrin receptor, HER2 receptors, or folate receptors which are the
focus of the targeted micelleplexes covered here. (19, 25, 30, 48) However, most manuscripts
attempt to prove active targeting to the cells in a direct comparison between nanoparticles with
and without the targeting ligand. Multiple studies have demonstrated that basic characteristics of
nanoparticles such as size, shape, charge, and other physical or chemical characteristics have an
impact on payload delivery.(23, 229, 249-254) Here, several biophysical characteristics of siRNA
micelleplexes made with PEI-PLC-PEG triblock co-polymers with and without folic acid were
analyzed to determine whether the addition of folic acid changes the nature of these micelleplexes.
Size and morphology measurements by TEM analysis revealed no noticeable changes between
micelleplexes with or without folic acid, but the addition of folic acid tended to decrease the zeta
potential of the micelleplexes. Likewise, CD spectroscopy demonstrated that there was no
difference in the ability to interact and condense siRNA regardless of the folic acid concentration
on the surface of the particles. Each polymer was able to condense siRNA without changing the A
form of the nucleic acid backbone, as shown in Figure 5.2. However, when higher concentrations
of folic acid were present on the surface of the micelleplexes, a 15-fold increase in the CMC values
was observed. This could be attributed to higher folic acid concentrations changing the hydrophilic
corona of the micelles and disrupting the micelle formation. Instability problems can cause
premature payload release or complete micelle disassociation into its monomer units when injected
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into the bloodstream. These concerns were emphasized by the FCS measurements which addressed
siRNA retention in the presence of serum. At low serum concentrations, mimicking in vitro
concentrations, siRNA release did not increase over time (Figure 5.3). However, at 90% serum
concentration, significant siRNA release was observed. Micelleplexes without folic acid displayed
releases of 0-15%, decreasing as the N/P ratio increased. For the targeted micelleplexes, the more
folic acid was present, the less stable the siRNA micelleplexes were over time. The targeted
micelleplexes released 35-80% of the loaded siRNA, but increased stability was achieved as the
N/P ratio increased. However, the mixed conjugate micelleplexes released 100% of their siRNA
load at N/P 5 and 10, and 80% at N/P 15. Interestingly, the targeted and null folate micelleplexes
outperformed unmodified PEI at each N/P ratio regarding stability. Overall, FCS data
demonstrates that there is optimal folic acid decoration which can be achieved and allows for a
targeting advantage, while not negatively affecting payload delivery. Overall, the presence of folic
acid on the surface of micelleplexes for siRNA retention, while in the presence of serum, has a
negative effect on stability. Lastly, siRNA uptake and protein knockdown was verified to show
efficacy in vitro in Figures 5.4 and 5.5. Previously published results, in combination with what is
shown here, demonstrate that FRα targeting is achieved and at time points beyond 4 hours.(48) In
conclusion, the presence of folic acid changes many biophysical characteristics of self-assembled
micelleplexes. Therefore, the comparison of non-targeted to targeted micelleplexes to determine
receptor targeting efficiency may not be the most precise way to assess targeting efficacy since
micelles can undergo drastic changes in their biophysical properties after targeting ligands are
coupled.
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CHAPTER 6 – INDIUM-LABELING OF SIRNA FOR SMALL ANIMAL SPECT
IMAGING

Please note that this chapter, in its entirety, has been published in Imaging: Materials and
protocols. The authors include myself and Dr. Olivia Merkel. I am the first author and wihtin this
book chapter I performed the experimental protocol and wrote the chapter.
S. Jones, OM. Merkel. “Indium-labeling of siRNA for small animal SPECT imaging”. Methods
in Molecular Biology (Springer 2016), RNA lmaging: Methods and protocols, 1372, 79-88.

6.1 Introduction
Since the Nobel Prize in physiology was awarded in 2006 to Andrew Fire and Greg Mello
for their work in RNA interference (RNAi), there has been an increase in the development of RNAi
as a therapeutic tool to transiently knock down specific proteins. Unfortunately, when it is
delivered in vivo, naked small interfering RNA (siRNA) is taken up very poorly into the cell due
to its molecular make up.(173, 174, 178, 255) To improve its uptake and specificity, siRNA can
for example be packaged inside nanoparticles. Nanoparticle delivery offers several benefits such
as increased stability, longer circulation time, capability to package multiple payloads, and specific
targeting to tumor sites. (54, 170)
The most common routes of nanoparticle administration for therapeutic use are
intravenous, transdermal, pulmonary administration, and intraocular.(256-258) For cancer
therapy, intravenous delivery of the nanoparticles is most ideal due to the ability of the
nanoparticles to inherently preferentially reach the tumors directly from the bloodstream due to
the enhanced permeation and retention (EPR) effect.(185) However, when nanoparticles are
administered intravenously, several obstacles need to be overcome. Among those obstacles are
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the circulation profile and deposition of the nanoparticles. Both of those are key components to
the success of any treatment.
In order to assess the efficacy of the nanoparticle deposition in the organ or tissue of
interest, single photon emission computed tomography (SPECT) imaging can be used. SPECT
imaging is often employed to detect radioactive species within the body.(259) More specifically,
for siRNA delivery, this can be utilized to trace where radioactive siRNA travels throughout the
bloodstream and where specifically it deposits inside the body. This approach provides useful
information about the obstacles that are needed to be overcome for intravenous delivery. More
specifically, SPECT imaging can illustrate whether the siRNA loaded nanoparticles are degraded
in circulation before reaching the tumor site, as well as its biodistribution.(260, 261) Due to the
need to overcome these hurdles for a successful treatment, siRNA imaging techniques are needed.
This chapter outlines the technique to label siRNA with a DTPA chelator. Once the siRNA is
sufficiently labeled with DTPA, it can be reacted with indium and annealed in order to become
radioactive. Once the indium has been chelated to the DTPA, the siRNA can then be packaged
inside a nanoparticle or other nanocarrier and imaged with a SPECT scanner.
6.2 Materials
6.2.1 siRNA Formulation
Due to their increased stability, high activity, and ability to be covalently modified, 2’-Omethylated 25/27mer DsiRNA targeted EGFP(262) from Integrated DNA Technologies (Leuven,
Belgium) was used and is recommended for use. For coupling of DTPA, amine-labeled siRNA is
recommended. Here, we used a duplex with an amino-hexyl modification at the 5-prime of the
antisense strand.
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1. siEGFP:

sense:

5’-pACCCUGAAGUUCAUCUGCACCACdCdG,

antisense:

3´-

mAmCmUGmGGmACmUUmCAmAGmUAmGAmCGUGGUGGC-C6H12NH2
6.2.2 Covalent modification of siRNA with pBn-SCN-Bn-DTPA
1. siEGFP - seen above.
2. pBn-SCN-Bn-DTPA (Macrocyclics).
3. 0.1M NaHCO3 in DEPC water – filtered through a 0.22 µm filter before use.
4. 2M NaOAc in DEPC water – filtered through a 0.22 µm filter before use.
5. Dried DMSO (about three mL).
6. 0.22 µm filter.
7. 2 mL centrifuge tube.
8. Metal spatula wrapped in parafilm – Used to weigh out pBn-SCN-Bn-DTPA (see Note 1).
9. Aluminum foil.
10. Vortex.
6.2.3 Precipitation of the siRNA-DTPA complex
1. 2M NaOAc in RNase free water – filtered through a 0.22 µm filter before use.
2. Absolute ethanol - filtered through a 0.22 µm filter before use.
3. 15 mL conical tube.
6.2.4 Isolation of the siRNA-DTPA complex
1. Ultracentrifuge (see Note 6).
2. Lysis Buffer from Absolutely RNA miRNA Kit (Agilent).
3. 2M NaOAc in RNase free water – filtered through a 0.22 µm filter before use.
4. Absolute ethanol - filtered through a 0.22 µm filter before use.
5. 5 RNeasy Midi Kit (10) columns (Qiagen).
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6.2.5 siRNA-DTPA Purification
1. Centrifuge.
2. Low salt buffer from the Absolutely RNA miRNA Kit (Agilent).
3. RNase free water.
4. Sterile 2 mL collection centrifuge tubes.
6.2.6 siRNA Concentration Measurement
1. Nanodrop.
2. RNase free water.
3. 0.5 mL tubes.
4. Parafilm.
5. Dry heat bath set to 94ºC.
6. Timer.
6.2.7 DTPA Concentration Measurement
1. Stock solution of the yttrium(III)-arsenazo III complex containing 5 µM arsenazo(III)
(Chem-Impex INT’L INC.), and 1.6 µM yttrium(III) chloride (Acros Organics) in a 0.15 M
NaOAc buffer at pH 4.
2. Stock soltuion of 0.123 mM DTPA dissolved in DI-H2O with 3 molar equivalents of NaOH
(see Note 2).
3. UV-Vis spectrophotometer.
4. UV-Vis disposable cuvette.
6.2.8 Indium Labeling
1. Radioactive Indium(III) chloride (Covidien, Mansfield, MA).
2. GE Healthcare Disposable PD-10 Desalting Columns.
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3. RNase free water.
4. Scintillation vials (make and model to fit gamma counter).
5. Gamma counter (e.g. Packard 5005).
6. Nanodrop.
6.2.9 Animal Imaging
1. Mice, e.g. 6 week old balb/c mice.
2. Sterile Insulin Syringes.
3. Sterile siRNA formulation, e.g. nanoparticles.
4. Mouse anesthesia.
5. SPECT imaging device and mouse cradle, e.g. Siemens E.CAM with custom-made
collimator.
6.3 Methods
6.3.1 React siRNA with pBn-SCN-DTPA:
1. Weigh out 5.11 mg of Double Stranded siRNA in a 2 mL centrifuge tube and dissolve it in
100 uL of RNase free water (see Note 3).
2. To the 2 mL tube, add 100 µL of filtered 0.1M NaHCO3.
3. Next, weigh out 9.76 mg of pBn-SCN-Bn-DTPA and dissolve it in 540 µL of dry DMSO
(see Note 1 and 4).
4. Add the 540 µL of the DTPA to siRNA mixture. The new total volume should be 740 µL
(see Note 5).
5. Wrap the solution in tin foil, vortex thoroughly, and incubate for 6 hours. Agitate the
solution every 30 minutes.
6.3.2 Precipitation of the siRNA-DTPA complex
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1. Add 74 µL of filtered 2 M Na-acetate to the mixture (10% of the total amount of mixture).
2. Transfer the mixture to a 15 mL conical tube.
3. Add filtered absolute ethanol so that the final concentration is 80% v/v.
4. Freeze solution overnight at -80ºC.
6.3.3 Isolation of the siRNA-DTPA complex
1. Centrifuge the sample for 30 minutes at 12,000g in an ultracentrifuge (see Note 6).
2. Discard the supernatant.
3. Add 2.5 mL of Lysis Buffer from “Absolutely RNA miRNA Kit” (Agilent).
4. Vortex the solution.
5. Add 250 µL of filtered 2M Na-Acetate.
6. Add 7.25 mL of filtered absolute ethanol for a total of 10mL (see Note 7).
7. Vortex the solution and equally distribute the 10 mL onto 5 RNeasy Midi Kit (10) Qiagen
Columns (see Note 8).
6.3.4 siRNA-DTPA Purification
1. Centrifuge the columns at 4,500g for 5 minutes, discard the flow through.
2. To each column, add 200 µL of the low salt buffer from the Absolutely RNA miRNA Kit
(Agilent).
3. Centrifuge the solution at 4,500g for 2 minutes, discard the flow through.
4. Repeat steps 2 and 3.
5. To dry the column, spin them down at 5,000g for 5 minutes.
6. Transfer the columns to a new collection tube and add 200 µL of 60ºC hot RNase free
water.
7. Centrifuge the solution at 5,000g for 5 minutes to collect the purified siRNA-DTPA.
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8. Add 100 µL of 60ºC hot RNase free water and centrifuge at 5,000g for 5 minutes.
9. Combine the flow through from all of the columns into one sterile 2 mL tube.
6.3.5 siRNA Concentration Measurement
1. Measure the siRNA concentration on a nanodrop (Thermo Scientific - Nanodrop 2000c).
Use RNase free water as your blank.
2. Under the hood, dilute the siRNA to a desired concentration and aliquot into 0.5 mL sterile
tubes (see Note 9).
3. Filter the siRNA-DTPA solution to make it sterile.
4. Parafilm each tube and anneal the siRNA at 94ºC for exactly 2 minutes.
5. Let the samples cool down to room temperature.
6. Freeze the samples and keep frozen until needed.
6.3.6 DTPA Concentration Measurement
1. Using a UV-Vis spectrophotometer (Cary – 50 Bio), you will create the standard curve for
DTPA concentrations.
2. Pipette 3 mL of the Y(III)-arsenazo III complex stock solution into a cuvette and read (652
nM) this as the blank.
3. Add 5 µL of the stock DTPA solution to the cuvette, gently mix, and read the solution again
(see Note 10).
4. Add another 5 µL of the stock DTPA solution, read, and repeat.
5. Do this until you have generated enough points for your standard curve.
6. Each new data point will have an additional 5 µL added into the cuvette.
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7. Once all the standards have been made and read on the spectrophotometer, discard the
solution inside the cuvette and put 3 mL of fresh Y(III)-arsenazo III complex stock solution
into the cuvette (see Note 11).
8. Add 5 µL of your siRNA-DTPA sample into the 3 mL and take the measurement.
9. Plot the standard curve for the DTPA concentrations versus absorbance and insert a linear
line of best fit.
10. Using the equation yielded from the line of best fit, plut the absorbance value obtained from
your sample measurement and plug that into the Y-value of the equation in order to solve
for X.
11. The X-value obtained will be the concentration of DTPA in your sample.
12. Now that the DTPA and siRNA concenctations have been found for the siRNA-DTPA
mixture, figure out the molar amounts of the siRNA and DTPA within your sample. From
here, you can determine the molar equivalency of the siRNA and DTPA (see Note 12).
6.3.7 Indium Labeling and Purification
1. React radioactive 111InCl3 with siRNA. In the example shown below, 116.9 MBq 111InCl3
were reacted with 15 nmol siRNA. Incubate for 30 min at room termperature.
2. Equilibrate a PD-10 column with Rnase free water by washing it with 25 ml.
3. Prepare 24 scintillation vials in a rack and label them from 1-24.
4. Place vial 1 underneath the PD-10 column and start adding the siRNA-Indium mixture to
the column slowly.
5. Collect 13 drops in the first vial as fraction 1 and then move on to the next vial. Collect 13
drops per fraction. Once the complete volume of the siRNA-Indium mixture is applied to
the column, add Rnase free water. Collect 24 fractions.
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6. Close the scintillation vial and measure the counts per minute (CPM) in every vial using a
gamma counter.
7. Plot the CPM versus the fraction number.
8. Determine the siRNA concentration in the peak fraction using a Nanodrop (Note 13).
6.3.8 Animal Imaging
1. Prepare the siRNA formulation to be administered, e.g. nanoparticles.In the example
below, micelles of polyethyleneimine-graft-polycaprolactone-block-poly(ethylene glycol)
were prepared with 2 nmol siRNA per animal which was equivalent to approximately 3
MBq per animal.
2. Anesthetize the animals and administer the siRNA formulation. In the example below,
injection to the tail vein was chosen.
3. Place the animals, one after the other, in the cradle and start the 360º imaging program
(Note 14).
6.4 Notes
1. Wrap the metal spatula in parafilm so the DTPA does not complex to the metal ions from
the spatula.
2. You should first dissolve the DTPA in DMSO before diluting in the DI-H2O with NaOH.
Make sure the DMSO is at least diluted out by a factor of 1:100.
3. Our siRNA had a MW of 17950.36 g/mol. Therefore we use 0.285 µmoles of siRNA.
4. Total pBn-SCN-DTPA (MW=649.9 g/mol) is 15.02 µmoles.
5. The solution turned cloudy upon the addition of the DTPA to the siRNA solution.
6. You should get a nice visible white pellet at the bottom of the 15 mL conical tube. A regular
centrifuge that reaches a speed of 12,000g may as well be used.
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7. Upon addition of the ethanol, the solution should turn slightly cloudy again.
8. You should put roughly 2 mL into each column due to the fact that each column can only
retain 1 mg RNA and a limited volume. If you add too much, you may lose some during
the purification steps.
9. To make calculations easier in the future, dilute the siRNA to either 100 mM or 50 mM.
Aliquot the samples into small portions to prevent several freeze-thaw cycles.
10. Mix the samples by gently pipetting up and down within the cuvette. Be careful not to
create any bubbles.
11. Make sure you rinse out the cuvette very well. When you read the fresh 3 mL of the
complex solution, verify that the values are in line with the previous measurements.
12. Since each siRNA strand has only 1 amine group for DTPA to complex to, if performed
correctly, your ratio should be approximately a 1:1 molar equivalence of DTPA and
siRNA. If the ratio of DTPA per siRNA is higher than 1:1, residual free DTPA was not
removed during the purification.
13. It may be necessary to combine 2 or more peak fractions based on the CPM values and
RNA concentrations. If free DTPA is present in the siRNA solution when it is radiolabeled,
a second small peak will appear around fraction 12, and free Indium appears around
fraction 20.
14. The imaging procedure can be repeated at any given time. The half-life of 111Indium is 2.6
days, and a significant amount of siRNA is typically excreted renally or even hepatically.
Therefore, imaging at time points later than 48 hours can become challenging.
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6.5 Conclusion
Within this protocol, a detailed procedure was dicussed to demonstrate an effective way to
radiolabel siRNA with radioactive In-111. Furthermore, a step-by-step guide to perform the
purification and analysis of the assay is entailed. This technique provides a facile method to
trace siRNA distribution in vivo which is administered in siRNA therapeutics.(25, 191) Due
to the nature of free siRNA being easily degraded in circulation and therefore usually
requiring a carrier to protect it, it is necessary to label the siRNA molecule itself rather than
the carrier. The caveat with this approach is that the signal acquired of In-111 may not reflect
intact or active siRNA. Therefore, it is imperative to include other experimental parameters
to ensure biological activity.
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Figure 6.1 Scatter plot obtained from creating the standard curve of the DTPA concentrations.
As seen below, the amount of DTPA added to the cuvette is on the X-axis, and Absorbance at
652 nm is on the Y-axis. From here, concentration of the DTPA inside the siRNA-DTPA
mixture can be obtained.
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Elution Profile of Indium-111
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Figure 6.2: Scatter plot obtained from purifying and eluting 111Indium-labeled siRNA over a
PD-10 column. The radioactivity as measured in counts per minute (CPM) are shown on the Yaxis as a function of the fraction eluted on the X-axis. A clear peak is shown in fraction 7.
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Figure 6.3: SPECT images of a 6 week-old balb/c mouse i.v. injected with 2.9 MBq 111Indiumlabeled siRNA formulated as micelles 2 h after injection. The formulation was obtained with a
polymer carrying a short, 500 Da, PEG chain which is the reason for the accumulation of the
micelles in the lung. Deposition in the liver and excretion through the kidneys into the bladder
can be observed as well.
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CHAPTER 7 – SPECT/CT AND BIOLUMENESENCE IMAGING OF FOLATE
RECEPTOR ALPHA TUMOR TARGETING WITHIN AN ORTHOTOPIC OVARAIN
CANCER MODEL
7.1 INTRODUCTION
Ovarian cancer remains one of the deadliest gynecological malignancies to date. With
current treatment options, 65% of all women who are diagnosed will eventually succumb to the
disease.(263, 264) A primary reason as to why patients have low survival rates is that a majority
of patients are diagnosed at an advanced stage. The disease progression of ovarian cancer, if left
untreated, produces aggressive and wide-spread metastatic lesions throughout the peritoneal
cavity.(64) These metastatic lesions become deadly to patients by compressing and compromising
vital organs. Primary treatments for these patients often include tumor de-bulking, along with a
combinational chemotherapy regimen of a platinum and taxane agents.(263, 265) Unfortunately,
with already wide-spread metastatic lesions, resistance and reoccurrence of the disease commonly
complicates outcomes.(48, 211, 266) Resistance mechanisms often include an increase in antiapoptotic proteins, increase activity of drug efflux pumps, or altered drug targets.(101, 118, 122,
123, 132, 153, 267, 268) If patients experience chemoresistance, treatment options become
considerably limited.
The American Cancer Society, along with Endocyte estimates that over 85% of ovarian
cancer patients have an overexpression of folate receptor alpha (FRα).(32, 33) Folate receptor is
expressed in four distinct isoforms: alpha, beta, gamma, and delta.(39, 40, 163) Both alpha and
beta isoforms are cell surface receptors that are glycosylphosphatidylinositol-anchored (GPI) and
linked to the membrane.(163) FRα and FRβ have a very select expression profiles. FRα is
expressed on the proximal side of the tubules of the kidneys, spleen, and certain lung tissues, as
well as a variety of cancers.(32, 33, 70, 71, 241) Additionally, FRβ is mainly expressed on
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activated macrophages. Both receptors express high affinities for folic acid (Kd = 1-10 nM).
Therefore, folate receptors have been exploited by researchers to deliver a targeted payload to
specific cells of interest by linking a targeting moiety of folic acid to either a drug itself or a
delivery vehicle. This approach has been implemented for treating a variety of cancers and
autoimmune diseases.(5, 209, 212, 221, 225) Accordingly, nanomedicine researchers have utilized
this approach to selectively deliver a nanoformulated payload to target cells, while decreasing off
target toxicity caused by uptake of the payload into healthy cells.
One type of payload that researchers have been utilizing in a targeted delivery approach is
small interfering RNA (siRNA). siRNA has shown promising potential in treating diseases, such
as cancer, by silencing genes that give rise to a diseased phenotype Here, we added a folic acid
targeting ligand to the surface of the nanocarriers to take advantage of the FRα overexpression
within our xenograft mouse model and to skew tissue distribution toward the tumor. To deliver the
siRNA, triblock copolymers were utilized containing polyethyleneimine (PEI) to electrostatically
condense and protect the siRNA. PEI has been documented to be an efficient carrier and
transfection reagent. The polymers here were modified with a polyethylene glycol (PEG) chain to
increase biocompatibility and circulation profiles, increase the stealth-like character of the
nanocarriers to avoid macrophage detection and to decrease the interaction with serum
proteins.(191, 221) Lastly, a polycaprolactone (PCL) block was added in the middle as a linker
between PEI and PEG to increase the hydrophobic content of the polymer, drive micelle formation,
and to aid in cleaving the polymer chains and releasing the siRNA once inside the cell due to its
susceptibility to hydrolytic degradation.(25, 269) Previous work performed with PEI-PCL-PEG,
or PPP, polymers has shown their ability to deliver siRNA in vitro to FRα overexpressing cells,
achieve a sustained protein knockdown, and display long-circulation profiles in vivo.(25, 48, 180,
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181, 183, 217) Here, we used modified architectures of the polymer and their block ratios in order
to display their efficacy in vivo and ultimately show their ability to mediate gene silencing in vivo.
Furthermore, we compared the FRα targeted and non-targeted formulations in a SKOV-3/LUC
FRα overexpressing cell line employed within a murine orthotopic xenograft model of ovarian
cancer.
7.2 MATERIALS AND METHODS
7.2.1 Materials:

Hetero-bifunctional poly(ethylene glycol) (3.5 kDa), as well as methyl

terminated monofunctional

poly(ethylene glycol) (5 kDa)

was purchased from JenKem

Technologies (Plano, TX, USA) and chemically modified based on previously published
protocols.(48) Hyper-branched polyethylenimine (hy-PEI, 25 kDa) was purchased from BASF
(Ludwigshafen, Germany). Dicer substrate double-stranded siRNA (DsiRNA) targeting the
Enhanced Green Fluorescent Protein gene (EGFP siRNA, 25/27), Firefly Luciferase (luc),
Negative Control (scr), as well as Alexa Fluor-488 labeled siRNA were purchased from Integrated
DNA Technologies (IDT, Coralville, IA, USA). Folic acid depleted Dulbecco’s Modified Eagle’s
Medium (10x) for cell culture, phosphate buffered saline (PBS), heat-inactivated fetal bovine
serum (FBS), D-(+)-glucose, and sodium bicarbonate were purchased from Sigma-Aldrich (St.
Louis, MO, USA). The chelator pBn-SCN-Bn-DTPA was purchased from Macrocyclics (Plano,
TX, USA) while arsenazo(III) was purchased from Chem-Impex INT’L INC (Wood Dale, IL,
USA), and yttrium(III) chloride was obtained from Acros Organics (Geel, Belgium).
7.2.2 Cell Culture: The SKOV-3 SKOV-3/LUC human ovarian cancer cell line was obtained
from ATTC (LG Promochem, Wesel, Germany). The SKOV-3/LUC cell line was engineered by
stably transfecting the parental SKOV-3 cell line to stably express the reporter gene luciferase as
previously published.(188) SKOV-3 and SKOV-3/LUC ovarian cancer cells were cultured in
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folate-free DMEM cell culture medium (Sigma-Aldrich) supplemented with 0.584 gm/L of Lglutamine, 3.7 gm/L sodium bicarbonate, 10% fetal bovine serum (Thermo Scientific Hyclone),
and 1% penicillin/streptomycin at 37 °C and 5% CO2. Cells were grown in 75 and 175 cm2 cell
culture flasks (Thermo Scientific) and passaged every 2-3 days when they had reached confluency.
7.2.3 Preparation of PEI-g-PCL-b-PEG-Fol Micelleplexes: Each polymer was dissolved in
water to yield a 1 mg/mL concentration based on the 25 kDa PEI content. Concentrations were
tested with a copper assay, as described before.(48) Once dissolved, samples were filtered through
a 0.22 μm filter for sterilization. Subsequently, micelleplexes were prepared for both in vitro and
in vivo work by mixing polymer and siRNA solutions together based on a previously published
protocol.(48)
7.2.4 In-111 siRNA Radiolabeling and Purification: To investigate in vitro cellular uptake and
in vivo pharmacokinetics and biodistribution, indium-111 labeled siRNA was synthesized based
upon a previously published protocol.(270) Briefly, siRNA modified with an amine functional
group on the 5’ end was labeled with the chelator, p-SCN-Bn-DTPA. After purification, it was
incubated with
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InCl3 for 30 minutes. Afterwards, the mixture was run though a PD-10 size

exclusion column in order to separate free In-111 fractions from siRNA-DTPA-In-111 fractions.
In-111 bound to siRNA was verified through gamma scintillation counting and UV absorption
detection at 260 nm. If needed, peak fractions were combined for in vivo studies.
7.2.5 Cellular Uptake of Micelleplexes by Gamma Counting: In 24-well plates (Corning
Incorporated, Corning, NY), 60,000 SKOV-3 cells were incubated over night at 37 °C and 5%
CO2. In each well, freshly made micelleplexes containing 50 pmol of siRNA-DTPA-In-111 were
added. Negative controls consisted of blank/untreated cells, while positive control cells were
treated with siRNA containing lipoplexes made with lipofectamine (Life Technologies, Carlsbad,
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CA, USA) and polyplexes made with unmodified hy-PEI. Cells were transfected for 4 hours at 37
°C and in the presence of 5% CO2. Cells were washed twice with 1X PBS + 2 mM EDTA,
trypsinized and spun down at 350 g for 5 min. After centrifugation, the cells were re-suspended
in 1X PBS + 2 mM EDTA buffer and analyzed via Packard Tricarb 2910TR liquid scintillation
counter (PerkinElmer, Waltham, MA). Samples were all run in triplicate and analysis of the data
was performed by GraphPad Prism 5.0 software for calculating mean values and standard
deviations.
7.2.6 Albumin Binding Assay: An albumin binding assay was performed to detect and mimic
plasma protein affinities with siRNA and siRNA containing micelleplexes. Procedures utilized
here followed a previously published protocol.(193, 271) To assess albumin binding, a
concentrated stock of albumin was made in PBS at 450 mg/mL containing 0.005% v/v Tween 80.
Further dilutions of the stock albumin were made in DMEM medium. Micelleplexes containing
In111-DTPA-siRNA were formed and incubated with 45 mg/mL, 4.5 mg/mL, 0 mg/mL albumin
(DMEM media) for 1 hour at 37 ˚C. After incubation, solutions were transferred to 30,000 MWCO
spin columns and centrifuged at 735 g for 15 minutes at room temperature. Following
centrifugation, the flow through was discarded and the remaining aliquot was analyzed for siRNA
content using gamma scintillation counting.
7.2.7 Confocal Scanning Laser Microscopy (CLSM): SKOV-3 cells were seeded in a Permanox
8 chamber slide (Nunc, Fisher Scientific, Waltham, MA, USA) at a density of 25,000 cells in 300
μL and incubated over-night at 37 °C and in the presence of 5% CO2. Micelleplexes were made
as described above using 40 pmol of AF-488 labeled siRNA. After incubating the cells with the
micelleplexes for 4 hours, the supernatant was decanted and cells washed with 300 μL of PBS for
2-3 minutes. Afterwards, cells were fixed with 4% paraformaldehyde solution in PBS for 20
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minutes at room temperature. Cells were then washed twice with 300 μL of PBS for 2-3 minutes
followed by DAPI nuclear staining at a concentration of 175 ng/mL (Life Technologies, Carlsbad,
CA, USA) for 20 minutes at room temperature while shaking. Cells were then washed twice with
300 μL of PBS. The chambers were removed, the slides were blotted to remove any excess wash
solution with a Kimwipe, and Fluorsave (CalBiochem, San Diego, CA, USA) was added to the
slide and coverslips mounted over the samples. The samples were incubated for at least 1-2 hours
in the dark to let the coverslip adhere to the chamber slide. For excitation of AF488, an excitation
wavelength of 490 nm was used while emission was detected with a spectral detector at 525 nm.
DAPI staining was excited with a UV laser that had an excitation wavelength of 364 nm, and
emission was detected at 385 nm. Images were recorded using a Zeiss LSM 780 confocal
microscope and overlaid with brightfield light to gain information about cellular structures.
7.2.8 In Vivo Pharmacokinetics, Biodistribution, and SPECT Imaging: All animal experiments
were approved by a Wayne State University Institutional Animal Care and Use Committee. For in
vivo experiments, 6-week-old female nude mice were purchased from Charles River Laboratories
and injected with 6 million SKOV-3/LUC cells intraperitoneally based on previously established
protocols (272-274). Mice were monitored and tumor growth was observed with bioluminescence
imaging using a Bruker Carestream In-Vivo Extreme (Billerica, MA, USA) for 6 weeks before
use. At four weeks post injection, the mice were placed on a folic acid-deficient diet (Envigo RMS,
Indianapolis, USA) in order to reduce their serum folate to a level near that of human serum and
to increase the folate receptor alpha status of the cancer cells.(271) On the day of the experiments,
mice were injected intraperitoneally (I.P.) or intravenously (I.V.) with targeted or non-targeted
micelleplexes containing 35 μg of siRNA-DTPA-In-111. After dosing, 25 μL of blood were drawn
retro-orbitally from the mice’s right eyes at 1, 3, 5, 15, 30, 60, and 120 min and analyzed by gamma
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counting for the presence of In111-DTPA-siRNA. SPECT/CT scans were taken on a Siemens
Inveon SPECT/CT (Siemens, Erlangen, Germany) at 4 hours and 24 hours post-injection. After
the second scan, mice were sacrificed for organ harvesting to assess biodistribution of the siRNA.
Once sacrificed, the liver, kidneys, lungs, brain, spleen, bowels, and tumors were dissected,
weighed, and analyzed via gamma counting for the presence of In111-DTPA-siRNA. Results in
counts per minute (CPM) of each tissue and blood sample were compared to a freshly made
standard curve of In-111 and normalized to the injected dose. All biodistribution results are given
as percent of the injected dose per gram of organ weight (%ID/g) while pharmacokinetic studies
are represented by percent injected dose per mL of blood (%ID/mL).
7.2.9 Bioluminescence Imaging (BLI): Tumor growth and luciferase knockdown of animals were
monitored on a Bruker Carestream In-Vivo Xtreme (Billerica, MA, USA). Tumor growth was
monitored every 2 weeks until the 6-week time point. Animals designated to BLI studies were
injected I.P. with 100 µL of a freshly prepared 15 mg/mL D-Luciferin (System Bioscience, San
Francisco, USA) stock solution in PBS per 10 g of their body weight. After ten minutes, mice were
treated with 3% isoflurane until sufficiently sedated. Maintenance isoflurane was used during
imaging to keep the mice sedated. BLI images were taken with a three-minute exposure under high
sensitivity and aperture of the lens set at an f-stop of 1.1. Simultaneously, X-ray images were taken
under standard 1.2 second exposure. Images were transferred to ImageJ and region of interests
(ROI) were drawn around the tumor and metastases to determine luciferase expression. Values
were normalized to the day 0 luciferase expression and analysis was performed by GraphPad Prism
5.0 software.
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7.3 RESULTS AND DISCUSSION
Previous in vitro studies performed in Chapter 4 with tri-block copolymers consisting of
polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol) (PEI-g-PCL-b-PEG-FOL)
with folic acid have demonstrated efficient siRNA delivery via folate receptor alpha (FRα)
targeting and protein knockdown. Here, we focused on the in vivo performance of these
micelleplexes by bioluminescence (BLI) and single-photon emission computed tomography
(SPECT) imaging. In order to utilize SPECT imaging capabilities and to monitor siRNA tumor
deposition and biodistribution, the siRNA needed to be labeled with Indium-111 (In-111).(270)
To determine whether chelation of In-111 effected siRNA uptake profiles of the targeted and nontargeted micelleplexes, gamma scintillation experiments were performed and compared with
CLSM results of fluorescently labeled siRNA as shown in Figures 7.1 and 7.2. After 4 hours post
transfection, uptake profiles of both targeted and non-targeted micelleplexes were analyzed in
comparison to lipofectamine and unmodified PEI. As shown in Figure 7.1, both micelleplexes
delivered indium labeled siRNA just as effectively as the unmodified PEI but not as efficient as
lipofectamine which was expected. Although uptake profiles of lipofectamine demonstrate greater
siRNA delivery, protein knockdown was shown in Chapter 3 to be similar when compared to the
targeted micelleplex.(48) Additionally, the tri-block copolymers were previously shown to be
better biocompatible than lipofectamine.(48) Therefore, although the uptake profile of
Lipofectamine seemingly demonstrates a greater payload delivery efficiency, the overall effect
was offset by its toxicity.
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Figure 7.1: siRNA uptake studies using gamma scintillation counting. Uptake study over 4 hours with
Indium-111 labeled siRNA for 4 hrs. Samples were run in triplicates and error bars represent the standard
deviation.

To visualize siRNA delivery and internalization within the cell, CLSM images were taken
of fluorescent siRNA delivered by different formulations, as shown in Figure 7.2. Figure 7.2 B
clearly demonstrates that the targeted micelleplexes experience an apparent targeting advantage
on cells which overexpress FRα. The FR-targeted micelleplexes seemingly coat the outside of the
cell, utilizing FR-mediated endocytosis which would result in greater siRNA accumulation
intracellularly over time. Conversely, null folate micelleplexes (Figure 7.2 C) do not undergo
receptor-mediated endocytosis, but are taken up by adsorptive endocytosis. As described
previously, these tri-block copolymers with folic acid were designed to encapsulate siRNA into
micelleplexes in order to hijack the cells’ normal receptor mediated endocytosis mechanisms, to
escape the endosome, and to release siRNA into the cytoplasm.(48) Therefore, FRα targeted
micelleplexes achieve a targeting advantage to deliver the siRNA over their non-targeted
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counterparts, which can be visually depicted in Figures 7.2 B and C. It should be noted that these
confocal images are not quantitative. Therefore, the total amount of siRNA shown in Figures 7.2
B and C may not be significantly different, as measured by flow cytometry. However, due to the
different mechanisms of uptake between targeted and non-targeted micelleplexes, the subcellular
distribution is different; which has been previously reported.(48, 245) The FRα targeted
micelleplexes deliver siRNA more efficiently into the cytoplasm, where the non-targeted
micelleplexes are entrapped within the endosomes.

A

B

C

Figure 7.2: siRNA uptake studies using confocal laser scanning microscopy. Confocal images were
taken of untreated cells (A), targeted micelleplexes (B), and null folate targeted conjugates (C).

As expected, due to its negative charge, hydrophilicity, and ease of degradation by
nucleases in circulation, naked siRNA has poor ability for cellular uptake and a short half-life in
vivo.(16, 193, 231) Modifications to the siRNA backbone such as C6 or 2’-O-(2-methoxyethyl)
can increase the stability of siRNA for longer lasting circulation. Additionally, previous studies
have demonstrated that positively charged polymers can electrostatically condense the siRNA and
subsequently protect it from RNase degradation and competing ion displacement.(48, 183, 275) In
order to investigate the potential for siRNA to be displaced and adsorbed by serum, an albumin
binding assay was performed. In this assay, siRNA or siRNA-containing polyplexes are filtered,
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whereas albumin bound siRNA or albumin bound micelleplexes are held back in the filtration
device. As shown in Figure 7.3, albumin binding of the micelleplexes was observed at a low serum
concentration (4.5 mg/mL) which mimics in vitro conditions and at a more physiologically
relevant concentration of serum (45 mg/mL).(276) At both serum concentrations, both the targeted
and non-targeted micelleplexes were filtered in a comparable manner with no statistical difference.
In comparison, similar studies performed with PEI-PEG complexes, showed albumin binding of
approximately 30% siRNA when incubated with low and physiologic concentrations of serum
albumin.(193) Here, we show a 14% albumin binding of siRNA from the micelleplexes at 4.5
mg/mL serum, and 25% albumin binding at 45 mg/mL for both targeted and non-targeted
micelleplexes. It should be noted, however, that although there is only 14% and 25% albumin
binding at both serum concentrations, this may not accurately represent the amount of siRNA that
will be bioavailable for knockdown. This is attributed to the possibility of both free siRNA and
micelleplexes binding to the serum and therefore exceeding the pore size for filtration. However,
the difference between results obtained with PEG-PEI polyplexes and the data obtained here for
micelleplexes at low serum concentrations could be due to the charge difference between the two
delivery systems. While the micelleplexes have only a slightly positive charge (around +5-10 mV),
the polyplexes described earlier (Chapter 3) demonstrated zeta potentials at or above + 20 mV.
With a decrease in the overall positive charge of the micelleplexes, there could be a subsequent
decrease in the serum albumin binding.
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Figure 7.3: Albumin binding study. Assessment of indium-111 labeled siRNA binding to albumin at
concentrations 4.5 and 45 mg/mL. Samples were run in triplicates.

Once stability and serum binding profiles were analyzed, in vivo pharmacokinetics of both
targeted and non-targeted micelleplexes formed with In-111 labeled siRNA were analyzed for both
administration routes. Previous studies performed with free, non-formulated In-111 labeled siRNA
showed an elimination half-life from the blood of approximately 15 minutes.(193) Here, I.V.
injected targeted micelleplexes had alpha phase half-lives of 13.2 min for the targeted and 4.95
min for the non-targeted formulations. This reflects that the distribution between compartments
was very fast in case of non-targeted micelleplexes, whereas targeted ones remained in the central
compartment a bit longer. Accordingly, the beta elimination phase half-lives were clearly different
with 117.8 min for the targeted and 22.31 min for the non-targeted formulation, explaining the
overall lower bioavailability of the non-targeted micelleplexes.

The bioavailability of the

micelleplexes was analyzed through statistical determination of the area under the curve (AUC).
Overall, both the targeted and non-targeted micelleplexes displayed much shorter circulation
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profiles than in previous reports with similar tri-block copolymers.(25, 183, 193) For I.P. injected
micelleplexes, the corresponding AUC for the targeted and non-targeted micelleplexes were 125.2
%ID min/mL and 157.4 %ID min/mL, respectively. This demonstrates the different absorption
profiles as reflected in the difference of the tmax values. While tmax for the non-targeted
micelleplexes was reached at 60 min, the absorption of the targeted micelleplexes from the
peritoneum into the circulation was less quantitative and reached a maximum at a tmax of 15 min
already. Afterwards, the targeted micelleplexes were slowly excreted, while absorption of the nontargeted micelleplexes lasted until 60 min post injection. Thus, the non-targeted formulation
reached a greater bioavailability when injected I.P. Conversely, when injected I.V., targeted
micelleplexes displayed a slightly better bioavailability with an AUC of 103.7 %ID min/mL versus
87.90 %ID min/mL for their non-targeted counterpart. Therefore, the AUC for I.P injected
micelleplexes was about 1.25-1.5 times greater than after I.V injection. The decreased
bioavailability of both micelleplexes, when compared to previously published data using similar
polymers, reflects that the nanoparticles are cleared from circulation relatively quickly. One
possible reason is simple excretion, but another explanation could as well be extravasation out of
the blood stream and into target or non-target tissues, which was investigated in the biodistribution
experiments. While free siRNA is likely cleaved by nucleases, adsorbed to proteins within the
bloodstream, or taken up by the kidney for excretion, micelleplexes have the capabilities to protect
and retain siRNA. This assumption is based on previously published data and results shown in
Figures 7.3 and 7.4.(48) The short circulation half-lives of both the targeted and non-targeted
micelleplexes are therefore most likely due to fast extravasation out of circulation and into organs
when compared to free siRNA, which is only excreted. The half-lives of each micelleplex at each
administration route were analyzed with a two-compartment PK model instead a one-compartment
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model based on curve fitting. The two-compartment model yielded a R2 values of 0.644 and 0.945
for the targeted and null-folate, respectively, while the R2 values in the one-compartment models
were 0.643 and 0.940. Since the micelleplexes show rapid accumulation in the liver, a twocompartment model seems more appropriate with the deeper compartment reflecting the
accumulation in liver, spleen, and at early times points the tumor.
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Figure 7.4: In vivo pharmacokinetic analysis of nude mice. Pharmacokinetic analysis of Indium-111
injected nude mice both intraperitoneally (n=6) (A) and intravenously (n=10) (B). Blood samples were
collected retro-orbitally at 1, 3, 5, 15, 30, 60, and 120 minutes’ post injection. Blood samples were analyzed
via gamma scintillation counting. Error bars represent standard deviation of the mean.

Mice were sacrificed 24 hours post I.V or I.P injection of targeted or non-targeted
micelleplexes, and their organs were harvested to determine the amount of siRNA taken up into
the tumor and other main organs. The biodistribution results of both administration routes can be
found in Figure 7.5. After I.P. injection, the two strongest signals were found within the kidneys
(7.78 and 7.36 %ID/g, respectively) and the tumor (including all metastatic sites) (5.63 and 5.28
%ID/g, respectively) for both the targeted and non-targeted micelleplexes. These results
demonstrate that with the used formulations, the targeting effect was minimal when the siRNA
loaded micelleplexes were injected I.P. When micelleplexes were injected I.V., the first pass
metabolism caused accumulation of the majority of the normalized injected dose per gram in the
liver (38% for targeted and 53% for non-targeted), as expected. There was a slight improvement
in the tumor uptake for the targeted versus non-targeted micelleplexes (3.4% and 2.4%,
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respectively). However, the strong accumulation in the liver explains the rapid clearance of the
micelleplexes from the circulation as described above. Unfortunately, this rapid deposition in a
deep compartment interferes with circulation and deposition in the target tissue. In comparison,
studies performed by Liu et al. demonstrated 17% ID/g tumor uptake with similar tri-block
copolymers.(25) However, the micelleplexes used by Li et al. showed approximately 6-fold higher
bioavailability and considerably slower deposition with approximately 8-fold less accumulation in
the liver which allowed for slow but highly efficient tumor targeting. Additionally, the previously
reported results were obtained in a subcutaneous ovarian cancer model. Here, we demonstrate
tumor uptake in a more clinically relevant orthotopic ovarian cancer model. This model more
accurately represents patient’s disease and is more predicative of drug efficacy but unfortunately,
in combination with the shorter circulation times of the formulations used here, did not reflect the
same targeting efficacy. Similarly, studies performed with FRα targeted gold nanospheres or PEG
coated gadolinium achieved 5.26% siRNA and 5% nanoparticle uptake in the tumor,
respectively.(277, 278) Especially in case of the I.P. administration route, we found considerable
siRNA uptake in the kidneys. This observation can be explained by siRNA preferentially
accumulating inside the kidneys. Although FRα is expressed within the proximal tubules of the
kidneys, and unavailable via access by the bloodstream, these data suggest that the uptake within
the kidneys is likely due to siRNA renal accumulation rather than active FRα targeting.(71, 213,
279) Taken together, our findings demonstrate that tumor accumulation of our tri-block
micelleplexes occurs mainly through passive targeting, potentially the EPR effect, rather than
active tumor targeting. The potential role of the EPR effect was only observed after I.P.
administration, however, whereas the tumors were not efficiently reached after I.V. injections due
to the short circulation times of the nanoparticles. This observation reinforces the idea that the EPR
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effect may not play an important role in nanoparticle delivery in a clinical setting.(13, 280, 281)
Compared to the results reported by Liu et al., this FRα delivery system has a greater amount of
off-target uptake, especially in the liver. This could be a result of the FRα micelleplexes bearing a
greater grafting degree and thus more folic acid on their surface, resulting in a higher valency.(25,
48) These data can likely be explained by the observation that targeted particles with higher
valency display a greater degree of off-target binding in vivo.(28)
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Figure 7.5: In vivo biodistribution analysis of nude mice. Biodistribution analysis of Indium-111 injected
nude mice both intraperitoneally (A) and intravenously (B). Animals were sacrificed and organs were
harvested 24 hours post injection and read under gamma scintillation counting.

SPECT/CT images of the targeted micelleplexes were taken 4 hours and 24 hours post I.P
injection. Those images are shown in Figure 7.6 A and B in all three anatomical planes. At 4 hours,
there was a surprising amount of localization within the primary tumor which could be due to an
initial effect of receptor-ligand interaction between the micelleplexes and the tumor cells. The two
additional signals in the coronal plane can be surely assigned to the kidneys, reflecting the
biodistribution results. Many metastatic lesions in ovarian cancer patients occur within the
peritoneum.(64) Likewise, many of the smaller metastatic tumors in the mice developed all around
the liver and on the caudal side of the diaphragm. As shown in the saggital plane image in Figure
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7.6 A, siRNA uptake was achieved within these metastatic lesions. Scans taken at the 24-hour
time point did not show significant retention of the siRNA within the primary tumor at this later
time point. Instead, the coronal plane image shows a strong signal in the liver which in this plane
covers the kidneys. In the saggital plane image, siRNA uptake in the kidneys, and possibly in the
metastatic lesions within the peritoneum located adjacent to the liver and diaphragm, can be found.
This result demonstrates that targeting effects of the micelleplexes were washed out after 24 hours,
leading to excretion via the kidneys and emphasizes the lack of impact of the EPR effect on short
circulating nanoparticles which was no longer observed at the 24 h time point.(13, 280, 281) Using
an orthotopic model which is closer to a clinical representation and function of the disease state,
we were able to better understand the fate of our micelleplexes. Overall, the SPECT/CT images
display nicely that siRNA is taken up by the primary and secondary tumors, and that potentially,
if sacrificed at an earlier time point, there may be an enhanced tumor targeting effect of siRNA
localized within the tumor that was washed out at 24 h post injection. Considering that the
circulation time of the micelleplexes used here was much shorter than described by Liu et al., an
earlier tmax for tumor deposition is not unlikely.
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A

B

Figure 7.6: In vivo SPECT/CT images. Biodistribution analysis of Indium-111 injected nude mice
intraperitoneally at 4 hours post injection (A) and 24 hours post injection (B). From left to right:
Transversal, coronal, saggital.

After pharmacokinetic, biodistribution, and tumor accumulation analysis, it was imperative
to assess the efficacy of the siRNA that localized within the tumor for protein knockdown. As the
animal model was based on injection of a luciferase expressing cell line, SKOV-3/LUC, it offered
the ability of measuring firefly luciferase expression in vivo. Therefore, we were able to monitor
tumor growth throughout the duration of the study, as well as luciferase knockdown by firefly
luciferase directed siRNA. In our animal model, as well as clinically, FRα is significantly overexpressed in ovarian tumors.(70, 71, 163) For the knockdown experiments, we utilized firefly
luciferase directed and scrambled siRNA to determine RNAi effects. As shown in Figure 7.7, we
analyzed luciferase knockdown over 72 hours after a single injection of 35 µg of siRNA. After 48
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hours, the micelleplexes containing luciferase directed siRNA showed an impressive 62%
knockdown. Conversely, the scrambled siRNA did not show any knockdown, but rather a drastic
increase in luciferase signal was measured, which was related to tumor growth. After 72 hours, we
saw a stark increase in the initially knocked down gene expression, signaling the end of the
transient knockdown. This observation was consistent with our previous data in Chapter 3 for
protein knockdown in vitro displaying the most efficient protein knockdown at 48 hours post
transfection.(48) Interestingly, the mice treated with scrambled siRNA displayed a decrease in the
overall luciferase signal after 48 hours. This could be due to necrotic tissue within the already
advanced tumors. Advanced ovarian cancers are known to grow rapidly with a very aggressive
disease progression.(64) This in vivo trend was promising due to the greater than 60% knockdown
of luciferase expression. In comparison, Bartlett et al., Gutbier et al., and Klein et al. all achieved
approximately a 50% in vivo knockdown with siRNA containing nanoparticles.(282-284) On the
contrary, Hobel et al. demonstrated that 0.1% of the total injected siRNA that reach the tumor was
capable of VEGF downregulation.(285) The knockdown is visualized in Figure 7.8 A-F which are
representative images of the bioluminescence recordings at time points 0, 48, and 72 hours post
injection. Animals treated with luciferase directed siRNA are shown in A-C, while animals treated
with scrambled siRNA treatment can be found in D-F. Here, it is obvious that luciferase protein
knockdown occurs after 24 and 48 hours, as shown in Figures 7.8 A and B, but then luciferase
expression increases at the 72-hour time point (8 C). Similarly, we can visually appreciate the
increase in signal after the treatment with scrambled siRNA between Figures 7.8 D and E. Overall,
our in vivo bioluminescence imaging data analysis shows a strong trend which indicates that folate
decorated micelleplexes can efficiently knock down luciferase expression by more than 60% in an
orthotopic xenograft mouse model of ovarian cancer. Unfortunately, humane endpoints were
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reached after 72 h which in this particular model involves ascites and serious weight loss.
Therefore, a second dose was not administered.
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Figure 7.7: In Vivo Bioluminescence luciferase knockdown. Luciferase knockdown in vivo after
injection of luciferase siRNA containing FRα targeted micelleplexes (n=6) and scramble siRNA containing
FRα targeted micelleplexes (n=4). Error bars represent SEM.
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Figure 7.8: In vivo Bioluminescence luciferase imaging. Bioluminescence images of luciferase
knockdown in vivo after injection of luciferase siRNA containing FRα targeted micelleplexes (A-C) and
scramble siRNA containing FRα targeted micelleplexes (D-F). Timepoints displayed here are 0 hours (A,
D), 48 hours (B, E), and 72 hours (C, F).

7.4 SUMMARY AND CONCLUSION
Ovarian cancer is the leading gynecologic malignancy and results in a significantly high
case-to-fatality ratio.(64) Three out of every four patients are diagnosed at an advanced stage.
Here, we assessed the in vivo functionality of FRα-targeted and non-targeted tri-block copolymers
containing siRNA within a SKOV-3 murine orthotopic xenograft ovarian cancer model. Initial
assessment of these micelleplexes needed to evaluate whether indium-labeling of siRNA altered
the uptake profiles of the micelleplexes from previously reported results. Figures 7.1 and 7.2
demonstrate that these micelleplexes can efficiently deliver siRNA to the cells, in vitro.
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Furthermore, the rational design for this delivery vector was to utilize and hijack the cells’ natural
FRα-mediated endocytosis mechanism for siRNA delivery. Therefore, theoretically, the targeted
micelleplexes would have a targeting benefit over the non-targeted micelleplexes due to the high
receptor expression within SKOV-3 cells. However, as demonstrated here, both micelleplexes can
efficiently deliver siRNA to the cell and ultimately were taken up into the tumor in this orthotopic
model, as shown in Figures 7.1, 7.2, and 7.5.
Stability testing of each micelleplex using low and high concentration levels of serum
displayed acceptable siRNA retention within the micelleplex. After 1 hour of incubation, at serum
levels mimicking in vivo conditions, 25% of the siRNA diffused out of the micelleplex. In vivo
pharmacokinetic analysis of both targeted and non-targeted micelleplexes was assessed after both
I.V and I.P administration. Overall, the AUC for I.P injected micelleplexes were about 1.25-1.5
times greater than the I.V injected ones. Interestingly, the non-targeted formulation had a greater
bioavailability than the targeted formulations in I.P. injected mice, but showed smaller AUCs when
injected I.V. Based on the stability and pharmacokinetic analysis here and in previously published
work, micelleplexes based on the tri-block copolymers described here are expected to be relatively
stable in vivo and to remain intact before reaching major organs.
In addition to the pharmacokinetic analysis, general biodistribution, tumor uptake, and
luciferase protein knockdown was assessed. When injected I.P., the two strongest signals of
biodistribution occurred within the kidneys (7.78 %ID/g for targeted and 7.36 %ID/g for nontargeted micelleplexes) and tumors (5.63 %ID/g targeted and 5.28 %ID/g non-targeted
micelleplexes). Due to the primary tumor and metastatic lesions being spread throughout the
peritoneal cavity, passive targeting of both micelleplexes may be a probable cause for decreasing
any observable receptor targeting effect achieved by local I.P. injection in tumor tissue. However,

150

due to the lack of micelleplexes reaching the tumor site after I.V. injection, the EPR effect likely
has little impact within this clinically relevant model. Liver uptake was minimal compared to the
kidneys and tumors when injected I.P., but still showed 1.5 times higher uptake for targeted than
non-targeted micelleplexes. Conversely, when injected I.V., a noticeable difference between both
formulations was observed regarding uptake in the liver. Targeted and non-targeted micelleplexes
accumulated with 39 and 53 %ID/g, respectively. Tumor uptake was also affected, dropping to 3.4
and 2.4 %ID/g for targeted and non-targeted micelleplexes. However, due to the wash-out of the
micelleplexes seen in the SPECT/CT images after the strong tumor uptake of the targeted
micelleplexes after 4 hours, leading to a diffuse uptake after 24 hours, a greater overall uptake and
targeting benefit would likely have been observed at earlier time points. This decrease in overall
uptake was expected because I.V. injected nanoparticles have to extravasate out of the blood vessel
in order to be taken up by tumor tissue where targeting ligands will then aid in the process of
intracellular delivery. SPECT/CT images displayed tumor uptake for targeted micelleplexes 4
hours post injection but reduced signals in primary tumors at 24 hours post injection. Negligible
uptake was seen in the brain and heart for either micelleplex with any injection route.
As the most successful tumor deposition was achieved after I.P injection of targeted
micelleplexes, we chose to utilize BLI to assess pharmacologic effects of siRNA delivery,
measured by luciferase knockdown. After a single injection of 35 µg of siRNA formulated in
targeted micelleplexes, an impressive 62% knockdown of luciferase was measured 48 hours after
injection. However, after 72 hours, the transient knockdown ended and a sharp increase in the
luciferase activity was noted. Tumors treated with targeted micelleplexes containing scrambled
siRNA displayed a steady increase in luciferase expression after injection.
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Overall, these tri-block copolymers displayed effective siRNA delivery profiles in vitro
and suitable siRNA retention in the presence of high serum concentrations. In vivo, these siRNA
containing micelleplexes achieved 5-6% tumor uptake in a SKOV-3 murine ovarian cancer
orthotopic xenograft model when injected I.P which yielded a 62% luciferase knockdown.
Therefore, this platform of amphiphilic tri-block copolymers provides a promising option for in
vivo siRNA delivery and gene knockdown in ovarian cancers.
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CHAPTER 8 – CONCLUSIONS
This goal of this dissertation was to successfully synthesize a tri-block copolymer that
could effectively deliver siRNA in a targeted manner towards FRα. FRα-mediated drug delivery
has promising therapeutic and imaging potential for treating auto-immune diseases and certain
cancers. Within this dissertation, the siRNA delivery efficiency of PEI-g-PCL-b-PEG-Fol
micelleplexes was demonstrated. Chapter 3 highlighted the FRα targeting efficiency and in vitro
protein knockdown capabilities. Furthermore, chapter 3 provided an alternative mechanism to
resensitize SKOV-3 ovarian cancer cells to paclitaxel treatment via TLR-4 knockdown. Following
preliminary studies, the receptor targeting mechanism of PEI-PCL-PEG-Fol micelleplexes was
explored further. Chapter 4 utilizes in vitro assays along with AFM techniques to study the effects
of monovalent and multivalent receptor binding. Additionally, binding studies were performed
with excess folic acid to revisit the concept of competition assays to prove or disprove receptor
targeting. Further biophysical studies were performed on the targeted and non-targeted tri-block
copolymers, which can be found in chapter 6. Overall, chapter 6 demonstrates that there is an
optimal folic acid concentration to achieve FRα targeting while not disrupting key biophysical
parameters of micelle formation and stability.
Lastly, in vivo efficacy was evaluated in an orthotopic xenograft mouse model in chapter
7. This model represents a more clinically relevant disease state when compared to patients. Within
this model, siRNA delivery was observed within the primary tumor and metastatic lesions.
However, both targeted and non-targeted micelleplexes effectively delivered siRNA suggesting
that uptake was primarily due to passive targeting. Overall, these PEI-g-PCL-b-PEG-Fol
micelleplexes provide a promising option for effective siRNA delivery and gene knockdown.
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ABSTRACT
FOLATE RECEPTOR ALPHA TARGETED DELIVERY AND CHARACTERIZATION
OF POLYETHYLENEIMINE-GRAFT-POLYCAPROLACTONE-BLOCKPOLY(ETHYLENE GLYCOL) CONTAINING SIRNA MICELLEPLEXES
by
STEVEN K. JONES
August 2017
Advisor: Dr. Olivia M. Merkel
Major: Cancer Biology
Degree: Doctor of Philosophy
This dissertation focuses on the ability of polyethyleneimine-graft-polycaprolactoneblock-poly(ethylene glycol) (PEI-g-PCL-b-PEG-Fol) folate-decorated tri-block copolymers
ability to deliver a targeted dose of siRNA. The micelleplexes that are formed upon electrostatic
interaction with siRNA are used to deliver siRNA in a targeted manner to ovarian cancer cells that
over-express Folate Receptor-α (FRα). Each conjugate showed suitable sizes below 200 nm with
full siRNA condensation ability. Furthermore, flow cytometry and western blot analysis
demonstrated that the best FRα-targeted polymer could effectively deliver siRNA which resulted
in protein knockdown of Toll-like receptor 4 (TLR4). Consequently, TLR4 knock down within
SKOV-3 cells re-sensitized them toward paclitaxel (PTX) treatment, and apoptotic events
increased. This study demonstrates that PEI-g-PCL-b-PEG-Fol conjugates are a reliable siRNA
delivery system and can mediate therapeutic TLR4 knockdown within ovarian cancer cells.
Subsequently, folate receptor binding studies were performed using Atomic Force
Microscopy (AFM) to assess the binding force and probability between folic acid decorated
micelleplexes and free folic acid. AFM cantilevers were decorated with active FRα and our studies

185

demonstrate that our micelleplexes have a stronger binding force and binding probability than free
folic acid. Both results show that the folate-decorated micelleplexes out-compete for the binding
of folic acid due to their multivalent nature and therefore stronger binding avidity. Uptake studies
with low concentrations of folic acid only show a slight inhibition of folic acid micelleplex uptake,
while not affecting the non-targeted micelleplexes. However, increasing concentrations of folic
acid seen within literature, inhibited the uptake of targeted and non-targeted micelleplexes. These
data suggest that excess folic does not block the micelleplexes from binding to the receptor, but
perhaps affecting all nanoparticle uptake due to a cellular event, a physical destabilization of the
cationic condensation of the nucleic acids, or causing an aggregation of the micelles therefore
affecting its uptake.
In vivo studies were performed with an orthotopic SKOV-3/luc xenograft model to assess
the conjugate’s effectiveness at targeted siRNA delivery and knockdown capabilities. A Bruker
In-Vivo Xtreme imaging system was utilized to monitor tumor growth and luciferase knockdown
while Indium-111 labeled siRNA was designed to monitor siRNA whole body distribution, tumor
targeting, and pharmacokinetic parameters by SPECT/CT and gamma scintillation counting. Upon
I.P. injection, both the targeted and non-targeted siRNA containing micelleplexes showed 5-6%
tumor uptake. However, when compared to scrambled siRNA, the targeted micelleplexes could
achieve a 62% luciferase knockdown. Overall, this platform for in vivo siRNA delivery with
amphiphilic tri-block copolymers provides a promising option for gene knockdown for ovarian
cancers.
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